Viewing Study NCT01763866

Home

Certify Doc

Genes

Clinical Trials

CompTox

DrugMatrix

Open Targets

Products

Support

Bugs

Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug

Ignite Creation Date: 2025-12-24 @ 4:38 PM

Ignite Modification Date: 2026-02-21 @ 2:54 PM

Study NCT ID: NCT01763866

Status: COMPLETED

Last Update Posted: 2022-11-08

First Post: 2013-01-07

Is NOT Gene Therapy: True

Has Adverse Events: True

Brief Title: LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2

Sponsor:

Organization:

Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Raw JSON

{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D006949', 'term': 'Hyperlipidemias'}, {'id': 'D006937', 'term': 'Hypercholesterolemia'}], 'ancestors': [{'id': 'D050171', 'term': 'Dyslipidemias'}, {'id': 'D052439', 'term': 'Lipid Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D009750', 'term': 'Nutritional and Metabolic Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C577155', 'term': 'evolocumab'}, {'id': 'D000069438', 'term': 'Ezetimibe'}, {'id': 'D000069059', 'term': 'Atorvastatin'}, {'id': 'D000068718', 'term': 'Rosuvastatin Calcium'}, {'id': 'D019821', 'term': 'Simvastatin'}], 'ancestors': [{'id': 'D001384', 'term': 'Azetidines'}, {'id': 'D001385', 'term': 'Azetines'}, {'id': 'D006573', 'term': 'Heterocyclic Compounds, 1-Ring'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}, {'id': 'D011758', 'term': 'Pyrroles'}, {'id': 'D001393', 'term': 'Azoles'}, {'id': 'D006538', 'term': 'Heptanoic Acids'}, {'id': 'D005227', 'term': 'Fatty Acids'}, {'id': 'D008055', 'term': 'Lipids'}, {'id': 'D013449', 'term': 'Sulfonamides'}, {'id': 'D000577', 'term': 'Amides'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D005464', 'term': 'Fluorobenzenes'}, {'id': 'D006845', 'term': 'Hydrocarbons, Fluorinated'}, {'id': 'D006846', 'term': 'Hydrocarbons, Halogenated'}, {'id': 'D006838', 'term': 'Hydrocarbons'}, {'id': 'D013450', 'term': 'Sulfones'}, {'id': 'D013457', 'term': 'Sulfur Compounds'}, {'id': 'D011743', 'term': 'Pyrimidines'}, {'id': 'D008148', 'term': 'Lovastatin'}, {'id': 'D009281', 'term': 'Naphthalenes'}, {'id': 'D011084', 'term': 'Polycyclic Aromatic Hydrocarbons'}, {'id': 'D006841', 'term': 'Hydrocarbons, Aromatic'}, {'id': 'D006844', 'term': 'Hydrocarbons, Cyclic'}, {'id': 'D011083', 'term': 'Polycyclic Compounds'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'phone': '866-572-6436', 'title': 'Study Director', 'organization': 'Amgen Inc.'}, 'certainAgreement': {'otherDetails': "The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.", 'restrictionType': 'OTHER', 'piSponsorEmployee': False, 'restrictiveAgreement': True}}, 'adverseEventsModule': {'timeFrame': 'From the first dose of blinded investigational product until the end of the study (up to 14 weeks).', 'description': 'Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.', 'eventGroups': [{'id': 'EG000', 'title': 'A10 PBO Q2W', 'description': 'Participants received atorvastatin 10 mg once daily during the 4 week lipid stabilization period and then in combination with placebo (PBO) subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once daily for up to 12 weeks.', 'otherNumAtRisk': 56, 'otherNumAffected': 5, 'seriousNumAtRisk': 56, 'seriousNumAffected': 1}, {'id': 'EG001', 'title': 'A10 PBO QM', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month (QM) and placebo tablets once daily for up to 12 weeks.', 'otherNumAtRisk': 55, 'otherNumAffected': 3, 'seriousNumAtRisk': 55, 'seriousNumAffected': 2}, {'id': 'EG002', 'title': 'A10 EZE (Q2W)', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe (EZE) orally once daily for up to 12 weeks.', 'otherNumAtRisk': 56, 'otherNumAffected': 9, 'seriousNumAtRisk': 56, 'seriousNumAffected': 0}, {'id': 'EG003', 'title': 'A10 EZE (QM)', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.', 'otherNumAtRisk': 55, 'otherNumAffected': 6, 'seriousNumAtRisk': 55, 'seriousNumAffected': 0}, {'id': 'EG004', 'title': 'A10 EvoMab Q2W', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab (EvoMab) by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.', 'otherNumAtRisk': 110, 'otherNumAffected': 9, 'seriousNumAtRisk': 110, 'seriousNumAffected': 4}, {'id': 'EG005', 'title': 'A10 EvoMab QM', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.', 'otherNumAtRisk': 110, 'otherNumAffected': 7, 'seriousNumAtRisk': 110, 'seriousNumAffected': 2}, {'id': 'EG006', 'title': 'A80 PBO Q2W', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.', 'otherNumAtRisk': 55, 'otherNumAffected': 7, 'seriousNumAtRisk': 55, 'seriousNumAffected': 2}, {'id': 'EG007', 'title': 'A80 PBO QM', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.', 'otherNumAtRisk': 55, 'otherNumAffected': 13, 'seriousNumAtRisk': 55, 'seriousNumAffected': 1}, {'id': 'EG008', 'title': 'A80 EZE (Q2W)', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once daily for up to 12 weeks.', 'otherNumAtRisk': 56, 'otherNumAffected': 8, 'seriousNumAtRisk': 56, 'seriousNumAffected': 1}, {'id': 'EG009', 'title': 'A80 EZE (QM)', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.', 'otherNumAtRisk': 54, 'otherNumAffected': 2, 'seriousNumAtRisk': 54, 'seriousNumAffected': 1}, {'id': 'EG010', 'title': 'A80 EvoMab Q2W', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.', 'otherNumAtRisk': 109, 'otherNumAffected': 11, 'seriousNumAtRisk': 109, 'seriousNumAffected': 3}, {'id': 'EG011', 'title': 'A80 EvoMab QM', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.', 'otherNumAtRisk': 110, 'otherNumAffected': 9, 'seriousNumAtRisk': 110, 'seriousNumAffected': 1}, {'id': 'EG012', 'title': 'R5 PBO Q2W', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.', 'otherNumAtRisk': 58, 'otherNumAffected': 11, 'seriousNumAtRisk': 58, 'seriousNumAffected': 1}, {'id': 'EG013', 'title': 'R5 PBO QM', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.', 'otherNumAtRisk': 57, 'otherNumAffected': 1, 'seriousNumAtRisk': 57, 'seriousNumAffected': 2}, {'id': 'EG014', 'title': 'R5 EvoMab Q2W', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.', 'otherNumAtRisk': 113, 'otherNumAffected': 6, 'seriousNumAtRisk': 113, 'seriousNumAffected': 3}, {'id': 'EG015', 'title': 'R5 EvoMab QM', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.', 'otherNumAtRisk': 115, 'otherNumAffected': 9, 'seriousNumAtRisk': 115, 'seriousNumAffected': 3}, {'id': 'EG016', 'title': 'R40 PBO Q2W', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.', 'otherNumAtRisk': 56, 'otherNumAffected': 3, 'seriousNumAtRisk': 56, 'seriousNumAffected': 2}, {'id': 'EG017', 'title': 'R40 PBO QM', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.', 'otherNumAtRisk': 55, 'otherNumAffected': 8, 'seriousNumAtRisk': 55, 'seriousNumAffected': 1}, {'id': 'EG018', 'title': 'R40 EvoMab Q2W', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.', 'otherNumAtRisk': 111, 'otherNumAffected': 5, 'seriousNumAtRisk': 111, 'seriousNumAffected': 1}, {'id': 'EG019', 'title': 'R40 EvoMab QM', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.', 'otherNumAtRisk': 112, 'otherNumAffected': 8, 'seriousNumAtRisk': 112, 'seriousNumAffected': 3}, {'id': 'EG020', 'title': 'S40 PBO Q2W', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.', 'otherNumAtRisk': 56, 'otherNumAffected': 3, 'seriousNumAtRisk': 56, 'seriousNumAffected': 0}, {'id': 'EG021', 'title': 'S40 PBO QM', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.', 'otherNumAtRisk': 55, 'otherNumAffected': 5, 'seriousNumAtRisk': 55, 'seriousNumAffected': 1}, {'id': 'EG022', 'title': 'S40 EvoMab Q2W', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.', 'otherNumAtRisk': 112, 'otherNumAffected': 18, 'seriousNumAtRisk': 112, 'seriousNumAffected': 2}, {'id': 'EG023', 'title': 'S40 EvoMab QM', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.', 'otherNumAtRisk': 115, 'otherNumAffected': 11, 'seriousNumAtRisk': 115, 'seriousNumAffected': 1}], 'otherEvents': [{'term': 'Constipation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 56, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 55, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 56, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 54, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 109, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 58, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 57, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 113, 'numAffected': 1}, {'groupId': 'EG015', 'numAtRisk': 115, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 111, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG020', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG021', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG022', 'numAtRisk': 112, 'numAffected': 2}, {'groupId': 'EG023', 'numAtRisk': 115, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Diarrhoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 55, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 110, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 55, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 55, 'numAffected': 4}, {'groupId': 'EG008', 'numAtRisk': 56, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 54, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 109, 'numAffected': 4}, {'groupId': 'EG011', 'numAtRisk': 110, 'numAffected': 2}, {'groupId': 'EG012', 'numAtRisk': 58, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 57, 'numAffected': 1}, {'groupId': 'EG014', 'numAtRisk': 113, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 115, 'numAffected': 2}, {'groupId': 'EG016', 'numAtRisk': 56, 'numAffected': 1}, {'groupId': 'EG017', 'numAtRisk': 55, 'numAffected': 1}, {'groupId': 'EG018', 'numAtRisk': 111, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 112, 'numAffected': 1}, {'groupId': 'EG020', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG021', 'numAtRisk': 55, 'numAffected': 1}, {'groupId': 'EG022', 'numAtRisk': 112, 'numAffected': 1}, {'groupId': 'EG023', 'numAtRisk': 115, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Back pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 56, 'numAffected': 3}, {'groupId': 'EG003', 'numAtRisk': 55, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 110, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 110, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 55, 'numAffected': 2}, {'groupId': 'EG007', 'numAtRisk': 55, 'numAffected': 2}, {'groupId': 'EG008', 'numAtRisk': 56, 'numAffected': 2}, {'groupId': 'EG009', 'numAtRisk': 54, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 109, 'numAffected': 3}, {'groupId': 'EG011', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 58, 'numAffected': 4}, {'groupId': 'EG013', 'numAtRisk': 57, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 113, 'numAffected': 1}, {'groupId': 'EG015', 'numAtRisk': 115, 'numAffected': 2}, {'groupId': 'EG016', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 55, 'numAffected': 5}, {'groupId': 'EG018', 'numAtRisk': 111, 'numAffected': 2}, {'groupId': 'EG019', 'numAtRisk': 112, 'numAffected': 1}, {'groupId': 'EG020', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG021', 'numAtRisk': 55, 'numAffected': 1}, {'groupId': 'EG022', 'numAtRisk': 112, 'numAffected': 6}, {'groupId': 'EG023', 'numAtRisk': 115, 'numAffected': 2}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Muscle spasms', 'stats': [{'groupId': 'EG000', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 56, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 55, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 110, 'numAffected': 3}, {'groupId': 'EG005', 'numAtRisk': 110, 'numAffected': 4}, {'groupId': 'EG006', 'numAtRisk': 55, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 55, 'numAffected': 2}, {'groupId': 'EG008', 'numAtRisk': 56, 'numAffected': 3}, {'groupId': 'EG009', 'numAtRisk': 54, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 109, 'numAffected': 2}, {'groupId': 'EG011', 'numAtRisk': 110, 'numAffected': 1}, {'groupId': 'EG012', 'numAtRisk': 58, 'numAffected': 1}, {'groupId': 'EG013', 'numAtRisk': 57, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 113, 'numAffected': 2}, {'groupId': 'EG015', 'numAtRisk': 115, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 55, 'numAffected': 1}, {'groupId': 'EG018', 'numAtRisk': 111, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 112, 'numAffected': 1}, {'groupId': 'EG020', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG021', 'numAtRisk': 55, 'numAffected': 1}, {'groupId': 'EG022', 'numAtRisk': 112, 'numAffected': 3}, {'groupId': 'EG023', 'numAtRisk': 115, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Myalgia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 56, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 55, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 56, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 110, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 55, 'numAffected': 3}, {'groupId': 'EG008', 'numAtRisk': 56, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 54, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 109, 'numAffected': 1}, {'groupId': 'EG011', 'numAtRisk': 110, 'numAffected': 2}, {'groupId': 'EG012', 'numAtRisk': 58, 'numAffected': 1}, {'groupId': 'EG013', 'numAtRisk': 57, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 113, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 115, 'numAffected': 2}, {'groupId': 'EG016', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 55, 'numAffected': 1}, {'groupId': 'EG018', 'numAtRisk': 111, 'numAffected': 1}, {'groupId': 'EG019', 'numAtRisk': 112, 'numAffected': 1}, {'groupId': 'EG020', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG021', 'numAtRisk': 55, 'numAffected': 1}, {'groupId': 'EG022', 'numAtRisk': 112, 'numAffected': 1}, {'groupId': 'EG023', 'numAtRisk': 115, 'numAffected': 3}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Dizziness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 56, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 55, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 110, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 110, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 55, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 55, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 56, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 54, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 109, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 110, 'numAffected': 1}, {'groupId': 'EG012', 'numAtRisk': 58, 'numAffected': 3}, {'groupId': 'EG013', 'numAtRisk': 57, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 113, 'numAffected': 1}, {'groupId': 'EG015', 'numAtRisk': 115, 'numAffected': 2}, {'groupId': 'EG016', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 111, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 112, 'numAffected': 1}, {'groupId': 'EG020', 'numAtRisk': 56, 'numAffected': 1}, {'groupId': 'EG021', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG022', 'numAtRisk': 112, 'numAffected': 3}, {'groupId': 'EG023', 'numAtRisk': 115, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Headache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 56, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 55, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 56, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 55, 'numAffected': 4}, {'groupId': 'EG004', 'numAtRisk': 110, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 55, 'numAffected': 2}, {'groupId': 'EG007', 'numAtRisk': 55, 'numAffected': 2}, {'groupId': 'EG008', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 54, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 109, 'numAffected': 1}, {'groupId': 'EG011', 'numAtRisk': 110, 'numAffected': 3}, {'groupId': 'EG012', 'numAtRisk': 58, 'numAffected': 3}, {'groupId': 'EG013', 'numAtRisk': 57, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 113, 'numAffected': 1}, {'groupId': 'EG015', 'numAtRisk': 115, 'numAffected': 1}, {'groupId': 'EG016', 'numAtRisk': 56, 'numAffected': 2}, {'groupId': 'EG017', 'numAtRisk': 55, 'numAffected': 1}, {'groupId': 'EG018', 'numAtRisk': 111, 'numAffected': 2}, {'groupId': 'EG019', 'numAtRisk': 112, 'numAffected': 3}, {'groupId': 'EG020', 'numAtRisk': 56, 'numAffected': 2}, {'groupId': 'EG021', 'numAtRisk': 55, 'numAffected': 1}, {'groupId': 'EG022', 'numAtRisk': 112, 'numAffected': 2}, {'groupId': 'EG023', 'numAtRisk': 115, 'numAffected': 5}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}], 'seriousEvents': [{'term': 'Acute coronary syndrome', 'stats': [{'groupId': 'EG000', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 110, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 54, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 109, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 58, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 57, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 113, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 115, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 111, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG020', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG021', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG022', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG023', 'numAtRisk': 115, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Acute myocardial infarction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 110, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 54, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 109, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 58, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 57, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 113, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 115, 'numAffected': 1}, {'groupId': 'EG016', 'numAtRisk': 56, 'numAffected': 1}, {'groupId': 'EG017', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 111, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG020', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG021', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG022', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG023', 'numAtRisk': 115, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Myocardial infarction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 54, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 109, 'numAffected': 1}, {'groupId': 'EG011', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 58, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 57, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 113, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 115, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 111, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG020', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG021', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG022', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG023', 'numAtRisk': 115, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Ventricular fibrillation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 54, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 109, 'numAffected': 1}, {'groupId': 'EG011', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 58, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 57, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 113, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 115, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 111, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG020', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG021', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG022', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG023', 'numAtRisk': 115, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Abdominal pain upper', 'stats': [{'groupId': 'EG000', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 54, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 109, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 58, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 57, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 113, 'numAffected': 1}, {'groupId': 'EG015', 'numAtRisk': 115, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 111, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG020', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG021', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG022', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG023', 'numAtRisk': 115, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Gastrointestinal haemorrhage', 'stats': [{'groupId': 'EG000', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 55, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 54, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 109, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 58, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 57, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 113, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 115, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 55, 'numAffected': 1}, {'groupId': 'EG018', 'numAtRisk': 111, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG020', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG021', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG022', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG023', 'numAtRisk': 115, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Hiatus hernia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 56, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 54, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 109, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 58, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 57, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 113, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 115, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 111, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG020', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG021', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG022', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG023', 'numAtRisk': 115, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Cholecystitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 54, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 109, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 58, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 57, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 113, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 115, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 111, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 112, 'numAffected': 1}, {'groupId': 'EG020', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG021', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG022', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG023', 'numAtRisk': 115, 'numAffected': 0}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Drug-induced liver injury', 'stats': [{'groupId': 'EG000', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 55, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 54, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 109, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 58, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 57, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 113, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 115, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 111, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG020', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG021', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG022', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG023', 'numAtRisk': 115, 'numAffected': 0}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Campylobacter infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 54, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 109, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 58, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 57, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 113, 'numAffected': 1}, {'groupId': 'EG015', 'numAtRisk': 115, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 111, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG020', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG021', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG022', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG023', 'numAtRisk': 115, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Gastroenteritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 55, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 54, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 109, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 58, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 57, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 113, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 115, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 111, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG020', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG021', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG022', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG023', 'numAtRisk': 115, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Herpes simplex meningoencephalitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 55, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 54, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 109, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 58, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 57, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 113, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 115, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 111, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG020', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG021', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG022', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG023', 'numAtRisk': 115, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Infected bites', 'stats': [{'groupId': 'EG000', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 54, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 109, 'numAffected': 1}, {'groupId': 'EG011', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 58, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 57, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 113, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 115, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 111, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG020', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG021', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG022', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG023', 'numAtRisk': 115, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Pneumonia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 110, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 54, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 109, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 58, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 57, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 113, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 115, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 111, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG020', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG021', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG022', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG023', 'numAtRisk': 115, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Pneumonia mycoplasmal', 'stats': [{'groupId': 'EG000', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 55, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 54, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 109, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 58, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 57, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 113, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 115, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 111, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG020', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG021', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG022', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG023', 'numAtRisk': 115, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Pyelonephritis acute', 'stats': [{'groupId': 'EG000', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 110, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 54, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 109, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 58, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 57, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 113, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 115, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 111, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG020', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG021', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG022', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG023', 'numAtRisk': 115, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Urinary tract infection bacterial', 'stats': [{'groupId': 'EG000', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 54, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 109, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 58, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 57, 'numAffected': 1}, {'groupId': 'EG014', 'numAtRisk': 113, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 115, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 111, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG020', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG021', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG022', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG023', 'numAtRisk': 115, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Injury', 'stats': [{'groupId': 'EG000', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 54, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 109, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 58, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 57, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 113, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 115, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 111, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 112, 'numAffected': 1}, {'groupId': 'EG020', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG021', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG022', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG023', 'numAtRisk': 115, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Radius fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 54, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 109, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 58, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 57, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 113, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 115, 'numAffected': 1}, {'groupId': 'EG016', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 111, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG020', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG021', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG022', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG023', 'numAtRisk': 115, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Troponin increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 54, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 109, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 58, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 57, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 113, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 115, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 111, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG020', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG021', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG022', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG023', 'numAtRisk': 115, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Dehydration', 'stats': [{'groupId': 'EG000', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 54, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 109, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 58, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 57, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 113, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 115, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 111, 'numAffected': 1}, {'groupId': 'EG019', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG020', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG021', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG022', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG023', 'numAtRisk': 115, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Myalgia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 55, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 54, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 109, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 58, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 57, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 113, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 115, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 111, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG020', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG021', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG022', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG023', 'numAtRisk': 115, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Rotator cuff syndrome', 'stats': [{'groupId': 'EG000', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 110, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 54, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 109, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 58, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 57, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 113, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 115, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 111, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG020', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG021', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG022', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG023', 'numAtRisk': 115, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Spinal pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 54, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 109, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 58, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 57, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 113, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 115, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 111, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG020', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG021', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG022', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG023', 'numAtRisk': 115, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Bladder neoplasm', 'stats': [{'groupId': 'EG000', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 56, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 54, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 109, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 58, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 57, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 113, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 115, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 111, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG020', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG021', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG022', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG023', 'numAtRisk': 115, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Colon cancer metastatic', 'stats': [{'groupId': 'EG000', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 54, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 109, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 58, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 57, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 113, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 115, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 111, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG020', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG021', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG022', 'numAtRisk': 112, 'numAffected': 1}, {'groupId': 'EG023', 'numAtRisk': 115, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Lung adenocarcinoma metastatic', 'stats': [{'groupId': 'EG000', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 54, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 109, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 58, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 57, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 113, 'numAffected': 1}, {'groupId': 'EG015', 'numAtRisk': 115, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 111, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG020', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG021', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG022', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG023', 'numAtRisk': 115, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Ovarian cancer', 'stats': [{'groupId': 'EG000', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 54, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 109, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 58, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 57, 'numAffected': 1}, {'groupId': 'EG014', 'numAtRisk': 113, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 115, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 111, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG020', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG021', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG022', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG023', 'numAtRisk': 115, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Pleomorphic adenoma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 54, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 109, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 58, 'numAffected': 1}, {'groupId': 'EG013', 'numAtRisk': 57, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 113, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 115, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 111, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG020', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG021', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG022', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG023', 'numAtRisk': 115, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Cerebrovascular accident', 'stats': [{'groupId': 'EG000', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 54, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 109, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 58, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 57, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 113, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 115, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 56, 'numAffected': 1}, {'groupId': 'EG017', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 111, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG020', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG021', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG022', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG023', 'numAtRisk': 115, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Coma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 54, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 109, 'numAffected': 1}, {'groupId': 'EG011', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 58, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 57, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 113, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 115, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 111, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG020', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG021', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG022', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG023', 'numAtRisk': 115, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Grand mal convulsion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 55, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 54, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 109, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 58, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 57, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 113, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 115, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 111, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG020', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG021', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG022', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG023', 'numAtRisk': 115, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Ischaemic stroke', 'stats': [{'groupId': 'EG000', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 54, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 109, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 58, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 57, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 113, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 115, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 111, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG020', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG021', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG022', 'numAtRisk': 112, 'numAffected': 1}, {'groupId': 'EG023', 'numAtRisk': 115, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Affective disorder', 'stats': [{'groupId': 'EG000', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 110, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 54, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 109, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 58, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 57, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 113, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 115, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 111, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG020', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG021', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG022', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG023', 'numAtRisk': 115, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Glomerulonephritis acute', 'stats': [{'groupId': 'EG000', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 54, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 109, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 58, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 57, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 113, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 115, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 111, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 112, 'numAffected': 1}, {'groupId': 'EG020', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG021', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG022', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG023', 'numAtRisk': 115, 'numAffected': 0}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Renal failure acute', 'stats': [{'groupId': 'EG000', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 54, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 109, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 58, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 57, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 113, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 115, 'numAffected': 1}, {'groupId': 'EG016', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 111, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG020', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG021', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG022', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG023', 'numAtRisk': 115, 'numAffected': 0}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Breast pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 110, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 54, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 109, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 58, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 57, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 113, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 115, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 111, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG020', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG021', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG022', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG023', 'numAtRisk': 115, 'numAffected': 0}], 'organSystem': 'Reproductive system and breast disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Pulmonary oedema', 'stats': [{'groupId': 'EG000', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 54, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 109, 'numAffected': 1}, {'groupId': 'EG011', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 58, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 57, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 113, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 115, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 111, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG020', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG021', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG022', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG023', 'numAtRisk': 115, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Hip arthroplasty', 'stats': [{'groupId': 'EG000', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 54, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 109, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 110, 'numAffected': 1}, {'groupId': 'EG012', 'numAtRisk': 58, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 57, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 113, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 115, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 111, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG020', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG021', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG022', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG023', 'numAtRisk': 115, 'numAffected': 0}], 'organSystem': 'Surgical and medical procedures', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Aortic aneurysm', 'stats': [{'groupId': 'EG000', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 54, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 109, 'numAffected': 1}, {'groupId': 'EG011', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 58, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 57, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 113, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 115, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 111, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG020', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG021', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG022', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG023', 'numAtRisk': 115, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Hypertensive crisis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 54, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 109, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 58, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 57, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 113, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 115, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 111, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG020', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG021', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG022', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG023', 'numAtRisk': 115, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Orthostatic hypotension', 'stats': [{'groupId': 'EG000', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 54, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 109, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 58, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 57, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 113, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 115, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 111, 'numAffected': 1}, {'groupId': 'EG019', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG020', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG021', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG022', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG023', 'numAtRisk': 115, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}, {'term': 'Peripheral artery stenosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 54, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 109, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 110, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 58, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 57, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 113, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 115, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 55, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 111, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG020', 'numAtRisk': 56, 'numAffected': 0}, {'groupId': 'EG021', 'numAtRisk': 55, 'numAffected': 1}, {'groupId': 'EG022', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG023', 'numAtRisk': 115, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 16.1'}], 'frequencyThreshold': '5'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '56', 'groupId': 'OG000'}, {'value': '55', 'groupId': 'OG001'}, {'value': '56', 'groupId': 'OG002'}, {'value': '55', 'groupId': 'OG003'}, {'value': '110', 'groupId': 'OG004'}, {'value': '110', 'groupId': 'OG005'}, {'value': '55', 'groupId': 'OG006'}, {'value': '55', 'groupId': 'OG007'}, {'value': '56', 'groupId': 'OG008'}, {'value': '54', 'groupId': 'OG009'}, {'value': '109', 'groupId': 'OG010'}, {'value': '110', 'groupId': 'OG011'}, {'value': '58', 'groupId': 'OG012'}, {'value': '57', 'groupId': 'OG013'}, {'value': '113', 'groupId': 'OG014'}, {'value': '115', 'groupId': 'OG015'}, {'value': '56', 'groupId': 'OG016'}, {'value': '55', 'groupId': 'OG017'}, {'value': '111', 'groupId': 'OG018'}, {'value': '112', 'groupId': 'OG019'}, {'value': '56', 'groupId': 'OG020'}, {'value': '55', 'groupId': 'OG021'}, {'value': '112', 'groupId': 'OG022'}, {'value': '115', 'groupId': 'OG023'}]}], 'groups': [{'id': 'OG000', 'title': 'A10 PBO Q2W', 'description': 'Participants received atorvastatin 10 mg once daily during the 4 week lipid stabilization period and then in combination with placebo (PBO) subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG001', 'title': 'A10 PBO QM', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month (QM) and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG002', 'title': 'A10 EZE (Q2W)', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe (EZE) orally once daily for up to 12 weeks.'}, {'id': 'OG003', 'title': 'A10 EZE (QM)', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.'}, {'id': 'OG004', 'title': 'A10 EvoMab Q2W', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab (EvoMab) by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG005', 'title': 'A10 EvoMab QM', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG006', 'title': 'A80 PBO Q2W', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG007', 'title': 'A80 PBO QM', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG008', 'title': 'A80 EZE (Q2W)', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once daily for up to 12 weeks.'}, {'id': 'OG009', 'title': 'A80 EZE (QM)', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.'}, {'id': 'OG010', 'title': 'A80 EvoMab Q2W', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG011', 'title': 'A80 EvoMab QM', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG012', 'title': 'R5 PBO Q2W', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG013', 'title': 'R5 PBO QM', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG014', 'title': 'R5 EvoMab Q2W', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG015', 'title': 'R5 EvoMab QM', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG016', 'title': 'R40 PBO Q2W', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG017', 'title': 'R40 PBO QM', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG018', 'title': 'R40 EvoMab Q2W', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG019', 'title': 'R40 EvoMab QM', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG020', 'title': 'S40 PBO Q2W', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG021', 'title': 'S40 PBO QM', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG022', 'title': 'S40 EvoMab Q2W', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG023', 'title': 'S40 EvoMab QM', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.'}], 'classes': [{'categories': [{'measurements': [{'value': '9.86', 'spread': '2.53', 'groupId': 'OG000'}, {'value': '0.97', 'spread': '2.82', 'groupId': 'OG001'}, {'value': '-21.96', 'spread': '2.63', 'groupId': 'OG002'}, {'value': '-17.08', 'spread': '2.78', 'groupId': 'OG003'}, {'value': '-61.56', 'spread': '1.81', 'groupId': 'OG004'}, {'value': '-58.19', 'spread': '1.99', 'groupId': 'OG005'}, {'value': '14.49', 'spread': '4.42', 'groupId': 'OG006'}, {'value': '11.83', 'spread': '3.85', 'groupId': 'OG007'}, {'value': '-14.60', 'spread': '4.29', 'groupId': 'OG008'}, {'value': '-19.80', 'spread': '3.85', 'groupId': 'OG009'}, {'value': '-61.80', 'spread': '3.04', 'groupId': 'OG010'}, {'value': '-58.68', 'spread': '2.74', 'groupId': 'OG011'}, {'value': '8.12', 'spread': '2.68', 'groupId': 'OG012'}, {'value': '5.10', 'spread': '2.62', 'groupId': 'OG013'}, {'value': '-60.09', 'spread': '1.94', 'groupId': 'OG014'}, {'value': '-59.40', 'spread': '1.87', 'groupId': 'OG015'}, {'value': '9.42', 'spread': '3.60', 'groupId': 'OG016'}, {'value': '2.59', 'spread': '4.30', 'groupId': 'OG017'}, {'value': '-58.89', 'spread': '2.58', 'groupId': 'OG018'}, {'value': '-52.40', 'spread': '2.98', 'groupId': 'OG019'}, {'value': '4.70', 'spread': '3.61', 'groupId': 'OG020'}, {'value': '3.40', 'spread': '4.94', 'groupId': 'OG021'}, {'value': '-65.86', 'spread': '3.05', 'groupId': 'OG022'}, {'value': '-57.02', 'spread': '3.93', 'groupId': 'OG023'}]}]}], 'analyses': [{'pValue': '<0.001', 'groupIds': ['OG000', 'OG004'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-71.42', 'ciLowerLimit': '-77.55', 'ciUpperLimit': '-65.29', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.11', 'groupDescription': 'The null hypothesis was that there was no difference in the percent change from Baseline at Week 12 in LDL-C between evolocumab and placebo, and the alternative hypothesis was that a mean difference did exist.', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG001', 'OG005'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-59.16', 'ciLowerLimit': '-65.94', 'ciUpperLimit': '-52.38', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.44', 'groupDescription': 'The null hypothesis was that there was no difference in the percent change from Baseline at Week 12 in LDL-C between evolocumab and placebo, and the alternative hypothesis was that a mean difference did exist.', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG002', 'OG004'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-39.60', 'ciLowerLimit': '-45.81', 'ciUpperLimit': '-33.40', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.15', 'groupDescription': 'The null hypothesis was that there was no mean difference in the percent change from Baseline at Week 12 in LDL-C between evolocumab and ezetimibe, and the alternative hypothesis was that a mean difference did exist.', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG003', 'OG005'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-41.10', 'ciLowerLimit': '-47.83', 'ciUpperLimit': '-34.37', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.41', 'groupDescription': 'The null hypothesis was that there was no mean difference in the percent change from Baseline at Week 12 in LDL-C between evolocumab and ezetimibe, and the alternative hypothesis was that a mean difference did exist.', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG006', 'OG010'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-76.29', 'ciLowerLimit': '-86.87', 'ciUpperLimit': '-65.72', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.36', 'groupDescription': 'The null hypothesis was that there was no difference in the percent change from Baseline at Week 12 in LDL-C between evolocumab and placebo, and the alternative hypothesis was that a mean difference did exist.', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG007', 'OG011'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-70.51', 'ciLowerLimit': '-79.81', 'ciUpperLimit': '-61.20', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.72', 'groupDescription': 'The null hypothesis was that there was no difference in the percent change from Baseline at Week 12 in LDL-C between evolocumab and placebo, and the alternative hypothesis was that a mean difference did exist.', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG008', 'OG010'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-47.20', 'ciLowerLimit': '-57.54', 'ciUpperLimit': '-36.86', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.24', 'groupDescription': 'The null hypothesis was that there was no mean difference in the percent change from Baseline at Week 12 in LDL-C between evolocumab and ezetimibe, and the alternative hypothesis was that a mean difference did exist.', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG009', 'OG011'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-38.88', 'ciLowerLimit': '-48.21', 'ciUpperLimit': '-29.56', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.73', 'groupDescription': 'The null hypothesis was that there was no mean difference in the percent change from Baseline at Week 12 in LDL-C between evolocumab and ezetimibe, and the alternative hypothesis was that a mean difference did exist.', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG012', 'OG014'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-68.21', 'ciLowerLimit': '-74.72', 'ciUpperLimit': '-61.70', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.30', 'groupDescription': 'The null hypothesis was that there was no difference in the percent change from Baseline at Week 12 in LDL-C between evolocumab and placebo, and the alternative hypothesis was that a mean difference did exist.', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG013', 'OG015'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-64.49', 'ciLowerLimit': '-70.84', 'ciUpperLimit': '-58.14', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.21', 'groupDescription': 'The null hypothesis was that there was no difference in the percent change from Baseline at Week 12 in LDL-C between evolocumab and placebo, and the alternative hypothesis was that a mean difference did exist.', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG016', 'OG018'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-68.31', 'ciLowerLimit': '-77.04', 'ciUpperLimit': '-59.57', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.42', 'groupDescription': 'The null hypothesis was that there was no difference in the percent change from Baseline at Week 12 in LDL-C between evolocumab and placebo, and the alternative hypothesis was that a mean difference did exist.', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG017', 'OG019'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-54.98', 'ciLowerLimit': '-65.31', 'ciUpperLimit': '-44.65', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.23', 'groupDescription': 'The null hypothesis was that there was no difference in the percent change from Baseline at Week 12 in LDL-C between evolocumab and placebo, and the alternative hypothesis was that a mean difference did exist.', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG020', 'OG022'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-70.56', 'ciLowerLimit': '-76.72', 'ciUpperLimit': '-64.41', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.12', 'groupDescription': 'The null hypothesis was that there was no difference in the percent change from Baseline at Week 12 in LDL-C between evolocumab and placebo, and the alternative hypothesis was that a mean difference did exist.', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG021', 'OG023'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-60.41', 'ciLowerLimit': '-69.11', 'ciUpperLimit': '-51.72', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.41', 'groupDescription': 'The null hypothesis was that there was no difference in the percent change from Baseline at Week 12 in LDL-C between evolocumab and placebo, and the alternative hypothesis was that a mean difference did exist.', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline and Week 12', 'unitOfMeasure': 'percent change', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set'}, {'type': 'PRIMARY', 'title': 'Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '56', 'groupId': 'OG000'}, {'value': '55', 'groupId': 'OG001'}, {'value': '56', 'groupId': 'OG002'}, {'value': '55', 'groupId': 'OG003'}, {'value': '110', 'groupId': 'OG004'}, {'value': '110', 'groupId': 'OG005'}, {'value': '55', 'groupId': 'OG006'}, {'value': '55', 'groupId': 'OG007'}, {'value': '56', 'groupId': 'OG008'}, {'value': '54', 'groupId': 'OG009'}, {'value': '109', 'groupId': 'OG010'}, {'value': '110', 'groupId': 'OG011'}, {'value': '58', 'groupId': 'OG012'}, {'value': '57', 'groupId': 'OG013'}, {'value': '113', 'groupId': 'OG014'}, {'value': '115', 'groupId': 'OG015'}, {'value': '56', 'groupId': 'OG016'}, {'value': '55', 'groupId': 'OG017'}, {'value': '111', 'groupId': 'OG018'}, {'value': '112', 'groupId': 'OG019'}, {'value': '56', 'groupId': 'OG020'}, {'value': '55', 'groupId': 'OG021'}, {'value': '112', 'groupId': 'OG022'}, {'value': '115', 'groupId': 'OG023'}]}], 'groups': [{'id': 'OG000', 'title': 'A10 PBO Q2W', 'description': 'Participants received atorvastatin 10 mg once daily during the 4 week lipid stabilization period and then in combination with placebo (PBO) subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG001', 'title': 'A10 PBO QM', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month (QM) and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG002', 'title': 'A10 EZE (Q2W)', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe (EZE) orally once daily for up to 12 weeks.'}, {'id': 'OG003', 'title': 'A10 EZE (QM)', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.'}, {'id': 'OG004', 'title': 'A10 EvoMab Q2W', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab (EvoMab) by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG005', 'title': 'A10 EvoMab QM', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG006', 'title': 'A80 PBO Q2W', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG007', 'title': 'A80 PBO QM', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG008', 'title': 'A80 EZE (Q2W)', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once daily for up to 12 weeks.'}, {'id': 'OG009', 'title': 'A80 EZE (QM)', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.'}, {'id': 'OG010', 'title': 'A80 EvoMab Q2W', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG011', 'title': 'A80 EvoMab QM', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG012', 'title': 'R5 PBO Q2W', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG013', 'title': 'R5 PBO QM', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG014', 'title': 'R5 EvoMab Q2W', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG015', 'title': 'R5 EvoMab QM', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG016', 'title': 'R40 PBO Q2W', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG017', 'title': 'R40 PBO QM', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG018', 'title': 'R40 EvoMab Q2W', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG019', 'title': 'R40 EvoMab QM', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG020', 'title': 'S40 PBO Q2W', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG021', 'title': 'S40 PBO QM', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG022', 'title': 'S40 EvoMab Q2W', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG023', 'title': 'S40 EvoMab QM', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.'}], 'classes': [{'categories': [{'measurements': [{'value': '8.54', 'spread': '2.24', 'groupId': 'OG000'}, {'value': '0.35', 'spread': '2.60', 'groupId': 'OG001'}, {'value': '-23.88', 'spread': '2.34', 'groupId': 'OG002'}, {'value': '-18.98', 'spread': '2.57', 'groupId': 'OG003'}, {'value': '-61.41', 'spread': '1.61', 'groupId': 'OG004'}, {'value': '-62.47', 'spread': '1.83', 'groupId': 'OG005'}, {'value': '13.12', 'spread': '3.99', 'groupId': 'OG006'}, {'value': '9.76', 'spread': '3.39', 'groupId': 'OG007'}, {'value': '-16.85', 'spread': '3.88', 'groupId': 'OG008'}, {'value': '-21.25', 'spread': '3.42', 'groupId': 'OG009'}, {'value': '-61.80', 'spread': '2.77', 'groupId': 'OG010'}, {'value': '-65.05', 'spread': '2.42', 'groupId': 'OG011'}, {'value': '7.55', 'spread': '2.39', 'groupId': 'OG012'}, {'value': '2.79', 'spread': '2.50', 'groupId': 'OG013'}, {'value': '-59.33', 'spread': '1.74', 'groupId': 'OG014'}, {'value': '-63.79', 'spread': '1.76', 'groupId': 'OG015'}, {'value': '6.57', 'spread': '3.11', 'groupId': 'OG016'}, {'value': '-0.02', 'spread': '3.51', 'groupId': 'OG017'}, {'value': '-59.08', 'spread': '2.23', 'groupId': 'OG018'}, {'value': '-62.94', 'spread': '2.44', 'groupId': 'OG019'}, {'value': '3.26', 'spread': '3.40', 'groupId': 'OG020'}, {'value': '6.00', 'spread': '4.80', 'groupId': 'OG021'}, {'value': '-66.17', 'spread': '2.93', 'groupId': 'OG022'}, {'value': '-62.45', 'spread': '3.85', 'groupId': 'OG023'}]}]}], 'analyses': [{'pValue': '<0.001', 'groupIds': ['OG000', 'OG004'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-69.95', 'ciLowerLimit': '-75.38', 'ciUpperLimit': '-64.51', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.76', 'groupDescription': 'The null hypothesis was that there was no difference in the percent change from Baseline in the average value of LDL-C at Weeks 10 and 12 between evolocumab and placebo, and the alternative hypothesis was that a mean difference did exist.', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG001', 'OG005'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-62.82', 'ciLowerLimit': '-69.06', 'ciUpperLimit': '-56.57', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.17', 'groupDescription': 'The null hypothesis was that there was no difference in the percent change from Baseline in the average value of LDL-C at Weeks 10 and 12 between evolocumab and placebo, and the alternative hypothesis was that a mean difference did exist.', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG002', 'OG004'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-37.53', 'ciLowerLimit': '-43.03', 'ciUpperLimit': '-32.03', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.79', 'groupDescription': 'The null hypothesis was that there was no difference in the percent change from Baseline in the average value of LDL-C at Weeks 10 and 12 between evolocumab and ezetimibe, and the alternative hypothesis was that a mean difference did exist.', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG003', 'OG005'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-43.49', 'ciLowerLimit': '-49.70', 'ciUpperLimit': '-37.28', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.15', 'groupDescription': 'The null hypothesis was that there was no difference in the percent change from Baseline in the average value of LDL-C at Weeks 10 and 12 between evolocumab and ezetimibe, and the alternative hypothesis was that a mean difference did exist.', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG006', 'OG010'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-74.92', 'ciLowerLimit': '-84.49', 'ciUpperLimit': '-65.35', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.85', 'groupDescription': 'The null hypothesis was that there was no difference in the percent change from Baseline in the average value of LDL-C at Weeks 10 and 12 between evolocumab and placebo, and the alternative hypothesis was that a mean difference did exist.', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG007', 'OG011'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-74.81', 'ciLowerLimit': '-83.00', 'ciUpperLimit': '-66.62', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.15', 'groupDescription': 'The null hypothesis was that there was no difference in the percent change from Baseline in the average value of LDL-C at Weeks 10 and 12 between evolocumab and placebo, and the alternative hypothesis was that a mean difference did exist.', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG008', 'OG010'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-44.95', 'ciLowerLimit': '-54.32', 'ciUpperLimit': '-35.57', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.75', 'groupDescription': 'The null hypothesis was that there was no difference in the percent change from Baseline in the average value of LDL-C at Weeks 10 and 12 between evolocumab and ezetimibe, and the alternative hypothesis was that a mean difference did exist.', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG009', 'OG011'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-43.81', 'ciLowerLimit': '-52.06', 'ciUpperLimit': '-35.55', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.19', 'groupDescription': 'The null hypothesis was that there was no difference in the percent change from Baseline in the average value of LDL-C at Weeks 10 and 12 between evolocumab and ezetimibe, and the alternative hypothesis was that a mean difference did exist.', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG012', 'OG014'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-66.88', 'ciLowerLimit': '-72.67', 'ciUpperLimit': '-61.08', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.93', 'groupDescription': 'The null hypothesis was that there was no difference in the percent change from Baseline in the average value of LDL-C at Weeks 10 and 12 between evolocumab and placebo, and the alternative hypothesis was that a mean difference did exist.', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG013', 'OG015'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-66.58', 'ciLowerLimit': '-72.60', 'ciUpperLimit': '-60.56', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.05', 'groupDescription': 'The null hypothesis was that there was no difference in the percent change from Baseline in the average value of LDL-C at Weeks 10 and 12 between evolocumab and placebo, and the alternative hypothesis was that a mean difference did exist.', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG016', 'OG018'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-65.66', 'ciLowerLimit': '-73.19', 'ciUpperLimit': '-58.12', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.81', 'groupDescription': 'The null hypothesis was that there was no difference in the percent change from Baseline in the average value of LDL-C at Weeks 10 and 12 between evolocumab and placebo, and the alternative hypothesis was that a mean difference did exist.', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG017', 'OG019'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-62.91', 'ciLowerLimit': '-71.37', 'ciUpperLimit': '-54.46', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.27', 'groupDescription': 'The null hypothesis was that there was no difference in the percent change from Baseline in the average value of LDL-C at Weeks 10 and 12 between evolocumab and placebo, and the alternative hypothesis was that a mean difference did exist.', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG020', 'OG022'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-69.43', 'ciLowerLimit': '-74.86', 'ciUpperLimit': '-64.01', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.74', 'groupDescription': 'The null hypothesis was that there was no difference in the percent change from Baseline in the average value of LDL-C at Weeks 10 and 12 between evolocumab and placebo, and the alternative hypothesis was that a mean difference did exist.', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG021', 'OG023'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-68.45', 'ciLowerLimit': '-76.68', 'ciUpperLimit': '-60.22', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.17', 'groupDescription': 'The null hypothesis was that there was no difference in the percent change from Baseline in the average value of LDL-C at Weeks 10 and 12 between evolocumab and placebo, and the alternative hypothesis was that a mean difference did exist.', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline and Weeks 10 and 12', 'unitOfMeasure': 'percent change', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in LDL-C at at the Mean of Weeks 10 and 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '56', 'groupId': 'OG000'}, {'value': '55', 'groupId': 'OG001'}, {'value': '56', 'groupId': 'OG002'}, {'value': '55', 'groupId': 'OG003'}, {'value': '110', 'groupId': 'OG004'}, {'value': '110', 'groupId': 'OG005'}, {'value': '55', 'groupId': 'OG006'}, {'value': '55', 'groupId': 'OG007'}, {'value': '56', 'groupId': 'OG008'}, {'value': '54', 'groupId': 'OG009'}, {'value': '109', 'groupId': 'OG010'}, {'value': '110', 'groupId': 'OG011'}, {'value': '58', 'groupId': 'OG012'}, {'value': '57', 'groupId': 'OG013'}, {'value': '113', 'groupId': 'OG014'}, {'value': '115', 'groupId': 'OG015'}, {'value': '56', 'groupId': 'OG016'}, {'value': '55', 'groupId': 'OG017'}, {'value': '111', 'groupId': 'OG018'}, {'value': '112', 'groupId': 'OG019'}, {'value': '56', 'groupId': 'OG020'}, {'value': '55', 'groupId': 'OG021'}, {'value': '112', 'groupId': 'OG022'}, {'value': '115', 'groupId': 'OG023'}]}], 'groups': [{'id': 'OG000', 'title': 'A10 PBO Q2W', 'description': 'Participants received atorvastatin 10 mg once daily during the 4 week lipid stabilization period and then in combination with placebo (PBO) subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG001', 'title': 'A10 PBO QM', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month (QM) and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG002', 'title': 'A10 EZE (Q2W)', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe (EZE) orally once daily for up to 12 weeks.'}, {'id': 'OG003', 'title': 'A10 EZE (QM)', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.'}, {'id': 'OG004', 'title': 'A10 EvoMab Q2W', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab (EvoMab) by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG005', 'title': 'A10 EvoMab QM', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG006', 'title': 'A80 PBO Q2W', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG007', 'title': 'A80 PBO QM', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG008', 'title': 'A80 EZE (Q2W)', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once daily for up to 12 weeks.'}, {'id': 'OG009', 'title': 'A80 EZE (QM)', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.'}, {'id': 'OG010', 'title': 'A80 EvoMab Q2W', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG011', 'title': 'A80 EvoMab QM', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG012', 'title': 'R5 PBO Q2W', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG013', 'title': 'R5 PBO QM', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG014', 'title': 'R5 EvoMab Q2W', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG015', 'title': 'R5 EvoMab QM', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG016', 'title': 'R40 PBO Q2W', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG017', 'title': 'R40 PBO QM', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG018', 'title': 'R40 EvoMab Q2W', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG019', 'title': 'R40 EvoMab QM', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG020', 'title': 'S40 PBO Q2W', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG021', 'title': 'S40 PBO QM', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG022', 'title': 'S40 EvoMab Q2W', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG023', 'title': 'S40 EvoMab QM', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.'}], 'classes': [{'categories': [{'measurements': [{'value': '6.8', 'spread': '3.7', 'groupId': 'OG000'}, {'value': '-0.4', 'spread': '4.4', 'groupId': 'OG001'}, {'value': '-32.4', 'spread': '3.8', 'groupId': 'OG002'}, {'value': '-25.1', 'spread': '4.3', 'groupId': 'OG003'}, {'value': '-76.8', 'spread': '2.7', 'groupId': 'OG004'}, {'value': '-80.1', 'spread': '3.1', 'groupId': 'OG005'}, {'value': '11.0', 'spread': '5.0', 'groupId': 'OG006'}, {'value': '5.5', 'spread': '3.7', 'groupId': 'OG007'}, {'value': '-13.0', 'spread': '4.9', 'groupId': 'OG008'}, {'value': '-21.3', 'spread': '3.7', 'groupId': 'OG009'}, {'value': '-58.8', 'spread': '3.5', 'groupId': 'OG010'}, {'value': '-60.1', 'spread': '2.6', 'groupId': 'OG011'}, {'value': '6.5', 'spread': '3.5', 'groupId': 'OG012'}, {'value': '0.1', 'spread': '4.2', 'groupId': 'OG013'}, {'value': '-68.9', 'spread': '2.5', 'groupId': 'OG014'}, {'value': '-77.8', 'spread': '3.0', 'groupId': 'OG015'}, {'value': '3.4', 'spread': '3.0', 'groupId': 'OG016'}, {'value': '-4.8', 'spread': '4.2', 'groupId': 'OG017'}, {'value': '-52.3', 'spread': '2.2', 'groupId': 'OG018'}, {'value': '-55.3', 'spread': '2.9', 'groupId': 'OG019'}, {'value': '-5.7', 'spread': '5.2', 'groupId': 'OG020'}, {'value': '1.7', 'spread': '6.5', 'groupId': 'OG021'}, {'value': '-83.8', 'spread': '4.5', 'groupId': 'OG022'}, {'value': '-78.4', 'spread': '5.1', 'groupId': 'OG023'}]}]}], 'analyses': [{'pValue': '<0.001', 'groupIds': ['OG000', 'OG004'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-83.6', 'ciLowerLimit': '-92.6', 'ciUpperLimit': '-74.6', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.5', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG001', 'OG005'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-79.7', 'ciLowerLimit': '-90.2', 'ciUpperLimit': '-69.2', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.3', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG002', 'OG004'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-44.4', 'ciLowerLimit': '-53.4', 'ciUpperLimit': '-35.3', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.4', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG003', 'OG005'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-55.0', 'ciLowerLimit': '-65.4', 'ciUpperLimit': '-44.6', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.3', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG006', 'OG010'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-69.9', 'ciLowerLimit': '-81.9', 'ciUpperLimit': '-57.8', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '6.1', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG007', 'OG011'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-65.6', 'ciLowerLimit': '-74.5', 'ciUpperLimit': '-56.7', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.5', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG008', 'OG010'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-45.8', 'ciLowerLimit': '-57.7', 'ciUpperLimit': '-33.9', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '6.0', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG009', 'OG011'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-38.8', 'ciLowerLimit': '-47.8', 'ciUpperLimit': '-29.9', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.5', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG012', 'OG014'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-75.4', 'ciLowerLimit': '-83.9', 'ciUpperLimit': '-67.0', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.3', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG013', 'OG015'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-77.9', 'ciLowerLimit': '-88.0', 'ciUpperLimit': '-67.8', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.1', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG016', 'OG018'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-55.8', 'ciLowerLimit': '-63.1', 'ciUpperLimit': '-48.4', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.7', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG017', 'OG019'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-50.6', 'ciLowerLimit': '-60.6', 'ciUpperLimit': '-40.6', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.1', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG020', 'OG022'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-78.1', 'ciLowerLimit': '-86.2', 'ciUpperLimit': '-70.0', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.1', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG021', 'OG023'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-80.1', 'ciLowerLimit': '-91.7', 'ciUpperLimit': '-68.6', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.8', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline and Weeks 10 and 12', 'unitOfMeasure': 'mg/dL', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in LDL-C at Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '56', 'groupId': 'OG000'}, {'value': '55', 'groupId': 'OG001'}, {'value': '56', 'groupId': 'OG002'}, {'value': '55', 'groupId': 'OG003'}, {'value': '110', 'groupId': 'OG004'}, {'value': '110', 'groupId': 'OG005'}, {'value': '55', 'groupId': 'OG006'}, {'value': '55', 'groupId': 'OG007'}, {'value': '56', 'groupId': 'OG008'}, {'value': '54', 'groupId': 'OG009'}, {'value': '109', 'groupId': 'OG010'}, {'value': '110', 'groupId': 'OG011'}, {'value': '58', 'groupId': 'OG012'}, {'value': '57', 'groupId': 'OG013'}, {'value': '113', 'groupId': 'OG014'}, {'value': '115', 'groupId': 'OG015'}, {'value': '56', 'groupId': 'OG016'}, {'value': '55', 'groupId': 'OG017'}, {'value': '111', 'groupId': 'OG018'}, {'value': '112', 'groupId': 'OG019'}, {'value': '56', 'groupId': 'OG020'}, {'value': '55', 'groupId': 'OG021'}, {'value': '112', 'groupId': 'OG022'}, {'value': '115', 'groupId': 'OG023'}]}], 'groups': [{'id': 'OG000', 'title': 'A10 PBO Q2W', 'description': 'Participants received atorvastatin 10 mg once daily during the 4 week lipid stabilization period and then in combination with placebo (PBO) subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG001', 'title': 'A10 PBO QM', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month (QM) and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG002', 'title': 'A10 EZE (Q2W)', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe (EZE) orally once daily for up to 12 weeks.'}, {'id': 'OG003', 'title': 'A10 EZE (QM)', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.'}, {'id': 'OG004', 'title': 'A10 EvoMab Q2W', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab (EvoMab) by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG005', 'title': 'A10 EvoMab QM', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG006', 'title': 'A80 PBO Q2W', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG007', 'title': 'A80 PBO QM', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG008', 'title': 'A80 EZE (Q2W)', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once daily for up to 12 weeks.'}, {'id': 'OG009', 'title': 'A80 EZE (QM)', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.'}, {'id': 'OG010', 'title': 'A80 EvoMab Q2W', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG011', 'title': 'A80 EvoMab QM', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG012', 'title': 'R5 PBO Q2W', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG013', 'title': 'R5 PBO QM', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG014', 'title': 'R5 EvoMab Q2W', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG015', 'title': 'R5 EvoMab QM', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG016', 'title': 'R40 PBO Q2W', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG017', 'title': 'R40 PBO QM', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG018', 'title': 'R40 EvoMab Q2W', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG019', 'title': 'R40 EvoMab QM', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG020', 'title': 'S40 PBO Q2W', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG021', 'title': 'S40 PBO QM', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG022', 'title': 'S40 EvoMab Q2W', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG023', 'title': 'S40 EvoMab QM', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.'}], 'classes': [{'categories': [{'measurements': [{'value': '8.6', 'spread': '4.0', 'groupId': 'OG000'}, {'value': '0.8', 'spread': '4.5', 'groupId': 'OG001'}, {'value': '-30.1', 'spread': '4.1', 'groupId': 'OG002'}, {'value': '-23.3', 'spread': '4.5', 'groupId': 'OG003'}, {'value': '-77.0', 'spread': '2.9', 'groupId': 'OG004'}, {'value': '-75.1', 'spread': '3.2', 'groupId': 'OG005'}, {'value': '12.7', 'spread': '5.3', 'groupId': 'OG006'}, {'value': '7.0', 'spread': '4.1', 'groupId': 'OG007'}, {'value': '-9.9', 'spread': '5.2', 'groupId': 'OG008'}, {'value': '-19.5', 'spread': '4.1', 'groupId': 'OG009'}, {'value': '-59.0', 'spread': '3.7', 'groupId': 'OG010'}, {'value': '-54.8', 'spread': '2.9', 'groupId': 'OG011'}, {'value': '7.8', 'spread': '3.8', 'groupId': 'OG012'}, {'value': '2.4', 'spread': '4.4', 'groupId': 'OG013'}, {'value': '-69.2', 'spread': '2.7', 'groupId': 'OG014'}, {'value': '-73.3', 'spread': '3.1', 'groupId': 'OG015'}, {'value': '5.1', 'spread': '3.2', 'groupId': 'OG016'}, {'value': '-2.0', 'spread': '4.7', 'groupId': 'OG017'}, {'value': '-52.1', 'spread': '2.3', 'groupId': 'OG018'}, {'value': '-46.7', 'spread': '3.3', 'groupId': 'OG019'}, {'value': '-4.5', 'spread': '5.3', 'groupId': 'OG020'}, {'value': '-0.6', 'spread': '6.6', 'groupId': 'OG021'}, {'value': '-83.5', 'spread': '4.6', 'groupId': 'OG022'}, {'value': '-72.5', 'spread': '5.2', 'groupId': 'OG023'}]}]}], 'analyses': [{'pValue': '<0.001', 'groupIds': ['OG000', 'OG004'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-85.5', 'ciLowerLimit': '-95.2', 'ciUpperLimit': '-75.9', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.9', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG001', 'OG005'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-75.8', 'ciLowerLimit': '-86.8', 'ciUpperLimit': '-64.9', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.5', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG002', 'OG004'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-46.8', 'ciLowerLimit': '-56.6', 'ciUpperLimit': '-37.1', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.9', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG003', 'OG005'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-51.7', 'ciLowerLimit': '-62.6', 'ciUpperLimit': '-40.9', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.5', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG006', 'OG010'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-71.7', 'ciLowerLimit': '-84.4', 'ciUpperLimit': '-59.0', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '6.4', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG007', 'OG011'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-61.8', 'ciLowerLimit': '-71.6', 'ciUpperLimit': '-52.0', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.0', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG008', 'OG010'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-49.0', 'ciLowerLimit': '-61.5', 'ciUpperLimit': '-36.6', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '6.3', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG009', 'OG011'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-35.3', 'ciLowerLimit': '-45.2', 'ciUpperLimit': '-25.5', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.0', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG012', 'OG014'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-77.1', 'ciLowerLimit': '-86.2', 'ciUpperLimit': '-67.9', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.6', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG013', 'OG015'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-75.8', 'ciLowerLimit': '-86.3', 'ciUpperLimit': '-65.3', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.3', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG016', 'OG018'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-57.2', 'ciLowerLimit': '-65.1', 'ciUpperLimit': '-49.4', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.0', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG017', 'OG019'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-44.6', 'ciLowerLimit': '-55.9', 'ciUpperLimit': '-33.4', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.7', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG020', 'OG022'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-79.0', 'ciLowerLimit': '-87.5', 'ciUpperLimit': '-70.4', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.3', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG021', 'OG023'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-71.9', 'ciLowerLimit': '-83.8', 'ciUpperLimit': '-60.0', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '6.0', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline and Week 12', 'unitOfMeasure': 'mg/dL', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set'}, {'type': 'SECONDARY', 'title': 'Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) at the Mean of Weeks 10 and 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '56', 'groupId': 'OG000'}, {'value': '55', 'groupId': 'OG001'}, {'value': '56', 'groupId': 'OG002'}, {'value': '55', 'groupId': 'OG003'}, {'value': '110', 'groupId': 'OG004'}, {'value': '110', 'groupId': 'OG005'}, {'value': '55', 'groupId': 'OG006'}, {'value': '55', 'groupId': 'OG007'}, {'value': '56', 'groupId': 'OG008'}, {'value': '54', 'groupId': 'OG009'}, {'value': '109', 'groupId': 'OG010'}, {'value': '110', 'groupId': 'OG011'}, {'value': '58', 'groupId': 'OG012'}, {'value': '57', 'groupId': 'OG013'}, {'value': '113', 'groupId': 'OG014'}, {'value': '115', 'groupId': 'OG015'}, {'value': '56', 'groupId': 'OG016'}, {'value': '55', 'groupId': 'OG017'}, {'value': '111', 'groupId': 'OG018'}, {'value': '112', 'groupId': 'OG019'}, {'value': '56', 'groupId': 'OG020'}, {'value': '55', 'groupId': 'OG021'}, {'value': '112', 'groupId': 'OG022'}, {'value': '115', 'groupId': 'OG023'}]}], 'groups': [{'id': 'OG000', 'title': 'A10 PBO Q2W', 'description': 'Participants received atorvastatin 10 mg once daily during the 4 week lipid stabilization period and then in combination with placebo (PBO) subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG001', 'title': 'A10 PBO QM', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month (QM) and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG002', 'title': 'A10 EZE (Q2W)', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe (EZE) orally once daily for up to 12 weeks.'}, {'id': 'OG003', 'title': 'A10 EZE (QM)', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.'}, {'id': 'OG004', 'title': 'A10 EvoMab Q2W', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab (EvoMab) by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG005', 'title': 'A10 EvoMab QM', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG006', 'title': 'A80 PBO Q2W', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG007', 'title': 'A80 PBO QM', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG008', 'title': 'A80 EZE (Q2W)', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once daily for up to 12 weeks.'}, {'id': 'OG009', 'title': 'A80 EZE (QM)', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.'}, {'id': 'OG010', 'title': 'A80 EvoMab Q2W', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG011', 'title': 'A80 EvoMab QM', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG012', 'title': 'R5 PBO Q2W', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG013', 'title': 'R5 PBO QM', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG014', 'title': 'R5 EvoMab Q2W', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG015', 'title': 'R5 EvoMab QM', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG016', 'title': 'R40 PBO Q2W', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG017', 'title': 'R40 PBO QM', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG018', 'title': 'R40 EvoMab Q2W', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG019', 'title': 'R40 EvoMab QM', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG020', 'title': 'S40 PBO Q2W', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG021', 'title': 'S40 PBO QM', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG022', 'title': 'S40 EvoMab Q2W', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG023', 'title': 'S40 EvoMab QM', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.'}], 'classes': [{'categories': [{'measurements': [{'value': '6.80', 'spread': '2.07', 'groupId': 'OG000'}, {'value': '1.28', 'spread': '2.44', 'groupId': 'OG001'}, {'value': '-20.71', 'spread': '2.15', 'groupId': 'OG002'}, {'value': '-16.56', 'spread': '2.41', 'groupId': 'OG003'}, {'value': '-53.48', 'spread': '1.48', 'groupId': 'OG004'}, {'value': '-56.09', 'spread': '1.71', 'groupId': 'OG005'}, {'value': '10.74', 'spread': '3.59', 'groupId': 'OG006'}, {'value': '8.45', 'spread': '3.13', 'groupId': 'OG007'}, {'value': '-16.19', 'spread': '3.49', 'groupId': 'OG008'}, {'value': '-18.79', 'spread': '3.16', 'groupId': 'OG009'}, {'value': '-54.44', 'spread': '2.49', 'groupId': 'OG010'}, {'value': '-56.31', 'spread': '2.23', 'groupId': 'OG011'}, {'value': '7.02', 'spread': '2.11', 'groupId': 'OG012'}, {'value': '3.73', 'spread': '2.32', 'groupId': 'OG013'}, {'value': '-52.59', 'spread': '1.54', 'groupId': 'OG014'}, {'value': '-55.47', 'spread': '1.64', 'groupId': 'OG015'}, {'value': '6.19', 'spread': '2.61', 'groupId': 'OG016'}, {'value': '1.58', 'spread': '2.90', 'groupId': 'OG017'}, {'value': '-52.08', 'spread': '1.88', 'groupId': 'OG018'}, {'value': '-55.72', 'spread': '2.01', 'groupId': 'OG019'}, {'value': '0.74', 'spread': '3.23', 'groupId': 'OG020'}, {'value': '6.81', 'spread': '4.35', 'groupId': 'OG021'}, {'value': '-59.33', 'spread': '2.79', 'groupId': 'OG022'}, {'value': '-56.01', 'spread': '3.49', 'groupId': 'OG023'}]}]}], 'analyses': [{'pValue': '<0.001', 'groupIds': ['OG000', 'OG004'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-60.28', 'ciLowerLimit': '-65.29', 'ciUpperLimit': '-55.27', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.54', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG001', 'OG005'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-57.37', 'ciLowerLimit': '-63.23', 'ciUpperLimit': '-51.51', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.97', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG002', 'OG004'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-32.77', 'ciLowerLimit': '-37.84', 'ciUpperLimit': '-27.70', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.57', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG003', 'OG005'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-39.53', 'ciLowerLimit': '-45.34', 'ciUpperLimit': '-33.71', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.95', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG006', 'OG010'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-65.17', 'ciLowerLimit': '-73.78', 'ciUpperLimit': '-56.56', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.37', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG007', 'OG011'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-64.76', 'ciLowerLimit': '-72.32', 'ciUpperLimit': '-57.19', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.84', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG008', 'OG010'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-38.25', 'ciLowerLimit': '-46.68', 'ciUpperLimit': '-29.81', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.28', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG009', 'OG011'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-37.52', 'ciLowerLimit': '-45.15', 'ciUpperLimit': '-29.90', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.87', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG012', 'OG014'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-59.61', 'ciLowerLimit': '-64.73', 'ciUpperLimit': '-54.48', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.60', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG013', 'OG015'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-59.20', 'ciLowerLimit': '-64.80', 'ciUpperLimit': '-53.60', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.83', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG016', 'OG018'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-58.27', 'ciLowerLimit': '-64.60', 'ciUpperLimit': '-51.94', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.20', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG017', 'OG019'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-57.31', 'ciLowerLimit': '-64.29', 'ciUpperLimit': '-50.32', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.53', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG020', 'OG022'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-60.06', 'ciLowerLimit': '-65.18', 'ciUpperLimit': '-54.94', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.59', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG021', 'OG023'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-62.82', 'ciLowerLimit': '-70.22', 'ciUpperLimit': '-55.42', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.75', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline and Weeks 10 and 12', 'unitOfMeasure': 'percent change', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set'}, {'type': 'SECONDARY', 'title': 'Percent Change From Baseline in Non-HDL-C at Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '56', 'groupId': 'OG000'}, {'value': '55', 'groupId': 'OG001'}, {'value': '56', 'groupId': 'OG002'}, {'value': '55', 'groupId': 'OG003'}, {'value': '110', 'groupId': 'OG004'}, {'value': '110', 'groupId': 'OG005'}, {'value': '55', 'groupId': 'OG006'}, {'value': '55', 'groupId': 'OG007'}, {'value': '56', 'groupId': 'OG008'}, {'value': '54', 'groupId': 'OG009'}, {'value': '109', 'groupId': 'OG010'}, {'value': '110', 'groupId': 'OG011'}, {'value': '58', 'groupId': 'OG012'}, {'value': '57', 'groupId': 'OG013'}, {'value': '113', 'groupId': 'OG014'}, {'value': '115', 'groupId': 'OG015'}, {'value': '56', 'groupId': 'OG016'}, {'value': '55', 'groupId': 'OG017'}, {'value': '111', 'groupId': 'OG018'}, {'value': '112', 'groupId': 'OG019'}, {'value': '56', 'groupId': 'OG020'}, {'value': '55', 'groupId': 'OG021'}, {'value': '112', 'groupId': 'OG022'}, {'value': '115', 'groupId': 'OG023'}]}], 'groups': [{'id': 'OG000', 'title': 'A10 PBO Q2W', 'description': 'Participants received atorvastatin 10 mg once daily during the 4 week lipid stabilization period and then in combination with placebo (PBO) subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG001', 'title': 'A10 PBO QM', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month (QM) and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG002', 'title': 'A10 EZE (Q2W)', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe (EZE) orally once daily for up to 12 weeks.'}, {'id': 'OG003', 'title': 'A10 EZE (QM)', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.'}, {'id': 'OG004', 'title': 'A10 EvoMab Q2W', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab (EvoMab) by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG005', 'title': 'A10 EvoMab QM', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG006', 'title': 'A80 PBO Q2W', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG007', 'title': 'A80 PBO QM', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG008', 'title': 'A80 EZE (Q2W)', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once daily for up to 12 weeks.'}, {'id': 'OG009', 'title': 'A80 EZE (QM)', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.'}, {'id': 'OG010', 'title': 'A80 EvoMab Q2W', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG011', 'title': 'A80 EvoMab QM', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG012', 'title': 'R5 PBO Q2W', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG013', 'title': 'R5 PBO QM', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG014', 'title': 'R5 EvoMab Q2W', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG015', 'title': 'R5 EvoMab QM', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG016', 'title': 'R40 PBO Q2W', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG017', 'title': 'R40 PBO QM', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG018', 'title': 'R40 EvoMab Q2W', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG019', 'title': 'R40 EvoMab QM', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG020', 'title': 'S40 PBO Q2W', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG021', 'title': 'S40 PBO QM', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG022', 'title': 'S40 EvoMab Q2W', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG023', 'title': 'S40 EvoMab QM', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.'}], 'classes': [{'categories': [{'measurements': [{'value': '8.25', 'spread': '2.32', 'groupId': 'OG000'}, {'value': '2.43', 'spread': '2.69', 'groupId': 'OG001'}, {'value': '-18.27', 'spread': '2.40', 'groupId': 'OG002'}, {'value': '-14.78', 'spread': '2.65', 'groupId': 'OG003'}, {'value': '-53.39', 'spread': '1.66', 'groupId': 'OG004'}, {'value': '-52.20', 'spread': '1.90', 'groupId': 'OG005'}, {'value': '11.79', 'spread': '3.87', 'groupId': 'OG006'}, {'value': '9.95', 'spread': '3.51', 'groupId': 'OG007'}, {'value': '-14.34', 'spread': '3.75', 'groupId': 'OG008'}, {'value': '-17.26', 'spread': '3.52', 'groupId': 'OG009'}, {'value': '-54.84', 'spread': '2.66', 'groupId': 'OG010'}, {'value': '-50.05', 'spread': '2.50', 'groupId': 'OG011'}, {'value': '7.92', 'spread': '2.40', 'groupId': 'OG012'}, {'value': '5.85', 'spread': '2.42', 'groupId': 'OG013'}, {'value': '-52.04', 'spread': '1.74', 'groupId': 'OG014'}, {'value': '-51.57', 'spread': '1.72', 'groupId': 'OG015'}, {'value': '8.61', 'spread': '3.04', 'groupId': 'OG016'}, {'value': '3.35', 'spread': '3.53', 'groupId': 'OG017'}, {'value': '-50.97', 'spread': '2.18', 'groupId': 'OG018'}, {'value': '-46.42', 'spread': '2.45', 'groupId': 'OG019'}, {'value': '1.89', 'spread': '3.38', 'groupId': 'OG020'}, {'value': '5.66', 'spread': '4.53', 'groupId': 'OG021'}, {'value': '-59.02', 'spread': '2.87', 'groupId': 'OG022'}, {'value': '-50.96', 'spread': '3.60', 'groupId': 'OG023'}]}]}], 'analyses': [{'pValue': '<0.001', 'groupIds': ['OG000', 'OG004'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-61.64', 'ciLowerLimit': '-67.25', 'ciUpperLimit': '-56.03', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.84', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG001', 'OG005'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-54.93', 'ciLowerLimit': '-61.40', 'ciUpperLimit': '-48.46', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.28', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG002', 'OG004'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-35.11', 'ciLowerLimit': '-40.79', 'ciUpperLimit': '-29.44', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.88', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG003', 'OG005'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-37.72', 'ciLowerLimit': '-44.15', 'ciUpperLimit': '-31.30', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.26', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG006', 'OG010'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-66.64', 'ciLowerLimit': '-75.88', 'ciUpperLimit': '-57.39', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.69', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG007', 'OG011'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-60.01', 'ciLowerLimit': '-68.49', 'ciUpperLimit': '-51.52', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.30', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG008', 'OG010'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-40.51', 'ciLowerLimit': '-49.55', 'ciUpperLimit': '-31.47', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.59', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG009', 'OG011'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-32.79', 'ciLowerLimit': '-41.30', 'ciUpperLimit': '-24.28', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.32', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG012', 'OG014'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-59.96', 'ciLowerLimit': '-65.78', 'ciUpperLimit': '-54.13', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.95', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG013', 'OG015'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-57.42', 'ciLowerLimit': '-63.27', 'ciUpperLimit': '-51.57', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.96', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG016', 'OG018'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-59.58', 'ciLowerLimit': '-66.95', 'ciUpperLimit': '-52.21', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.73', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG017', 'OG019'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-49.76', 'ciLowerLimit': '-58.26', 'ciUpperLimit': '-41.27', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.30', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG020', 'OG022'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-60.91', 'ciLowerLimit': '-66.57', 'ciUpperLimit': '-55.24', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.87', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG021', 'OG023'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-56.63', 'ciLowerLimit': '-64.63', 'ciUpperLimit': '-48.62', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.06', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline and Week 12', 'unitOfMeasure': 'percent change', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set'}, {'type': 'SECONDARY', 'title': 'Percent Change From Baseline in Apolipoprotein B at the Mean of Weeks 10 and 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '56', 'groupId': 'OG000'}, {'value': '55', 'groupId': 'OG001'}, {'value': '56', 'groupId': 'OG002'}, {'value': '55', 'groupId': 'OG003'}, {'value': '110', 'groupId': 'OG004'}, {'value': '110', 'groupId': 'OG005'}, {'value': '55', 'groupId': 'OG006'}, {'value': '55', 'groupId': 'OG007'}, {'value': '56', 'groupId': 'OG008'}, {'value': '54', 'groupId': 'OG009'}, {'value': '109', 'groupId': 'OG010'}, {'value': '110', 'groupId': 'OG011'}, {'value': '58', 'groupId': 'OG012'}, {'value': '57', 'groupId': 'OG013'}, {'value': '113', 'groupId': 'OG014'}, {'value': '115', 'groupId': 'OG015'}, {'value': '56', 'groupId': 'OG016'}, {'value': '55', 'groupId': 'OG017'}, {'value': '111', 'groupId': 'OG018'}, {'value': '112', 'groupId': 'OG019'}, {'value': '56', 'groupId': 'OG020'}, {'value': '55', 'groupId': 'OG021'}, {'value': '112', 'groupId': 'OG022'}, {'value': '115', 'groupId': 'OG023'}]}], 'groups': [{'id': 'OG000', 'title': 'A10 PBO Q2W', 'description': 'Participants received atorvastatin 10 mg once daily during the 4 week lipid stabilization period and then in combination with placebo (PBO) subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG001', 'title': 'A10 PBO QM', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month (QM) and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG002', 'title': 'A10 EZE (Q2W)', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe (EZE) orally once daily for up to 12 weeks.'}, {'id': 'OG003', 'title': 'A10 EZE (QM)', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.'}, {'id': 'OG004', 'title': 'A10 EvoMab Q2W', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab (EvoMab) by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG005', 'title': 'A10 EvoMab QM', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG006', 'title': 'A80 PBO Q2W', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG007', 'title': 'A80 PBO QM', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG008', 'title': 'A80 EZE (Q2W)', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once daily for up to 12 weeks.'}, {'id': 'OG009', 'title': 'A80 EZE (QM)', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.'}, {'id': 'OG010', 'title': 'A80 EvoMab Q2W', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG011', 'title': 'A80 EvoMab QM', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG012', 'title': 'R5 PBO Q2W', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG013', 'title': 'R5 PBO QM', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG014', 'title': 'R5 EvoMab Q2W', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG015', 'title': 'R5 EvoMab QM', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG016', 'title': 'R40 PBO Q2W', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG017', 'title': 'R40 PBO QM', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG018', 'title': 'R40 EvoMab Q2W', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG019', 'title': 'R40 EvoMab QM', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG020', 'title': 'S40 PBO Q2W', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG021', 'title': 'S40 PBO QM', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG022', 'title': 'S40 EvoMab Q2W', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG023', 'title': 'S40 EvoMab QM', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.'}], 'classes': [{'categories': [{'measurements': [{'value': '7.55', 'spread': '1.89', 'groupId': 'OG000'}, {'value': '0.81', 'spread': '2.19', 'groupId': 'OG001'}, {'value': '-17.29', 'spread': '2.00', 'groupId': 'OG002'}, {'value': '-11.43', 'spread': '2.20', 'groupId': 'OG003'}, {'value': '-50.95', 'spread': '1.38', 'groupId': 'OG004'}, {'value': '-51.44', 'spread': '1.52', 'groupId': 'OG005'}, {'value': '10.20', 'spread': '3.02', 'groupId': 'OG006'}, {'value': '5.48', 'spread': '2.83', 'groupId': 'OG007'}, {'value': '-14.22', 'spread': '2.98', 'groupId': 'OG008'}, {'value': '-13.62', 'spread': '2.87', 'groupId': 'OG009'}, {'value': '-49.14', 'spread': '2.13', 'groupId': 'OG010'}, {'value': '-53.26', 'spread': '2.02', 'groupId': 'OG011'}, {'value': '5.07', 'spread': '1.97', 'groupId': 'OG012'}, {'value': '2.54', 'spread': '1.89', 'groupId': 'OG013'}, {'value': '-49.79', 'spread': '1.46', 'groupId': 'OG014'}, {'value': '-53.59', 'spread': '1.32', 'groupId': 'OG015'}, {'value': '3.71', 'spread': '2.46', 'groupId': 'OG016'}, {'value': '1.98', 'spread': '2.57', 'groupId': 'OG017'}, {'value': '-47.07', 'spread': '1.76', 'groupId': 'OG018'}, {'value': '-52.95', 'spread': '1.76', 'groupId': 'OG019'}, {'value': '-0.31', 'spread': '3.02', 'groupId': 'OG020'}, {'value': '2.49', 'spread': '4.67', 'groupId': 'OG021'}, {'value': '-55.65', 'spread': '2.63', 'groupId': 'OG022'}, {'value': '-54.37', 'spread': '3.93', 'groupId': 'OG023'}]}]}], 'analyses': [{'pValue': '<0.001', 'groupIds': ['OG000', 'OG004'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-58.49', 'ciLowerLimit': '-63.10', 'ciUpperLimit': '-53.89', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.34', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG001', 'OG005'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-52.25', 'ciLowerLimit': '-57.49', 'ciUpperLimit': '-47.01', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.66', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG002', 'OG004'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-33.66', 'ciLowerLimit': '-38.33', 'ciUpperLimit': '-28.98', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.37', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG003', 'OG005'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-40.01', 'ciLowerLimit': '-45.27', 'ciUpperLimit': '-34.74', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.67', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG006', 'OG010'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-59.34', 'ciLowerLimit': '-66.61', 'ciUpperLimit': '-52.07', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.69', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG007', 'OG011'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-58.74', 'ciLowerLimit': '-65.56', 'ciUpperLimit': '-51.93', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.46', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG008', 'OG010'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-34.92', 'ciLowerLimit': '-42.09', 'ciUpperLimit': '-27.75', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.64', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG009', 'OG011'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-39.64', 'ciLowerLimit': '-46.57', 'ciUpperLimit': '-32.71', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.52', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG012', 'OG014'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-54.86', 'ciLowerLimit': '-59.66', 'ciUpperLimit': '-50.05', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.43', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG013', 'OG015'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-56.14', 'ciLowerLimit': '-60.66', 'ciUpperLimit': '-51.61', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.29', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG016', 'OG018'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-50.78', 'ciLowerLimit': '-56.72', 'ciUpperLimit': '-44.83', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.01', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG017', 'OG019'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-54.94', 'ciLowerLimit': '-61.11', 'ciUpperLimit': '-48.76', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.12', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG020', 'OG022'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-55.34', 'ciLowerLimit': '-59.94', 'ciUpperLimit': '-50.74', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.33', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG021', 'OG023'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-56.87', 'ciLowerLimit': '-63.27', 'ciUpperLimit': '-50.46', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.24', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline and Weeks 10 and 12', 'unitOfMeasure': 'percent change', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set'}, {'type': 'SECONDARY', 'title': 'Percent Change From Baseline in Apolipoprotein B at Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '56', 'groupId': 'OG000'}, {'value': '55', 'groupId': 'OG001'}, {'value': '56', 'groupId': 'OG002'}, {'value': '55', 'groupId': 'OG003'}, {'value': '110', 'groupId': 'OG004'}, {'value': '110', 'groupId': 'OG005'}, {'value': '55', 'groupId': 'OG006'}, {'value': '55', 'groupId': 'OG007'}, {'value': '56', 'groupId': 'OG008'}, {'value': '54', 'groupId': 'OG009'}, {'value': '109', 'groupId': 'OG010'}, {'value': '110', 'groupId': 'OG011'}, {'value': '58', 'groupId': 'OG012'}, {'value': '57', 'groupId': 'OG013'}, {'value': '113', 'groupId': 'OG014'}, {'value': '115', 'groupId': 'OG015'}, {'value': '56', 'groupId': 'OG016'}, {'value': '55', 'groupId': 'OG017'}, {'value': '111', 'groupId': 'OG018'}, {'value': '112', 'groupId': 'OG019'}, {'value': '56', 'groupId': 'OG020'}, {'value': '55', 'groupId': 'OG021'}, {'value': '112', 'groupId': 'OG022'}, {'value': '115', 'groupId': 'OG023'}]}], 'groups': [{'id': 'OG000', 'title': 'A10 PBO Q2W', 'description': 'Participants received atorvastatin 10 mg once daily during the 4 week lipid stabilization period and then in combination with placebo (PBO) subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG001', 'title': 'A10 PBO QM', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month (QM) and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG002', 'title': 'A10 EZE (Q2W)', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe (EZE) orally once daily for up to 12 weeks.'}, {'id': 'OG003', 'title': 'A10 EZE (QM)', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.'}, {'id': 'OG004', 'title': 'A10 EvoMab Q2W', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab (EvoMab) by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG005', 'title': 'A10 EvoMab QM', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG006', 'title': 'A80 PBO Q2W', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG007', 'title': 'A80 PBO QM', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG008', 'title': 'A80 EZE (Q2W)', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once daily for up to 12 weeks.'}, {'id': 'OG009', 'title': 'A80 EZE (QM)', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.'}, {'id': 'OG010', 'title': 'A80 EvoMab Q2W', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG011', 'title': 'A80 EvoMab QM', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG012', 'title': 'R5 PBO Q2W', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG013', 'title': 'R5 PBO QM', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG014', 'title': 'R5 EvoMab Q2W', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG015', 'title': 'R5 EvoMab QM', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG016', 'title': 'R40 PBO Q2W', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG017', 'title': 'R40 PBO QM', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG018', 'title': 'R40 EvoMab Q2W', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG019', 'title': 'R40 EvoMab QM', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG020', 'title': 'S40 PBO Q2W', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG021', 'title': 'S40 PBO QM', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG022', 'title': 'S40 EvoMab Q2W', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG023', 'title': 'S40 EvoMab QM', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.'}], 'classes': [{'categories': [{'measurements': [{'value': '7.89', 'spread': '2.16', 'groupId': 'OG000'}, {'value': '0.21', 'spread': '2.43', 'groupId': 'OG001'}, {'value': '-15.98', 'spread': '2.26', 'groupId': 'OG002'}, {'value': '-10.95', 'spread': '2.44', 'groupId': 'OG003'}, {'value': '-50.90', 'spread': '1.56', 'groupId': 'OG004'}, {'value': '-47.15', 'spread': '1.70', 'groupId': 'OG005'}, {'value': '11.64', 'spread': '3.28', 'groupId': 'OG006'}, {'value': '6.54', 'spread': '3.22', 'groupId': 'OG007'}, {'value': '-12.31', 'spread': '3.20', 'groupId': 'OG008'}, {'value': '-12.16', 'spread': '3.24', 'groupId': 'OG009'}, {'value': '-49.77', 'spread': '2.28', 'groupId': 'OG010'}, {'value': '-46.47', 'spread': '2.31', 'groupId': 'OG011'}, {'value': '6.35', 'spread': '2.10', 'groupId': 'OG012'}, {'value': '4.63', 'spread': '2.11', 'groupId': 'OG013'}, {'value': '-50.15', 'spread': '1.54', 'groupId': 'OG014'}, {'value': '-48.58', 'spread': '1.49', 'groupId': 'OG015'}, {'value': '4.91', 'spread': '2.71', 'groupId': 'OG016'}, {'value': '3.24', 'spread': '3.13', 'groupId': 'OG017'}, {'value': '-45.61', 'spread': '1.93', 'groupId': 'OG018'}, {'value': '-43.71', 'spread': '2.13', 'groupId': 'OG019'}, {'value': '0.35', 'spread': '3.17', 'groupId': 'OG020'}, {'value': '3.57', 'spread': '4.74', 'groupId': 'OG021'}, {'value': '-55.95', 'spread': '2.72', 'groupId': 'OG022'}, {'value': '-49.16', 'spread': '3.97', 'groupId': 'OG023'}]}]}], 'analyses': [{'pValue': '<0.001', 'groupIds': ['OG000', 'OG004'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-58.79', 'ciLowerLimit': '-64.03', 'ciUpperLimit': '-53.55', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.66', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG001', 'OG005'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-47.36', 'ciLowerLimit': '-53.20', 'ciUpperLimit': '-41.52', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.96', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG002', 'OG004'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-34.92', 'ciLowerLimit': '-40.23', 'ciUpperLimit': '-29.60', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.69', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG003', 'OG005'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-36.21', 'ciLowerLimit': '-42.06', 'ciUpperLimit': '-30.35', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.97', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG006', 'OG010'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-61.40', 'ciLowerLimit': '-69.27', 'ciUpperLimit': '-53.54', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.99', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG007', 'OG011'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-53.01', 'ciLowerLimit': '-60.77', 'ciUpperLimit': '-45.25', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.93', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG008', 'OG010'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-37.45', 'ciLowerLimit': '-45.17', 'ciUpperLimit': '-29.74', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.91', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG009', 'OG011'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-34.31', 'ciLowerLimit': '-42.15', 'ciUpperLimit': '-26.47', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.98', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG012', 'OG014'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-56.50', 'ciLowerLimit': '-61.60', 'ciUpperLimit': '-51.40', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.58', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG013', 'OG015'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-53.21', 'ciLowerLimit': '-58.29', 'ciUpperLimit': '-48.13', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.57', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG016', 'OG018'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-50.52', 'ciLowerLimit': '-57.06', 'ciUpperLimit': '-43.99', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.31', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG017', 'OG019'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-46.95', 'ciLowerLimit': '-54.43', 'ciUpperLimit': '-39.47', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.78', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG020', 'OG022'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-56.30', 'ciLowerLimit': '-61.47', 'ciUpperLimit': '-51.14', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.61', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG021', 'OG023'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-52.73', 'ciLowerLimit': '-59.40', 'ciUpperLimit': '-46.06', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.38', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline and Week 12', 'unitOfMeasure': 'percent change', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set'}, {'type': 'SECONDARY', 'title': 'Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at the Mean of Weeks 10 and 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '56', 'groupId': 'OG000'}, {'value': '55', 'groupId': 'OG001'}, {'value': '56', 'groupId': 'OG002'}, {'value': '55', 'groupId': 'OG003'}, {'value': '110', 'groupId': 'OG004'}, {'value': '110', 'groupId': 'OG005'}, {'value': '55', 'groupId': 'OG006'}, {'value': '55', 'groupId': 'OG007'}, {'value': '56', 'groupId': 'OG008'}, {'value': '54', 'groupId': 'OG009'}, {'value': '109', 'groupId': 'OG010'}, {'value': '110', 'groupId': 'OG011'}, {'value': '58', 'groupId': 'OG012'}, {'value': '57', 'groupId': 'OG013'}, {'value': '113', 'groupId': 'OG014'}, {'value': '115', 'groupId': 'OG015'}, {'value': '56', 'groupId': 'OG016'}, {'value': '55', 'groupId': 'OG017'}, {'value': '111', 'groupId': 'OG018'}, {'value': '112', 'groupId': 'OG019'}, {'value': '56', 'groupId': 'OG020'}, {'value': '55', 'groupId': 'OG021'}, {'value': '112', 'groupId': 'OG022'}, {'value': '115', 'groupId': 'OG023'}]}], 'groups': [{'id': 'OG000', 'title': 'A10 PBO Q2W', 'description': 'Participants received atorvastatin 10 mg once daily during the 4 week lipid stabilization period and then in combination with placebo (PBO) subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG001', 'title': 'A10 PBO QM', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month (QM) and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG002', 'title': 'A10 EZE (Q2W)', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe (EZE) orally once daily for up to 12 weeks.'}, {'id': 'OG003', 'title': 'A10 EZE (QM)', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.'}, {'id': 'OG004', 'title': 'A10 EvoMab Q2W', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab (EvoMab) by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG005', 'title': 'A10 EvoMab QM', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG006', 'title': 'A80 PBO Q2W', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG007', 'title': 'A80 PBO QM', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG008', 'title': 'A80 EZE (Q2W)', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once daily for up to 12 weeks.'}, {'id': 'OG009', 'title': 'A80 EZE (QM)', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.'}, {'id': 'OG010', 'title': 'A80 EvoMab Q2W', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG011', 'title': 'A80 EvoMab QM', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG012', 'title': 'R5 PBO Q2W', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG013', 'title': 'R5 PBO QM', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG014', 'title': 'R5 EvoMab Q2W', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG015', 'title': 'R5 EvoMab QM', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG016', 'title': 'R40 PBO Q2W', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG017', 'title': 'R40 PBO QM', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG018', 'title': 'R40 EvoMab Q2W', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG019', 'title': 'R40 EvoMab QM', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG020', 'title': 'S40 PBO Q2W', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG021', 'title': 'S40 PBO QM', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG022', 'title': 'S40 EvoMab Q2W', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG023', 'title': 'S40 EvoMab QM', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.'}], 'classes': [{'categories': [{'measurements': [{'value': '5.96', 'spread': '1.76', 'groupId': 'OG000'}, {'value': '2.24', 'spread': '2.11', 'groupId': 'OG001'}, {'value': '-14.39', 'spread': '1.83', 'groupId': 'OG002'}, {'value': '-10.86', 'spread': '2.08', 'groupId': 'OG003'}, {'value': '-40.44', 'spread': '1.26', 'groupId': 'OG004'}, {'value': '-42.45', 'spread': '1.48', 'groupId': 'OG005'}, {'value': '4.26', 'spread': '2.59', 'groupId': 'OG006'}, {'value': '6.42', 'spread': '2.34', 'groupId': 'OG007'}, {'value': '-11.92', 'spread': '2.52', 'groupId': 'OG008'}, {'value': '-12.25', 'spread': '2.35', 'groupId': 'OG009'}, {'value': '-40.22', 'spread': '1.80', 'groupId': 'OG010'}, {'value': '-40.43', 'spread': '1.66', 'groupId': 'OG011'}, {'value': '5.41', 'spread': '1.96', 'groupId': 'OG012'}, {'value': '5.02', 'spread': '2.25', 'groupId': 'OG013'}, {'value': '-39.33', 'spread': '1.43', 'groupId': 'OG014'}, {'value': '-42.00', 'spread': '1.59', 'groupId': 'OG015'}, {'value': '4.55', 'spread': '1.98', 'groupId': 'OG016'}, {'value': '1.71', 'spread': '2.36', 'groupId': 'OG017'}, {'value': '-36.04', 'spread': '1.42', 'groupId': 'OG018'}, {'value': '-38.62', 'spread': '1.64', 'groupId': 'OG019'}, {'value': '-0.14', 'spread': '2.79', 'groupId': 'OG020'}, {'value': '5.45', 'spread': '3.50', 'groupId': 'OG021'}, {'value': '-47.20', 'spread': '2.37', 'groupId': 'OG022'}, {'value': '-43.17', 'spread': '2.85', 'groupId': 'OG023'}]}]}], 'analyses': [{'pValue': '<0.001', 'groupIds': ['OG000', 'OG004'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-46.41', 'ciLowerLimit': '-50.66', 'ciUpperLimit': '-42.15', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.16', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG001', 'OG005'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-44.69', 'ciLowerLimit': '-49.75', 'ciUpperLimit': '-39.63', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.57', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG002', 'OG004'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-26.06', 'ciLowerLimit': '-30.36', 'ciUpperLimit': '-21.75', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.19', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG003', 'OG005'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-31.59', 'ciLowerLimit': '-36.61', 'ciUpperLimit': '-26.57', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.55', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG006', 'OG010'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-44.48', 'ciLowerLimit': '-50.69', 'ciUpperLimit': '-38.27', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.15', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG007', 'OG011'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-46.85', 'ciLowerLimit': '-52.48', 'ciUpperLimit': '-41.21', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.86', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG008', 'OG010'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-28.30', 'ciLowerLimit': '-34.39', 'ciUpperLimit': '-22.21', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.09', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG009', 'OG011'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-28.18', 'ciLowerLimit': '-33.86', 'ciUpperLimit': '-22.50', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.88', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG012', 'OG014'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-44.73', 'ciLowerLimit': '-49.50', 'ciUpperLimit': '-39.97', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.41', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG013', 'OG015'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-47.01', 'ciLowerLimit': '-52.46', 'ciUpperLimit': '-41.57', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.75', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG016', 'OG018'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-40.59', 'ciLowerLimit': '-45.38', 'ciUpperLimit': '-35.79', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.43', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG017', 'OG019'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-40.33', 'ciLowerLimit': '-46.00', 'ciUpperLimit': '-34.66', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.87', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG020', 'OG022'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-47.05', 'ciLowerLimit': '-51.76', 'ciUpperLimit': '-42.35', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.38', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG021', 'OG023'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-48.62', 'ciLowerLimit': '-54.27', 'ciUpperLimit': '-42.98', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.86', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline and Weeks 10 and 12', 'unitOfMeasure': 'percent change', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set'}, {'type': 'SECONDARY', 'title': 'Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '56', 'groupId': 'OG000'}, {'value': '55', 'groupId': 'OG001'}, {'value': '56', 'groupId': 'OG002'}, {'value': '55', 'groupId': 'OG003'}, {'value': '110', 'groupId': 'OG004'}, {'value': '110', 'groupId': 'OG005'}, {'value': '55', 'groupId': 'OG006'}, {'value': '55', 'groupId': 'OG007'}, {'value': '56', 'groupId': 'OG008'}, {'value': '54', 'groupId': 'OG009'}, {'value': '109', 'groupId': 'OG010'}, {'value': '110', 'groupId': 'OG011'}, {'value': '58', 'groupId': 'OG012'}, {'value': '57', 'groupId': 'OG013'}, {'value': '113', 'groupId': 'OG014'}, {'value': '115', 'groupId': 'OG015'}, {'value': '56', 'groupId': 'OG016'}, {'value': '55', 'groupId': 'OG017'}, {'value': '111', 'groupId': 'OG018'}, {'value': '112', 'groupId': 'OG019'}, {'value': '56', 'groupId': 'OG020'}, {'value': '55', 'groupId': 'OG021'}, {'value': '112', 'groupId': 'OG022'}, {'value': '115', 'groupId': 'OG023'}]}], 'groups': [{'id': 'OG000', 'title': 'A10 PBO Q2W', 'description': 'Participants received atorvastatin 10 mg once daily during the 4 week lipid stabilization period and then in combination with placebo (PBO) subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG001', 'title': 'A10 PBO QM', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month (QM) and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG002', 'title': 'A10 EZE (Q2W)', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe (EZE) orally once daily for up to 12 weeks.'}, {'id': 'OG003', 'title': 'A10 EZE (QM)', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.'}, {'id': 'OG004', 'title': 'A10 EvoMab Q2W', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab (EvoMab) by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG005', 'title': 'A10 EvoMab QM', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG006', 'title': 'A80 PBO Q2W', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG007', 'title': 'A80 PBO QM', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG008', 'title': 'A80 EZE (Q2W)', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once daily for up to 12 weeks.'}, {'id': 'OG009', 'title': 'A80 EZE (QM)', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.'}, {'id': 'OG010', 'title': 'A80 EvoMab Q2W', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG011', 'title': 'A80 EvoMab QM', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG012', 'title': 'R5 PBO Q2W', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG013', 'title': 'R5 PBO QM', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG014', 'title': 'R5 EvoMab Q2W', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG015', 'title': 'R5 EvoMab QM', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG016', 'title': 'R40 PBO Q2W', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG017', 'title': 'R40 PBO QM', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG018', 'title': 'R40 EvoMab Q2W', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG019', 'title': 'R40 EvoMab QM', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG020', 'title': 'S40 PBO Q2W', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG021', 'title': 'S40 PBO QM', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG022', 'title': 'S40 EvoMab Q2W', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG023', 'title': 'S40 EvoMab QM', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.'}], 'classes': [{'categories': [{'measurements': [{'value': '6.09', 'spread': '2.02', 'groupId': 'OG000'}, {'value': '2.80', 'spread': '2.31', 'groupId': 'OG001'}, {'value': '-12.14', 'spread': '2.10', 'groupId': 'OG002'}, {'value': '-9.85', 'spread': '2.28', 'groupId': 'OG003'}, {'value': '-40.74', 'spread': '1.45', 'groupId': 'OG004'}, {'value': '-40.07', 'spread': '1.63', 'groupId': 'OG005'}, {'value': '4.31', 'spread': '2.75', 'groupId': 'OG006'}, {'value': '6.18', 'spread': '2.73', 'groupId': 'OG007'}, {'value': '-10.53', 'spread': '2.66', 'groupId': 'OG008'}, {'value': '-11.06', 'spread': '2.73', 'groupId': 'OG009'}, {'value': '-40.79', 'spread': '1.89', 'groupId': 'OG010'}, {'value': '-36.25', 'spread': '1.94', 'groupId': 'OG011'}, {'value': '4.68', 'spread': '2.28', 'groupId': 'OG012'}, {'value': '6.07', 'spread': '2.36', 'groupId': 'OG013'}, {'value': '-38.57', 'spread': '1.64', 'groupId': 'OG014'}, {'value': '-39.26', 'spread': '1.68', 'groupId': 'OG015'}, {'value': '5.96', 'spread': '2.28', 'groupId': 'OG016'}, {'value': '2.69', 'spread': '2.80', 'groupId': 'OG017'}, {'value': '-35.17', 'spread': '1.63', 'groupId': 'OG018'}, {'value': '-32.30', 'spread': '1.94', 'groupId': 'OG019'}, {'value': '-0.20', 'spread': '2.81', 'groupId': 'OG020'}, {'value': '5.13', 'spread': '3.62', 'groupId': 'OG021'}, {'value': '-47.24', 'spread': '2.38', 'groupId': 'OG022'}, {'value': '-39.47', 'spread': '2.92', 'groupId': 'OG023'}]}]}], 'analyses': [{'pValue': '<0.001', 'groupIds': ['OG000', 'OG004'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-46.83', 'ciLowerLimit': '-51.73', 'ciUpperLimit': '-41.94', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.48', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG001', 'OG005'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-42.86', 'ciLowerLimit': '-48.43', 'ciUpperLimit': '-37.30', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.82', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG002', 'OG004'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-28.60', 'ciLowerLimit': '-33.56', 'ciUpperLimit': '-23.65', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.51', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG003', 'OG005'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-30.22', 'ciLowerLimit': '-35.74', 'ciUpperLimit': '-24.70', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.80', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG006', 'OG010'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-45.10', 'ciLowerLimit': '-51.66', 'ciUpperLimit': '-38.54', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.33', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG007', 'OG011'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-42.43', 'ciLowerLimit': '-49.01', 'ciUpperLimit': '-35.85', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.34', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG008', 'OG010'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-30.26', 'ciLowerLimit': '-36.68', 'ciUpperLimit': '-23.84', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.26', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG009', 'OG011'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-25.19', 'ciLowerLimit': '-31.79', 'ciUpperLimit': '-18.59', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.35', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG012', 'OG014'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-43.25', 'ciLowerLimit': '-48.77', 'ciUpperLimit': '-37.74', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.79', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG013', 'OG015'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-45.33', 'ciLowerLimit': '-51.04', 'ciUpperLimit': '-39.61', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.89', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG016', 'OG018'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-41.13', 'ciLowerLimit': '-46.65', 'ciUpperLimit': '-35.61', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.79', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG017', 'OG019'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-34.99', 'ciLowerLimit': '-41.72', 'ciUpperLimit': '-28.25', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.41', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG020', 'OG022'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-47.04', 'ciLowerLimit': '-51.83', 'ciUpperLimit': '-42.25', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.43', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG021', 'OG023'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-44.60', 'ciLowerLimit': '-50.67', 'ciUpperLimit': '-38.54', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.07', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline and Week 12', 'unitOfMeasure': 'percent change', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set'}, {'type': 'SECONDARY', 'title': 'Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at the Mean of Weeks 10 and 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '56', 'groupId': 'OG000'}, {'value': '55', 'groupId': 'OG001'}, {'value': '56', 'groupId': 'OG002'}, {'value': '55', 'groupId': 'OG003'}, {'value': '110', 'groupId': 'OG004'}, {'value': '110', 'groupId': 'OG005'}, {'value': '55', 'groupId': 'OG006'}, {'value': '55', 'groupId': 'OG007'}, {'value': '56', 'groupId': 'OG008'}, {'value': '54', 'groupId': 'OG009'}, {'value': '109', 'groupId': 'OG010'}, {'value': '110', 'groupId': 'OG011'}, {'value': '58', 'groupId': 'OG012'}, {'value': '57', 'groupId': 'OG013'}, {'value': '113', 'groupId': 'OG014'}, {'value': '115', 'groupId': 'OG015'}, {'value': '56', 'groupId': 'OG016'}, {'value': '55', 'groupId': 'OG017'}, {'value': '111', 'groupId': 'OG018'}, {'value': '112', 'groupId': 'OG019'}, {'value': '56', 'groupId': 'OG020'}, {'value': '55', 'groupId': 'OG021'}, {'value': '112', 'groupId': 'OG022'}, {'value': '115', 'groupId': 'OG023'}]}], 'groups': [{'id': 'OG000', 'title': 'A10 PBO Q2W', 'description': 'Participants received atorvastatin 10 mg once daily during the 4 week lipid stabilization period and then in combination with placebo (PBO) subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG001', 'title': 'A10 PBO QM', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month (QM) and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG002', 'title': 'A10 EZE (Q2W)', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe (EZE) orally once daily for up to 12 weeks.'}, {'id': 'OG003', 'title': 'A10 EZE (QM)', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.'}, {'id': 'OG004', 'title': 'A10 EvoMab Q2W', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab (EvoMab) by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG005', 'title': 'A10 EvoMab QM', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG006', 'title': 'A80 PBO Q2W', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG007', 'title': 'A80 PBO QM', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG008', 'title': 'A80 EZE (Q2W)', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once daily for up to 12 weeks.'}, {'id': 'OG009', 'title': 'A80 EZE (QM)', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.'}, {'id': 'OG010', 'title': 'A80 EvoMab Q2W', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG011', 'title': 'A80 EvoMab QM', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG012', 'title': 'R5 PBO Q2W', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG013', 'title': 'R5 PBO QM', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG014', 'title': 'R5 EvoMab Q2W', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG015', 'title': 'R5 EvoMab QM', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG016', 'title': 'R40 PBO Q2W', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG017', 'title': 'R40 PBO QM', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG018', 'title': 'R40 EvoMab Q2W', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG019', 'title': 'R40 EvoMab QM', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG020', 'title': 'S40 PBO Q2W', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG021', 'title': 'S40 PBO QM', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG022', 'title': 'S40 EvoMab Q2W', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG023', 'title': 'S40 EvoMab QM', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.'}], 'classes': [{'categories': [{'measurements': [{'value': '6.41', 'spread': '2.03', 'groupId': 'OG000'}, {'value': '0.78', 'spread': '2.29', 'groupId': 'OG001'}, {'value': '-15.77', 'spread': '2.14', 'groupId': 'OG002'}, {'value': '-11.47', 'spread': '2.29', 'groupId': 'OG003'}, {'value': '-53.56', 'spread': '1.48', 'groupId': 'OG004'}, {'value': '-53.33', 'spread': '1.58', 'groupId': 'OG005'}, {'value': '4.48', 'spread': '3.04', 'groupId': 'OG006'}, {'value': '5.79', 'spread': '2.79', 'groupId': 'OG007'}, {'value': '-15.17', 'spread': '2.99', 'groupId': 'OG008'}, {'value': '-12.91', 'spread': '2.80', 'groupId': 'OG009'}, {'value': '-52.43', 'spread': '2.14', 'groupId': 'OG010'}, {'value': '-56.20', 'spread': '1.98', 'groupId': 'OG011'}, {'value': '2.82', 'spread': '2.26', 'groupId': 'OG012'}, {'value': '2.58', 'spread': '2.05', 'groupId': 'OG013'}, {'value': '-52.46', 'spread': '1.67', 'groupId': 'OG014'}, {'value': '-56.66', 'spread': '1.43', 'groupId': 'OG015'}, {'value': '2.17', 'spread': '2.56', 'groupId': 'OG016'}, {'value': '2.60', 'spread': '2.97', 'groupId': 'OG017'}, {'value': '-48.47', 'spread': '1.83', 'groupId': 'OG018'}, {'value': '-54.17', 'spread': '2.04', 'groupId': 'OG019'}, {'value': '-1.00', 'spread': '3.12', 'groupId': 'OG020'}, {'value': '-1.42', 'spread': '4.22', 'groupId': 'OG021'}, {'value': '-58.76', 'spread': '2.73', 'groupId': 'OG022'}, {'value': '-57.47', 'spread': '3.55', 'groupId': 'OG023'}]}]}], 'analyses': [{'pValue': '<0.001', 'groupIds': ['OG000', 'OG004'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-59.97', 'ciLowerLimit': '-64.91', 'ciUpperLimit': '-55.03', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.51', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG001', 'OG005'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-54.11', 'ciLowerLimit': '-59.57', 'ciUpperLimit': '-48.64', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.77', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG002', 'OG004'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-37.79', 'ciLowerLimit': '-42.80', 'ciUpperLimit': '-32.77', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.54', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG003', 'OG005'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-41.86', 'ciLowerLimit': '-47.34', 'ciUpperLimit': '-36.67', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.78', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG006', 'OG010'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-56.90', 'ciLowerLimit': '-64.22', 'ciUpperLimit': '-49.59', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.71', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG007', 'OG011'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-61.99', 'ciLowerLimit': '-68.68', 'ciUpperLimit': '-55.29', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.39', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG008', 'OG010'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-37.26', 'ciLowerLimit': '-44.48', 'ciUpperLimit': '-30.04', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.66', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG009', 'OG011'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-43.29', 'ciLowerLimit': '-50.07', 'ciUpperLimit': '-36.51', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.44', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG012', 'OG014'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-55.29', 'ciLowerLimit': '-60.79', 'ciUpperLimit': '-49.79', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.78', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG013', 'OG015'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-59.24', 'ciLowerLimit': '-64.16', 'ciUpperLimit': '-54.32', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.49', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG016', 'OG018'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-50.63', 'ciLowerLimit': '-56.82', 'ciUpperLimit': '-44.45', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.13', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG017', 'OG019'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-56.78', 'ciLowerLimit': '-63.91', 'ciUpperLimit': '-49.64', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.61', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG020', 'OG022'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-57.75', 'ciLowerLimit': '-62.51', 'ciUpperLimit': '-52.99', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.41', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG021', 'OG023'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-56.06', 'ciLowerLimit': '-61.85', 'ciUpperLimit': '-50.27', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.93', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline and Weeks 10 and 12', 'unitOfMeasure': 'percent change', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set'}, {'type': 'SECONDARY', 'title': 'Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '56', 'groupId': 'OG000'}, {'value': '55', 'groupId': 'OG001'}, {'value': '56', 'groupId': 'OG002'}, {'value': '55', 'groupId': 'OG003'}, {'value': '110', 'groupId': 'OG004'}, {'value': '110', 'groupId': 'OG005'}, {'value': '55', 'groupId': 'OG006'}, {'value': '55', 'groupId': 'OG007'}, {'value': '56', 'groupId': 'OG008'}, {'value': '54', 'groupId': 'OG009'}, {'value': '109', 'groupId': 'OG010'}, {'value': '110', 'groupId': 'OG011'}, {'value': '58', 'groupId': 'OG012'}, {'value': '57', 'groupId': 'OG013'}, {'value': '113', 'groupId': 'OG014'}, {'value': '115', 'groupId': 'OG015'}, {'value': '56', 'groupId': 'OG016'}, {'value': '55', 'groupId': 'OG017'}, {'value': '111', 'groupId': 'OG018'}, {'value': '112', 'groupId': 'OG019'}, {'value': '56', 'groupId': 'OG020'}, {'value': '55', 'groupId': 'OG021'}, {'value': '112', 'groupId': 'OG022'}, {'value': '115', 'groupId': 'OG023'}]}], 'groups': [{'id': 'OG000', 'title': 'A10 PBO Q2W', 'description': 'Participants received atorvastatin 10 mg once daily during the 4 week lipid stabilization period and then in combination with placebo (PBO) subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG001', 'title': 'A10 PBO QM', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month (QM) and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG002', 'title': 'A10 EZE (Q2W)', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe (EZE) orally once daily for up to 12 weeks.'}, {'id': 'OG003', 'title': 'A10 EZE (QM)', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.'}, {'id': 'OG004', 'title': 'A10 EvoMab Q2W', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab (EvoMab) by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG005', 'title': 'A10 EvoMab QM', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG006', 'title': 'A80 PBO Q2W', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG007', 'title': 'A80 PBO QM', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG008', 'title': 'A80 EZE (Q2W)', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once daily for up to 12 weeks.'}, {'id': 'OG009', 'title': 'A80 EZE (QM)', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.'}, {'id': 'OG010', 'title': 'A80 EvoMab Q2W', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG011', 'title': 'A80 EvoMab QM', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG012', 'title': 'R5 PBO Q2W', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG013', 'title': 'R5 PBO QM', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG014', 'title': 'R5 EvoMab Q2W', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG015', 'title': 'R5 EvoMab QM', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG016', 'title': 'R40 PBO Q2W', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG017', 'title': 'R40 PBO QM', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG018', 'title': 'R40 EvoMab Q2W', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG019', 'title': 'R40 EvoMab QM', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG020', 'title': 'S40 PBO Q2W', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG021', 'title': 'S40 PBO QM', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG022', 'title': 'S40 EvoMab Q2W', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG023', 'title': 'S40 EvoMab QM', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.'}], 'classes': [{'categories': [{'measurements': [{'value': '6.13', 'spread': '2.20', 'groupId': 'OG000'}, {'value': '-1.21', 'spread': '2.41', 'groupId': 'OG001'}, {'value': '-14.51', 'spread': '2.31', 'groupId': 'OG002'}, {'value': '-12.33', 'spread': '2.41', 'groupId': 'OG003'}, {'value': '-54.17', 'spread': '1.59', 'groupId': 'OG004'}, {'value': '-49.65', 'spread': '1.69', 'groupId': 'OG005'}, {'value': '4.19', 'spread': '3.25', 'groupId': 'OG006'}, {'value': '6.50', 'spread': '3.18', 'groupId': 'OG007'}, {'value': '-13.69', 'spread': '3.17', 'groupId': 'OG008'}, {'value': '-12.19', 'spread': '3.17', 'groupId': 'OG009'}, {'value': '-53.59', 'spread': '2.26', 'groupId': 'OG010'}, {'value': '-50.76', 'spread': '2.26', 'groupId': 'OG011'}, {'value': '1.44', 'spread': '2.30', 'groupId': 'OG012'}, {'value': '4.00', 'spread': '2.27', 'groupId': 'OG013'}, {'value': '-52.97', 'spread': '1.69', 'groupId': 'OG014'}, {'value': '-52.13', 'spread': '1.60', 'groupId': 'OG015'}, {'value': '1.64', 'spread': '2.75', 'groupId': 'OG016'}, {'value': '3.16', 'spread': '3.51', 'groupId': 'OG017'}, {'value': '-47.53', 'spread': '1.96', 'groupId': 'OG018'}, {'value': '-45.65', 'spread': '2.39', 'groupId': 'OG019'}, {'value': '-1.80', 'spread': '3.21', 'groupId': 'OG020'}, {'value': '-0.52', 'spread': '4.29', 'groupId': 'OG021'}, {'value': '-59.53', 'spread': '2.77', 'groupId': 'OG022'}, {'value': '-52.56', 'spread': '3.59', 'groupId': 'OG023'}]}]}], 'analyses': [{'pValue': '<0.001', 'groupIds': ['OG000', 'OG004'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-60.29', 'ciLowerLimit': '-65.65', 'ciUpperLimit': '-54.94', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.71', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG001', 'OG005'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-48.44', 'ciLowerLimit': '-54.23', 'ciUpperLimit': '-42.65', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.94', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG002', 'OG004'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-39.66', 'ciLowerLimit': '-45.09', 'ciUpperLimit': '-34.23', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.75', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG003', 'OG005'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-37.32', 'ciLowerLimit': '-43.12', 'ciUpperLimit': '-31.52', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.94', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG006', 'OG010'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-57.77', 'ciLowerLimit': '-65.55', 'ciUpperLimit': '-49.99', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.95', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG007', 'OG011'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-57.26', 'ciLowerLimit': '-64.91', 'ciUpperLimit': '-49.60', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.88', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG008', 'OG010'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-39.90', 'ciLowerLimit': '-47.53', 'ciUpperLimit': '-32.26', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.87', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG009', 'OG011'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-38.57', 'ciLowerLimit': '-46.26', 'ciUpperLimit': '-30.88', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.90', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG012', 'OG014'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-54.41', 'ciLowerLimit': '-59.99', 'ciUpperLimit': '-48.82', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.83', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG013', 'OG015'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-56.13', 'ciLowerLimit': '-61.58', 'ciUpperLimit': '-50.68', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.76', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG016', 'OG018'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-49.17', 'ciLowerLimit': '-55.80', 'ciUpperLimit': '-42.53', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.36', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG017', 'OG019'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-48.81', 'ciLowerLimit': '-57.21', 'ciUpperLimit': '-40.40', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.25', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG020', 'OG022'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-57.73', 'ciLowerLimit': '-62.82', 'ciUpperLimit': '-52.65', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.57', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG021', 'OG023'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-52.04', 'ciLowerLimit': '-58.10', 'ciUpperLimit': '-45.98', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.07', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline and Week 12', 'unitOfMeasure': 'percent change', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Who Achieved a Mean LDL-C at Weeks 10 and 12 of Less Than 70 mg/dL', 'denoms': [{'units': 'Participants', 'counts': [{'value': '56', 'groupId': 'OG000'}, {'value': '55', 'groupId': 'OG001'}, {'value': '56', 'groupId': 'OG002'}, {'value': '55', 'groupId': 'OG003'}, {'value': '110', 'groupId': 'OG004'}, {'value': '110', 'groupId': 'OG005'}, {'value': '55', 'groupId': 'OG006'}, {'value': '55', 'groupId': 'OG007'}, {'value': '56', 'groupId': 'OG008'}, {'value': '54', 'groupId': 'OG009'}, {'value': '109', 'groupId': 'OG010'}, {'value': '110', 'groupId': 'OG011'}, {'value': '58', 'groupId': 'OG012'}, {'value': '57', 'groupId': 'OG013'}, {'value': '113', 'groupId': 'OG014'}, {'value': '115', 'groupId': 'OG015'}, {'value': '56', 'groupId': 'OG016'}, {'value': '55', 'groupId': 'OG017'}, {'value': '111', 'groupId': 'OG018'}, {'value': '112', 'groupId': 'OG019'}, {'value': '56', 'groupId': 'OG020'}, {'value': '55', 'groupId': 'OG021'}, {'value': '112', 'groupId': 'OG022'}, {'value': '115', 'groupId': 'OG023'}]}], 'groups': [{'id': 'OG000', 'title': 'A10 PBO Q2W', 'description': 'Participants received atorvastatin 10 mg once daily during the 4 week lipid stabilization period and then in combination with placebo (PBO) subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG001', 'title': 'A10 PBO QM', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month (QM) and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG002', 'title': 'A10 EZE (Q2W)', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe (EZE) orally once daily for up to 12 weeks.'}, {'id': 'OG003', 'title': 'A10 EZE (QM)', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.'}, {'id': 'OG004', 'title': 'A10 EvoMab Q2W', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab (EvoMab) by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG005', 'title': 'A10 EvoMab QM', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG006', 'title': 'A80 PBO Q2W', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG007', 'title': 'A80 PBO QM', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG008', 'title': 'A80 EZE (Q2W)', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once daily for up to 12 weeks.'}, {'id': 'OG009', 'title': 'A80 EZE (QM)', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.'}, {'id': 'OG010', 'title': 'A80 EvoMab Q2W', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG011', 'title': 'A80 EvoMab QM', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG012', 'title': 'R5 PBO Q2W', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG013', 'title': 'R5 PBO QM', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG014', 'title': 'R5 EvoMab Q2W', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG015', 'title': 'R5 EvoMab QM', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG016', 'title': 'R40 PBO Q2W', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG017', 'title': 'R40 PBO QM', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG018', 'title': 'R40 EvoMab Q2W', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG019', 'title': 'R40 EvoMab QM', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG020', 'title': 'S40 PBO Q2W', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG021', 'title': 'S40 PBO QM', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG022', 'title': 'S40 EvoMab Q2W', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG023', 'title': 'S40 EvoMab QM', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.'}], 'classes': [{'categories': [{'measurements': [{'value': '5.7', 'groupId': 'OG000', 'lowerLimit': '1.9', 'upperLimit': '15.4'}, {'value': '5.6', 'groupId': 'OG001', 'lowerLimit': '1.9', 'upperLimit': '15.1'}, {'value': '20.0', 'groupId': 'OG002', 'lowerLimit': '11.2', 'upperLimit': '33.0'}, {'value': '16.7', 'groupId': 'OG003', 'lowerLimit': '9.0', 'upperLimit': '28.7'}, {'value': '88.1', 'groupId': 'OG004', 'lowerLimit': '80.7', 'upperLimit': '92.9'}, {'value': '85.8', 'groupId': 'OG005', 'lowerLimit': '78.0', 'upperLimit': '91.2'}, {'value': '13.7', 'groupId': 'OG006', 'lowerLimit': '6.8', 'upperLimit': '25.7'}, {'value': '9.3', 'groupId': 'OG007', 'lowerLimit': '4.0', 'upperLimit': '19.9'}, {'value': '50.9', 'groupId': 'OG008', 'lowerLimit': '38.1', 'upperLimit': '63.6'}, {'value': '62.3', 'groupId': 'OG009', 'lowerLimit': '48.8', 'upperLimit': '74.1'}, {'value': '94.4', 'groupId': 'OG010', 'lowerLimit': '88.4', 'upperLimit': '97.4'}, {'value': '92.5', 'groupId': 'OG011', 'lowerLimit': '85.9', 'upperLimit': '96.2'}, {'value': '7.0', 'groupId': 'OG012', 'lowerLimit': '2.8', 'upperLimit': '16.7'}, {'value': '5.3', 'groupId': 'OG013', 'lowerLimit': '1.8', 'upperLimit': '14.4'}, {'value': '88.7', 'groupId': 'OG014', 'lowerLimit': '81.2', 'upperLimit': '93.4'}, {'value': '89.9', 'groupId': 'OG015', 'lowerLimit': '82.8', 'upperLimit': '94.3'}, {'value': '38.9', 'groupId': 'OG016', 'lowerLimit': '27.0', 'upperLimit': '52.2'}, {'value': '28.8', 'groupId': 'OG017', 'lowerLimit': '18.3', 'upperLimit': '42.3'}, {'value': '93.5', 'groupId': 'OG018', 'lowerLimit': '87.1', 'upperLimit': '96.8'}, {'value': '94.5', 'groupId': 'OG019', 'lowerLimit': '88.6', 'upperLimit': '97.5'}, {'value': '1.9', 'groupId': 'OG020', 'lowerLimit': '0.3', 'upperLimit': '9.8'}, {'value': '3.9', 'groupId': 'OG021', 'lowerLimit': '1.1', 'upperLimit': '13.2'}, {'value': '93.6', 'groupId': 'OG022', 'lowerLimit': '87.3', 'upperLimit': '96.9'}, {'value': '88.5', 'groupId': 'OG023', 'lowerLimit': '81.3', 'upperLimit': '93.2'}]}]}], 'analyses': [{'pValue': '<0.001', 'groupIds': ['OG000', 'OG004'], 'paramType': 'Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '82.4', 'ciLowerLimit': '70.2', 'ciUpperLimit': '88.5', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'Based on Cochran-Mantel Haenszel test stratified by the stratification factors (entry statin therapy and simvastatin contraindicated therapy usage)'}, {'pValue': '<0.001', 'groupIds': ['OG001', 'OG005'], 'paramType': 'Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '80.3', 'ciLowerLimit': '67.9', 'ciUpperLimit': '86.8', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'Based on Cochran-Mantel Haenszel test stratified by the stratification factors (entry statin therapy and simvastatin contraindicated therapy usage).'}, {'pValue': '<0.001', 'groupIds': ['OG002', 'OG004'], 'paramType': 'Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '68.1', 'ciLowerLimit': '53.1', 'ciUpperLimit': '78.1', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'Based on Cochran-Mantel Haenszel test stratified by the stratification factors (entry statin therapy and simvastatin contraindicated therapy usage).'}, {'pValue': '<0.001', 'groupIds': ['OG003', 'OG005'], 'paramType': 'Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '69.2', 'ciLowerLimit': '54.8', 'ciUpperLimit': '78.5', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'Based on Cochran-Mantel Haenszel test stratified by the stratification factors (entry statin therapy and simvastatin contraindicated therapy usage)'}, {'pValue': '<0.001', 'groupIds': ['OG006', 'OG010'], 'paramType': 'Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '80.7', 'ciLowerLimit': '67.3', 'ciUpperLimit': '88.3', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'Based on Cochran-Mantel Haenszel test stratified by the stratification factors (entry statin therapy and simvastatin contraindicated therapy usage).'}, {'pValue': '<0.001', 'groupIds': ['OG007', 'OG011'], 'paramType': 'Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '83.3', 'ciLowerLimit': '70.7', 'ciUpperLimit': '89.6', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'Based on Cochran-Mantel Haenszel test stratified by the stratification factors (entry statin therapy and simvastatin contraindicated therapy usage)'}, {'pValue': '<0.001', 'groupIds': ['OG008', 'OG010'], 'paramType': 'Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '43.5', 'ciLowerLimit': '29.5', 'ciUpperLimit': '56.7', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'Based on Cochran-Mantel Haenszel test stratified by the stratification factors (entry statin therapy and simvastatin contraindicated therapy usage).'}, {'pValue': '<0.001', 'groupIds': ['OG009', 'OG011'], 'paramType': 'Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '30.3', 'ciLowerLimit': '16.7', 'ciUpperLimit': '44.2', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'Based on Cochran-Mantel Haenszel test stratified by the stratification factors (entry statin therapy and simvastatin contraindicated therapy usage).'}, {'pValue': '<0.001', 'groupIds': ['OG012', 'OG014'], 'paramType': 'Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '81.7', 'ciLowerLimit': '69.5', 'ciUpperLimit': '88.0', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'Based on Cochran-Mantel Haenszel test stratified by the stratification factors (entry statin therapy and simvastatin contraindicated therapy usage).'}, {'pValue': '<0.001', 'groupIds': ['OG013', 'OG015'], 'paramType': 'Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '84.6', 'ciLowerLimit': '73.1', 'ciUpperLimit': '90.2', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'Based on Cochran-Mantel Haenszel test stratified by the stratification factors (entry statin therapy and simvastatin contraindicated therapy usage).'}, {'pValue': '<0.001', 'groupIds': ['OG016', 'OG018'], 'paramType': 'Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '54.6', 'ciLowerLimit': '39.8', 'ciUpperLimit': '66.9', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'Based on Cochran-Mantel Haenszel test stratified by the stratification factors (entry statin therapy and simvastatin contraindicated therapy usage).'}, {'pValue': '<0.001', 'groupIds': ['OG017', 'OG019'], 'paramType': 'Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '65.7', 'ciLowerLimit': '51.0', 'ciUpperLimit': '76.6', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'Based on Cochran-Mantel Haenszel test stratified by the stratification factors (entry statin therapy and simvastatin contraindicated therapy usage).'}, {'pValue': '<0.001', 'groupIds': ['OG020', 'OG022'], 'paramType': 'Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '91.7', 'ciLowerLimit': '81.6', 'ciUpperLimit': '95.3', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'Based on Cochran-Mantel Haenszel test stratified by the stratification factors (entry statin therapy and simvastatin contraindicated therapy usage).'}, {'pValue': '<0.001', 'groupIds': ['OG021', 'OG023'], 'paramType': 'Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '84.6', 'ciLowerLimit': '72.8', 'ciUpperLimit': '90.0', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'Based on Cochran-Mantel Haenszel test stratified by the stratification factors (entry statin therapy and simvastatin contraindicated therapy usage).'}], 'paramType': 'NUMBER', 'timeFrame': 'Weeks 10 and 12', 'unitOfMeasure': 'percentage of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Who Achieved LDL-C < 70 mg/dL at Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '56', 'groupId': 'OG000'}, {'value': '55', 'groupId': 'OG001'}, {'value': '56', 'groupId': 'OG002'}, {'value': '55', 'groupId': 'OG003'}, {'value': '110', 'groupId': 'OG004'}, {'value': '110', 'groupId': 'OG005'}, {'value': '55', 'groupId': 'OG006'}, {'value': '55', 'groupId': 'OG007'}, {'value': '56', 'groupId': 'OG008'}, {'value': '54', 'groupId': 'OG009'}, {'value': '109', 'groupId': 'OG010'}, {'value': '110', 'groupId': 'OG011'}, {'value': '58', 'groupId': 'OG012'}, {'value': '57', 'groupId': 'OG013'}, {'value': '113', 'groupId': 'OG014'}, {'value': '115', 'groupId': 'OG015'}, {'value': '56', 'groupId': 'OG016'}, {'value': '55', 'groupId': 'OG017'}, {'value': '111', 'groupId': 'OG018'}, {'value': '112', 'groupId': 'OG019'}, {'value': '56', 'groupId': 'OG020'}, {'value': '55', 'groupId': 'OG021'}, {'value': '112', 'groupId': 'OG022'}, {'value': '115', 'groupId': 'OG023'}]}], 'groups': [{'id': 'OG000', 'title': 'A10 PBO Q2W', 'description': 'Participants received atorvastatin 10 mg once daily during the 4 week lipid stabilization period and then in combination with placebo (PBO) subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG001', 'title': 'A10 PBO QM', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month (QM) and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG002', 'title': 'A10 EZE (Q2W)', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe (EZE) orally once daily for up to 12 weeks.'}, {'id': 'OG003', 'title': 'A10 EZE (QM)', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.'}, {'id': 'OG004', 'title': 'A10 EvoMab Q2W', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab (EvoMab) by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG005', 'title': 'A10 EvoMab QM', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG006', 'title': 'A80 PBO Q2W', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG007', 'title': 'A80 PBO QM', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG008', 'title': 'A80 EZE (Q2W)', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once daily for up to 12 weeks.'}, {'id': 'OG009', 'title': 'A80 EZE (QM)', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.'}, {'id': 'OG010', 'title': 'A80 EvoMab Q2W', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG011', 'title': 'A80 EvoMab QM', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG012', 'title': 'R5 PBO Q2W', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG013', 'title': 'R5 PBO QM', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG014', 'title': 'R5 EvoMab Q2W', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG015', 'title': 'R5 EvoMab QM', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG016', 'title': 'R40 PBO Q2W', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG017', 'title': 'R40 PBO QM', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG018', 'title': 'R40 EvoMab Q2W', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG019', 'title': 'R40 EvoMab QM', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG020', 'title': 'S40 PBO Q2W', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG021', 'title': 'S40 PBO QM', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG022', 'title': 'S40 EvoMab Q2W', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG023', 'title': 'S40 EvoMab QM', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.'}], 'classes': [{'categories': [{'measurements': [{'value': '2.0', 'groupId': 'OG000', 'lowerLimit': '0.3', 'upperLimit': '10.3'}, {'value': '5.9', 'groupId': 'OG001', 'lowerLimit': '2.0', 'upperLimit': '15.9'}, {'value': '22.4', 'groupId': 'OG002', 'lowerLimit': '13.0', 'upperLimit': '35.9'}, {'value': '19.2', 'groupId': 'OG003', 'lowerLimit': '10.8', 'upperLimit': '31.9'}, {'value': '85.4', 'groupId': 'OG004', 'lowerLimit': '77.4', 'upperLimit': '91.0'}, {'value': '84.2', 'groupId': 'OG005', 'lowerLimit': '75.8', 'upperLimit': '90.0'}, {'value': '13.0', 'groupId': 'OG006', 'lowerLimit': '6.1', 'upperLimit': '25.7'}, {'value': '9.8', 'groupId': 'OG007', 'lowerLimit': '4.3', 'upperLimit': '21.0'}, {'value': '52.0', 'groupId': 'OG008', 'lowerLimit': '38.5', 'upperLimit': '65.2'}, {'value': '55.8', 'groupId': 'OG009', 'lowerLimit': '42.3', 'upperLimit': '68.4'}, {'value': '93.1', 'groupId': 'OG010', 'lowerLimit': '86.5', 'upperLimit': '96.6'}, {'value': '91.0', 'groupId': 'OG011', 'lowerLimit': '83.8', 'upperLimit': '95.2'}, {'value': '7.7', 'groupId': 'OG012', 'lowerLimit': '3.0', 'upperLimit': '18.2'}, {'value': '5.5', 'groupId': 'OG013', 'lowerLimit': '1.9', 'upperLimit': '14.9'}, {'value': '85.0', 'groupId': 'OG014', 'lowerLimit': '76.7', 'upperLimit': '90.7'}, {'value': '86.5', 'groupId': 'OG015', 'lowerLimit': '78.7', 'upperLimit': '91.8'}, {'value': '39.6', 'groupId': 'OG016', 'lowerLimit': '27.6', 'upperLimit': '53.1'}, {'value': '28.0', 'groupId': 'OG017', 'lowerLimit': '17.5', 'upperLimit': '41.7'}, {'value': '92.3', 'groupId': 'OG018', 'lowerLimit': '85.6', 'upperLimit': '96.1'}, {'value': '92.3', 'groupId': 'OG019', 'lowerLimit': '85.6', 'upperLimit': '96.1'}, {'value': '1.9', 'groupId': 'OG020', 'lowerLimit': '0.3', 'upperLimit': '10.1'}, {'value': '6.4', 'groupId': 'OG021', 'lowerLimit': '2.2', 'upperLimit': '17.2'}, {'value': '94.4', 'groupId': 'OG022', 'lowerLimit': '88.4', 'upperLimit': '97.4'}, {'value': '84.8', 'groupId': 'OG023', 'lowerLimit': '76.7', 'upperLimit': '90.4'}]}]}], 'analyses': [{'pValue': '<0.001', 'groupIds': ['OG000', 'OG004'], 'paramType': 'Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '83.5', 'ciLowerLimit': '71.9', 'ciUpperLimit': '89.2', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'Based on Cochran-Mantel Haenszel test stratified by the stratification factors (entry statin therapy and simvastatin contraindicated therapy usage)'}, {'pValue': '<0.001', 'groupIds': ['OG001', 'OG005'], 'paramType': 'Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '78.3', 'ciLowerLimit': '65.2', 'ciUpperLimit': '85.3', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'Based on Cochran-Mantel Haenszel test stratified by the stratification factors (entry statin therapy and simvastatin contraindicated therapy usage).'}, {'pValue': '<0.001', 'groupIds': ['OG002', 'OG004'], 'paramType': 'Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '63.0', 'ciLowerLimit': '47.3', 'ciUpperLimit': '73.9', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'Based on Cochran-Mantel Haenszel test stratified by the stratification factors (entry statin therapy and simvastatin contraindicated therapy usage).'}, {'pValue': '<0.001', 'groupIds': ['OG003', 'OG005'], 'paramType': 'Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '64.9', 'ciLowerLimit': '49.8', 'ciUpperLimit': '75.2', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'Based on Cochran-Mantel Haenszel test stratified by the stratification factors (entry statin therapy and simvastatin contraindicated therapy usage)'}, {'pValue': '<0.001', 'groupIds': ['OG006', 'OG010'], 'paramType': 'Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '80.1', 'ciLowerLimit': '65.8', 'ciUpperLimit': '87.9', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'Based on Cochran-Mantel Haenszel test stratified by the stratification factors (entry statin therapy and simvastatin contraindicated therapy usage).'}, {'pValue': '<0.001', 'groupIds': ['OG007', 'OG011'], 'paramType': 'Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '81.2', 'ciLowerLimit': '67.9', 'ciUpperLimit': '88.1', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'Based on Cochran-Mantel Haenszel test stratified by the stratification factors (entry statin therapy and simvastatin contraindicated therapy usage)'}, {'pValue': '<0.001', 'groupIds': ['OG008', 'OG010'], 'paramType': 'Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '41.1', 'ciLowerLimit': '26.4', 'ciUpperLimit': '55.1', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'Based on Cochran-Mantel Haenszel test stratified by the stratification factors (entry statin therapy and simvastatin contraindicated therapy usage).'}, {'pValue': '<0.001', 'groupIds': ['OG009', 'OG011'], 'paramType': 'Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '35.2', 'ciLowerLimit': '20.7', 'ciUpperLimit': '49.3', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'Based on Cochran-Mantel Haenszel test stratified by the stratification factors (entry statin therapy and simvastatin contraindicated therapy usage).'}, {'pValue': '<0.001', 'groupIds': ['OG012', 'OG014'], 'paramType': 'Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '77.3', 'ciLowerLimit': '63.9', 'ciUpperLimit': '84.7', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'Based on Cochran-Mantel Haenszel test stratified by the stratification factors (entry statin therapy and simvastatin contraindicated therapy usage).'}, {'pValue': '<0.001', 'groupIds': ['OG013', 'OG015'], 'paramType': 'Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '81.1', 'ciLowerLimit': '68.8', 'ciUpperLimit': '87.5', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'Based on Cochran-Mantel Haenszel test stratified by the stratification factors (entry statin therapy and simvastatin contraindicated therapy usage).'}, {'pValue': '<0.001', 'groupIds': ['OG016', 'OG018'], 'paramType': 'Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '52.7', 'ciLowerLimit': '37.6', 'ciUpperLimit': '65.3', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'Based on Cochran-Mantel Haenszel test stratified by the stratification factors (entry statin therapy and simvastatin contraindicated therapy usage).'}, {'pValue': '<0.001', 'groupIds': ['OG017', 'OG019'], 'paramType': 'Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '64.3', 'ciLowerLimit': '49.1', 'ciUpperLimit': '75.5', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'Based on Cochran-Mantel Haenszel test stratified by the stratification factors (entry statin therapy and simvastatin contraindicated therapy usage).'}, {'pValue': '<0.001', 'groupIds': ['OG020', 'OG022'], 'paramType': 'Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '92.5', 'ciLowerLimit': '82.3', 'ciUpperLimit': '95.9', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'Based on Cochran-Mantel Haenszel test stratified by the stratification factors (entry statin therapy and simvastatin contraindicated therapy usage).'}, {'pValue': '<0.001', 'groupIds': ['OG021', 'OG023'], 'paramType': 'Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '78.4', 'ciLowerLimit': '64.9', 'ciUpperLimit': '85.4', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'Based on Cochran-Mantel Haenszel test stratified by the stratification factors (entry statin therapy and simvastatin contraindicated therapy usage).'}], 'paramType': 'NUMBER', 'timeFrame': 'Week 12', 'unitOfMeasure': 'percentage of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set'}, {'type': 'SECONDARY', 'title': 'Percent Change From Baseline in Lipoprotein(a) at the Mean of Weeks 10 and 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '56', 'groupId': 'OG000'}, {'value': '55', 'groupId': 'OG001'}, {'value': '56', 'groupId': 'OG002'}, {'value': '55', 'groupId': 'OG003'}, {'value': '110', 'groupId': 'OG004'}, {'value': '110', 'groupId': 'OG005'}, {'value': '55', 'groupId': 'OG006'}, {'value': '55', 'groupId': 'OG007'}, {'value': '56', 'groupId': 'OG008'}, {'value': '54', 'groupId': 'OG009'}, {'value': '109', 'groupId': 'OG010'}, {'value': '110', 'groupId': 'OG011'}, {'value': '58', 'groupId': 'OG012'}, {'value': '57', 'groupId': 'OG013'}, {'value': '113', 'groupId': 'OG014'}, {'value': '115', 'groupId': 'OG015'}, {'value': '56', 'groupId': 'OG016'}, {'value': '55', 'groupId': 'OG017'}, {'value': '111', 'groupId': 'OG018'}, {'value': '112', 'groupId': 'OG019'}, {'value': '56', 'groupId': 'OG020'}, {'value': '55', 'groupId': 'OG021'}, {'value': '112', 'groupId': 'OG022'}, {'value': '115', 'groupId': 'OG023'}]}], 'groups': [{'id': 'OG000', 'title': 'A10 PBO Q2W', 'description': 'Participants received atorvastatin 10 mg once daily during the 4 week lipid stabilization period and then in combination with placebo (PBO) subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG001', 'title': 'A10 PBO QM', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month (QM) and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG002', 'title': 'A10 EZE (Q2W)', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe (EZE) orally once daily for up to 12 weeks.'}, {'id': 'OG003', 'title': 'A10 EZE (QM)', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.'}, {'id': 'OG004', 'title': 'A10 EvoMab Q2W', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab (EvoMab) by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG005', 'title': 'A10 EvoMab QM', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG006', 'title': 'A80 PBO Q2W', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG007', 'title': 'A80 PBO QM', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG008', 'title': 'A80 EZE (Q2W)', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once daily for up to 12 weeks.'}, {'id': 'OG009', 'title': 'A80 EZE (QM)', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.'}, {'id': 'OG010', 'title': 'A80 EvoMab Q2W', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG011', 'title': 'A80 EvoMab QM', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG012', 'title': 'R5 PBO Q2W', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG013', 'title': 'R5 PBO QM', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG014', 'title': 'R5 EvoMab Q2W', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG015', 'title': 'R5 EvoMab QM', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG016', 'title': 'R40 PBO Q2W', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG017', 'title': 'R40 PBO QM', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG018', 'title': 'R40 EvoMab Q2W', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG019', 'title': 'R40 EvoMab QM', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG020', 'title': 'S40 PBO Q2W', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG021', 'title': 'S40 PBO QM', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG022', 'title': 'S40 EvoMab Q2W', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG023', 'title': 'S40 EvoMab QM', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.'}], 'classes': [{'categories': [{'measurements': [{'value': '6.07', 'spread': '2.86', 'groupId': 'OG000'}, {'value': '-0.77', 'spread': '3.28', 'groupId': 'OG001'}, {'value': '1.44', 'spread': '3.02', 'groupId': 'OG002'}, {'value': '6.85', 'spread': '3.29', 'groupId': 'OG003'}, {'value': '-26.01', 'spread': '2.08', 'groupId': 'OG004'}, {'value': '-22.64', 'spread': '2.27', 'groupId': 'OG005'}, {'value': '-3.45', 'spread': '2.99', 'groupId': 'OG006'}, {'value': '1.51', 'spread': '3.35', 'groupId': 'OG007'}, {'value': '8.05', 'spread': '2.94', 'groupId': 'OG008'}, {'value': '9.96', 'spread': '3.40', 'groupId': 'OG009'}, {'value': '-23.97', 'spread': '2.10', 'groupId': 'OG010'}, {'value': '-27.46', 'spread': '2.39', 'groupId': 'OG011'}, {'value': '11.41', 'spread': '3.00', 'groupId': 'OG012'}, {'value': '3.65', 'spread': '3.56', 'groupId': 'OG013'}, {'value': '-24.26', 'spread': '2.21', 'groupId': 'OG014'}, {'value': '-23.16', 'spread': '2.50', 'groupId': 'OG015'}, {'value': '8.59', 'spread': '2.98', 'groupId': 'OG016'}, {'value': '6.26', 'spread': '3.59', 'groupId': 'OG017'}, {'value': '-24.96', 'spread': '2.12', 'groupId': 'OG018'}, {'value': '-25.93', 'spread': '2.46', 'groupId': 'OG019'}, {'value': '-10.57', 'spread': '4.49', 'groupId': 'OG020'}, {'value': '-4.99', 'spread': '5.37', 'groupId': 'OG021'}, {'value': '-38.64', 'spread': '3.92', 'groupId': 'OG022'}, {'value': '-32.16', 'spread': '4.50', 'groupId': 'OG023'}]}]}], 'analyses': [{'pValue': '<0.001', 'groupIds': ['OG000', 'OG004'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-32.08', 'ciLowerLimit': '-39.06', 'ciUpperLimit': '-25.11', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.54', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG001', 'OG005'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-21.86', 'ciLowerLimit': '-29.70', 'ciUpperLimit': '-14.03', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.98', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG002', 'OG004'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-27.45', 'ciLowerLimit': '-34.53', 'ciUpperLimit': '-20.38', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.59', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG003', 'OG005'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-29.49', 'ciLowerLimit': '-37.36', 'ciUpperLimit': '-21.62', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.99', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG006', 'OG010'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-20.52', 'ciLowerLimit': '-27.71', 'ciUpperLimit': '-13.33', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.65', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG007', 'OG011'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-28.96', 'ciLowerLimit': '-37.01', 'ciUpperLimit': '-20.92', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.08', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG008', 'OG010'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-32.02', 'ciLowerLimit': '-39.11', 'ciUpperLimit': '-24.93', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.60', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG009', 'OG011'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-37.42', 'ciLowerLimit': '-45.61', 'ciUpperLimit': '-29.23', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.15', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG012', 'OG014'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-35.66', 'ciLowerLimit': '-42.94', 'ciUpperLimit': '-28.38', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.69', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG013', 'OG015'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-26.81', 'ciLowerLimit': '-35.36', 'ciUpperLimit': '-18.27', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.33', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG016', 'OG018'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-33.56', 'ciLowerLimit': '-40.74', 'ciUpperLimit': '-26.37', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.64', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG017', 'OG019'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-32.19', 'ciLowerLimit': '-40.80', 'ciUpperLimit': '-23.58', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.36', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG020', 'OG022'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-28.07', 'ciLowerLimit': '-34.91', 'ciUpperLimit': '-21.23', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.46', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG021', 'OG023'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-27.16', 'ciLowerLimit': '-34.59', 'ciUpperLimit': '-19.73', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.76', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline and Weeks 10 and 12', 'unitOfMeasure': 'percent change', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set'}, {'type': 'SECONDARY', 'title': 'Percent Change From Baseline in Lipoprotein(a) at Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '56', 'groupId': 'OG000'}, {'value': '55', 'groupId': 'OG001'}, {'value': '56', 'groupId': 'OG002'}, {'value': '55', 'groupId': 'OG003'}, {'value': '110', 'groupId': 'OG004'}, {'value': '110', 'groupId': 'OG005'}, {'value': '55', 'groupId': 'OG006'}, {'value': '55', 'groupId': 'OG007'}, {'value': '56', 'groupId': 'OG008'}, {'value': '54', 'groupId': 'OG009'}, {'value': '109', 'groupId': 'OG010'}, {'value': '110', 'groupId': 'OG011'}, {'value': '58', 'groupId': 'OG012'}, {'value': '57', 'groupId': 'OG013'}, {'value': '113', 'groupId': 'OG014'}, {'value': '115', 'groupId': 'OG015'}, {'value': '56', 'groupId': 'OG016'}, {'value': '55', 'groupId': 'OG017'}, {'value': '111', 'groupId': 'OG018'}, {'value': '112', 'groupId': 'OG019'}, {'value': '56', 'groupId': 'OG020'}, {'value': '55', 'groupId': 'OG021'}, {'value': '112', 'groupId': 'OG022'}, {'value': '115', 'groupId': 'OG023'}]}], 'groups': [{'id': 'OG000', 'title': 'A10 PBO Q2W', 'description': 'Participants received atorvastatin 10 mg once daily during the 4 week lipid stabilization period and then in combination with placebo (PBO) subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG001', 'title': 'A10 PBO QM', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month (QM) and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG002', 'title': 'A10 EZE (Q2W)', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe (EZE) orally once daily for up to 12 weeks.'}, {'id': 'OG003', 'title': 'A10 EZE (QM)', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.'}, {'id': 'OG004', 'title': 'A10 EvoMab Q2W', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab (EvoMab) by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG005', 'title': 'A10 EvoMab QM', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG006', 'title': 'A80 PBO Q2W', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG007', 'title': 'A80 PBO QM', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG008', 'title': 'A80 EZE (Q2W)', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once daily for up to 12 weeks.'}, {'id': 'OG009', 'title': 'A80 EZE (QM)', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.'}, {'id': 'OG010', 'title': 'A80 EvoMab Q2W', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG011', 'title': 'A80 EvoMab QM', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG012', 'title': 'R5 PBO Q2W', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG013', 'title': 'R5 PBO QM', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG014', 'title': 'R5 EvoMab Q2W', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG015', 'title': 'R5 EvoMab QM', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG016', 'title': 'R40 PBO Q2W', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG017', 'title': 'R40 PBO QM', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG018', 'title': 'R40 EvoMab Q2W', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG019', 'title': 'R40 EvoMab QM', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG020', 'title': 'S40 PBO Q2W', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG021', 'title': 'S40 PBO QM', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG022', 'title': 'S40 EvoMab Q2W', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG023', 'title': 'S40 EvoMab QM', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.'}], 'classes': [{'categories': [{'measurements': [{'value': '7.34', 'spread': '3.13', 'groupId': 'OG000'}, {'value': '-0.43', 'spread': '3.38', 'groupId': 'OG001'}, {'value': '3.29', 'spread': '3.28', 'groupId': 'OG002'}, {'value': '7.18', 'spread': '3.38', 'groupId': 'OG003'}, {'value': '-25.87', 'spread': '2.26', 'groupId': 'OG004'}, {'value': '-20.25', 'spread': '2.36', 'groupId': 'OG005'}, {'value': '-2.23', 'spread': '3.35', 'groupId': 'OG006'}, {'value': '3.41', 'spread': '3.54', 'groupId': 'OG007'}, {'value': '8.01', 'spread': '3.26', 'groupId': 'OG008'}, {'value': '10.20', 'spread': '3.57', 'groupId': 'OG009'}, {'value': '-24.61', 'spread': '2.31', 'groupId': 'OG010'}, {'value': '-24.68', 'spread': '2.53', 'groupId': 'OG011'}, {'value': '11.40', 'spread': '3.37', 'groupId': 'OG012'}, {'value': '4.49', 'spread': '3.68', 'groupId': 'OG013'}, {'value': '-25.09', 'spread': '2.47', 'groupId': 'OG014'}, {'value': '-20.85', 'spread': '2.59', 'groupId': 'OG015'}, {'value': '10.38', 'spread': '3.09', 'groupId': 'OG016'}, {'value': '10.21', 'spread': '4.36', 'groupId': 'OG017'}, {'value': '-26.11', 'spread': '2.21', 'groupId': 'OG018'}, {'value': '-21.97', 'spread': '2.97', 'groupId': 'OG019'}, {'value': '-6.81', 'spread': '4.57', 'groupId': 'OG020'}, {'value': '-1.06', 'spread': '5.67', 'groupId': 'OG021'}, {'value': '-38.06', 'spread': '3.96', 'groupId': 'OG022'}, {'value': '-29.23', 'spread': '4.68', 'groupId': 'OG023'}]}]}], 'analyses': [{'pValue': '<0.001', 'groupIds': ['OG000', 'OG004'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-33.20', 'ciLowerLimit': '-40.81', 'ciUpperLimit': '-25.60', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.86', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG001', 'OG005'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-19.82', 'ciLowerLimit': '-27.92', 'ciUpperLimit': '-11.72', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.11', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG002', 'OG004'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-29.16', 'ciLowerLimit': '-36.87', 'ciUpperLimit': '-21.44', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.91', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG003', 'OG005'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-27.44', 'ciLowerLimit': '-35.56', 'ciUpperLimit': '-19.32', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.12', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG006', 'OG010'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-22.38', 'ciLowerLimit': '-30.39', 'ciUpperLimit': '-14.36', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.07', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG007', 'OG011'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-28.10', 'ciLowerLimit': '-36.62', 'ciUpperLimit': '-19.58', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.32', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG008', 'OG010'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-32.62', 'ciLowerLimit': '-40.46', 'ciUpperLimit': '-24.78', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.98', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG009', 'OG011'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-34.88', 'ciLowerLimit': '-43.52', 'ciUpperLimit': '-26.25', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.38', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG012', 'OG014'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-36.50', 'ciLowerLimit': '-44.69', 'ciUpperLimit': '-28.30', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.15', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG013', 'OG015'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-25.34', 'ciLowerLimit': '-34.19', 'ciUpperLimit': '-16.49', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.48', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG016', 'OG018'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-36.48', 'ciLowerLimit': '-43.95', 'ciUpperLimit': '-29.02', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.78', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG017', 'OG019'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-32.17', 'ciLowerLimit': '-42.61', 'ciUpperLimit': '-21.74', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.28', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG020', 'OG022'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-31.25', 'ciLowerLimit': '-38.40', 'ciUpperLimit': '-24.10', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.62', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG021', 'OG023'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-28.17', 'ciLowerLimit': '-36.79', 'ciUpperLimit': '-19.55', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.36', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline and Week 12', 'unitOfMeasure': 'percent change', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set'}, {'type': 'SECONDARY', 'title': 'Percent Change From Baseline in Triglycerides at the Mean of Weeks 10 and 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '56', 'groupId': 'OG000'}, {'value': '55', 'groupId': 'OG001'}, {'value': '56', 'groupId': 'OG002'}, {'value': '55', 'groupId': 'OG003'}, {'value': '110', 'groupId': 'OG004'}, {'value': '110', 'groupId': 'OG005'}, {'value': '55', 'groupId': 'OG006'}, {'value': '55', 'groupId': 'OG007'}, {'value': '56', 'groupId': 'OG008'}, {'value': '54', 'groupId': 'OG009'}, {'value': '109', 'groupId': 'OG010'}, {'value': '110', 'groupId': 'OG011'}, {'value': '58', 'groupId': 'OG012'}, {'value': '57', 'groupId': 'OG013'}, {'value': '113', 'groupId': 'OG014'}, {'value': '115', 'groupId': 'OG015'}, {'value': '56', 'groupId': 'OG016'}, {'value': '55', 'groupId': 'OG017'}, {'value': '111', 'groupId': 'OG018'}, {'value': '112', 'groupId': 'OG019'}, {'value': '56', 'groupId': 'OG020'}, {'value': '55', 'groupId': 'OG021'}, {'value': '112', 'groupId': 'OG022'}, {'value': '115', 'groupId': 'OG023'}]}], 'groups': [{'id': 'OG000', 'title': 'A10 PBO Q2W', 'description': 'Participants received atorvastatin 10 mg once daily during the 4 week lipid stabilization period and then in combination with placebo (PBO) subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG001', 'title': 'A10 PBO QM', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month (QM) and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG002', 'title': 'A10 EZE (Q2W)', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe (EZE) orally once daily for up to 12 weeks.'}, {'id': 'OG003', 'title': 'A10 EZE (QM)', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.'}, {'id': 'OG004', 'title': 'A10 EvoMab Q2W', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab (EvoMab) by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG005', 'title': 'A10 EvoMab QM', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG006', 'title': 'A80 PBO Q2W', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG007', 'title': 'A80 PBO QM', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG008', 'title': 'A80 EZE (Q2W)', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once daily for up to 12 weeks.'}, {'id': 'OG009', 'title': 'A80 EZE (QM)', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.'}, {'id': 'OG010', 'title': 'A80 EvoMab Q2W', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG011', 'title': 'A80 EvoMab QM', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG012', 'title': 'R5 PBO Q2W', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG013', 'title': 'R5 PBO QM', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG014', 'title': 'R5 EvoMab Q2W', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG015', 'title': 'R5 EvoMab QM', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG016', 'title': 'R40 PBO Q2W', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG017', 'title': 'R40 PBO QM', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG018', 'title': 'R40 EvoMab Q2W', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG019', 'title': 'R40 EvoMab QM', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG020', 'title': 'S40 PBO Q2W', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG021', 'title': 'S40 PBO QM', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG022', 'title': 'S40 EvoMab Q2W', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG023', 'title': 'S40 EvoMab QM', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.'}], 'classes': [{'categories': [{'measurements': [{'value': '6.49', 'spread': '3.94', 'groupId': 'OG000'}, {'value': '9.17', 'spread': '4.41', 'groupId': 'OG001'}, {'value': '-3.16', 'spread': '4.10', 'groupId': 'OG002'}, {'value': '1.57', 'spread': '4.35', 'groupId': 'OG003'}, {'value': '-5.61', 'spread': '2.81', 'groupId': 'OG004'}, {'value': '-13.38', 'spread': '3.08', 'groupId': 'OG005'}, {'value': '6.16', 'spread': '4.02', 'groupId': 'OG006'}, {'value': '8.05', 'spread': '4.35', 'groupId': 'OG007'}, {'value': '-8.10', 'spread': '3.92', 'groupId': 'OG008'}, {'value': '-4.86', 'spread': '4.39', 'groupId': 'OG009'}, {'value': '-9.27', 'spread': '2.80', 'groupId': 'OG010'}, {'value': '-6.36', 'spread': '3.11', 'groupId': 'OG011'}, {'value': '12.43', 'spread': '4.19', 'groupId': 'OG012'}, {'value': '12.26', 'spread': '4.67', 'groupId': 'OG013'}, {'value': '-10.28', 'spread': '3.04', 'groupId': 'OG014'}, {'value': '-7.26', 'spread': '3.29', 'groupId': 'OG015'}, {'value': '8.44', 'spread': '3.76', 'groupId': 'OG016'}, {'value': '10.75', 'spread': '3.98', 'groupId': 'OG017'}, {'value': '-9.15', 'spread': '2.70', 'groupId': 'OG018'}, {'value': '-15.43', 'spread': '2.77', 'groupId': 'OG019'}, {'value': '9.29', 'spread': '6.97', 'groupId': 'OG020'}, {'value': '13.78', 'spread': '7.44', 'groupId': 'OG021'}, {'value': '-11.67', 'spread': '5.97', 'groupId': 'OG022'}, {'value': '-15.93', 'spread': '6.15', 'groupId': 'OG023'}]}]}], 'analyses': [{'pValue': '0.20', 'groupIds': ['OG000', 'OG004'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-12.10', 'ciLowerLimit': '-21.63', 'ciUpperLimit': '-2.58', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.83', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '0.003', 'groupIds': ['OG001', 'OG005'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-22.55', 'ciLowerLimit': '-33.13', 'ciUpperLimit': '-11.97', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.36', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '1.00', 'groupIds': ['OG002', 'OG004'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-2.45', 'ciLowerLimit': '-12.09', 'ciUpperLimit': '7.19', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.89', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '0.053', 'groupIds': ['OG003', 'OG005'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-14.95', 'ciLowerLimit': '-25.46', 'ciUpperLimit': '-4.44', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.33', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '0.073', 'groupIds': ['OG006', 'OG010'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-15.43', 'ciLowerLimit': '-25.06', 'ciUpperLimit': '-5.79', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.89', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '0.027', 'groupIds': ['OG007', 'OG011'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-14.41', 'ciLowerLimit': '-24.90', 'ciUpperLimit': '-3.92', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.32', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '1.00', 'groupIds': ['OG008', 'OG010'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-1.17', 'ciLowerLimit': '-10.63', 'ciUpperLimit': '8.30', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.80', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '0.63', 'groupIds': ['OG009', 'OG011'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-1.51', 'ciLowerLimit': '-12.12', 'ciUpperLimit': '9.11', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.38', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG012', 'OG014'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-22.72', 'ciLowerLimit': '-32.90', 'ciUpperLimit': '-12.54', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.15', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '0.007', 'groupIds': ['OG013', 'OG015'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-19.52', 'ciLowerLimit': '-30.76', 'ciUpperLimit': '-8.28', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.69', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '0.002', 'groupIds': ['OG016', 'OG018'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-17.59', 'ciLowerLimit': '-26.71', 'ciUpperLimit': '-8.46', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.62', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG017', 'OG019'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-26.18', 'ciLowerLimit': '-35.76', 'ciUpperLimit': '-16.59', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.85', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG020', 'OG022'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-20.97', 'ciLowerLimit': '-32.38', 'ciUpperLimit': '-9.55', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.78', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG021', 'OG023'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-29.71', 'ciLowerLimit': '-40.84', 'ciUpperLimit': '-18.57', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.64', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline and Weeks 10 and 12', 'unitOfMeasure': 'percent change', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set'}, {'type': 'SECONDARY', 'title': 'Percent Change From Baseline in Triglycerides at Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '56', 'groupId': 'OG000'}, {'value': '55', 'groupId': 'OG001'}, {'value': '56', 'groupId': 'OG002'}, {'value': '55', 'groupId': 'OG003'}, {'value': '110', 'groupId': 'OG004'}, {'value': '110', 'groupId': 'OG005'}, {'value': '55', 'groupId': 'OG006'}, {'value': '55', 'groupId': 'OG007'}, {'value': '56', 'groupId': 'OG008'}, {'value': '54', 'groupId': 'OG009'}, {'value': '109', 'groupId': 'OG010'}, {'value': '110', 'groupId': 'OG011'}, {'value': '58', 'groupId': 'OG012'}, {'value': '57', 'groupId': 'OG013'}, {'value': '113', 'groupId': 'OG014'}, {'value': '115', 'groupId': 'OG015'}, {'value': '56', 'groupId': 'OG016'}, {'value': '55', 'groupId': 'OG017'}, {'value': '111', 'groupId': 'OG018'}, {'value': '112', 'groupId': 'OG019'}, {'value': '56', 'groupId': 'OG020'}, {'value': '55', 'groupId': 'OG021'}, {'value': '112', 'groupId': 'OG022'}, {'value': '115', 'groupId': 'OG023'}]}], 'groups': [{'id': 'OG000', 'title': 'A10 PBO Q2W', 'description': 'Participants received atorvastatin 10 mg once daily during the 4 week lipid stabilization period and then in combination with placebo (PBO) subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG001', 'title': 'A10 PBO QM', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month (QM) and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG002', 'title': 'A10 EZE (Q2W)', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe (EZE) orally once daily for up to 12 weeks.'}, {'id': 'OG003', 'title': 'A10 EZE (QM)', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.'}, {'id': 'OG004', 'title': 'A10 EvoMab Q2W', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab (EvoMab) by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG005', 'title': 'A10 EvoMab QM', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG006', 'title': 'A80 PBO Q2W', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG007', 'title': 'A80 PBO QM', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG008', 'title': 'A80 EZE (Q2W)', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once daily for up to 12 weeks.'}, {'id': 'OG009', 'title': 'A80 EZE (QM)', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.'}, {'id': 'OG010', 'title': 'A80 EvoMab Q2W', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG011', 'title': 'A80 EvoMab QM', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG012', 'title': 'R5 PBO Q2W', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG013', 'title': 'R5 PBO QM', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG014', 'title': 'R5 EvoMab Q2W', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG015', 'title': 'R5 EvoMab QM', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG016', 'title': 'R40 PBO Q2W', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG017', 'title': 'R40 PBO QM', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG018', 'title': 'R40 EvoMab Q2W', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG019', 'title': 'R40 EvoMab QM', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG020', 'title': 'S40 PBO Q2W', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG021', 'title': 'S40 PBO QM', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG022', 'title': 'S40 EvoMab Q2W', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG023', 'title': 'S40 EvoMab QM', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.'}], 'classes': [{'categories': [{'measurements': [{'value': '8.27', 'spread': '5.23', 'groupId': 'OG000'}, {'value': '14.35', 'spread': '5.92', 'groupId': 'OG001'}, {'value': '-0.43', 'spread': '5.39', 'groupId': 'OG002'}, {'value': '4.88', 'spread': '5.84', 'groupId': 'OG003'}, {'value': '-3.79', 'spread': '3.72', 'groupId': 'OG004'}, {'value': '-13.26', 'spread': '4.17', 'groupId': 'OG005'}, {'value': '6.65', 'spread': '4.45', 'groupId': 'OG006'}, {'value': '8.22', 'spread': '5.22', 'groupId': 'OG007'}, {'value': '-7.40', 'spread': '4.32', 'groupId': 'OG008'}, {'value': '-3.11', 'spread': '5.23', 'groupId': 'OG009'}, {'value': '-10.07', 'spread': '3.05', 'groupId': 'OG010'}, {'value': '-1.10', 'spread': '3.74', 'groupId': 'OG011'}, {'value': '13.57', 'spread': '5.76', 'groupId': 'OG012'}, {'value': '12.96', 'spread': '5.32', 'groupId': 'OG013'}, {'value': '-4.46', 'spread': '4.16', 'groupId': 'OG014'}, {'value': '-6.88', 'spread': '3.80', 'groupId': 'OG015'}, {'value': '10.97', 'spread': '4.66', 'groupId': 'OG016'}, {'value': '10.00', 'spread': '4.38', 'groupId': 'OG017'}, {'value': '-5.58', 'spread': '3.34', 'groupId': 'OG018'}, {'value': '-10.51', 'spread': '3.04', 'groupId': 'OG019'}, {'value': '8.07', 'spread': '6.88', 'groupId': 'OG020'}, {'value': '16.72', 'spread': '7.88', 'groupId': 'OG021'}, {'value': '-13.71', 'spread': '5.91', 'groupId': 'OG022'}, {'value': '-14.65', 'spread': '6.39', 'groupId': 'OG023'}]}]}], 'analyses': [{'pValue': '0.20', 'groupIds': ['OG000', 'OG004'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-12.06', 'ciLowerLimit': '-24.69', 'ciUpperLimit': '0.57', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '6.41', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '0.003', 'groupIds': ['OG001', 'OG005'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-27.60', 'ciLowerLimit': '-41.86', 'ciUpperLimit': '-13.35', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '7.23', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '1.00', 'groupIds': ['OG002', 'OG004'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-3.37', 'ciLowerLimit': '-16.16', 'ciUpperLimit': '9.43', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '6.49', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '0.053', 'groupIds': ['OG003', 'OG005'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-18.13', 'ciLowerLimit': '-32.28', 'ciUpperLimit': '-3.99', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '7.18', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '0.073', 'groupIds': ['OG006', 'OG010'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-16.72', 'ciLowerLimit': '-27.34', 'ciUpperLimit': '-6.10', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.39', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '0.027', 'groupIds': ['OG007', 'OG011'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-9.31', 'ciLowerLimit': '-21.92', 'ciUpperLimit': '3.29', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '6.39', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '1.00', 'groupIds': ['OG008', 'OG010'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-2.67', 'ciLowerLimit': '-13.05', 'ciUpperLimit': '7.72', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.27', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '0.63', 'groupIds': ['OG009', 'OG011'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '2.02', 'ciLowerLimit': '-10.66', 'ciUpperLimit': '14.69', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '6.43', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG012', 'OG014'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-18.03', 'ciLowerLimit': '-32.03', 'ciUpperLimit': '-4.04', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '7.08', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '0.007', 'groupIds': ['OG013', 'OG015'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-19.83', 'ciLowerLimit': '-32.71', 'ciUpperLimit': '-6.96', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '6.52', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '0.002', 'groupIds': ['OG016', 'OG018'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-16.55', 'ciLowerLimit': '-27.84', 'ciUpperLimit': '-5.26', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.71', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG017', 'OG019'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-20.51', 'ciLowerLimit': '-31.04', 'ciUpperLimit': '-9.98', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.33', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG020', 'OG022'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-21.78', 'ciLowerLimit': '-32.88', 'ciUpperLimit': '-10.68', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.62', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG021', 'OG023'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-31.36', 'ciLowerLimit': '-44.10', 'ciUpperLimit': '-18.62', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '6.45', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline and Week 12', 'unitOfMeasure': 'percent change', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set'}, {'type': 'SECONDARY', 'title': 'Percent Change From Baseline in Very Low-Density Cholesterol (VLDL-C) at the Mean of Weeks 10 and 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '56', 'groupId': 'OG000'}, {'value': '55', 'groupId': 'OG001'}, {'value': '56', 'groupId': 'OG002'}, {'value': '55', 'groupId': 'OG003'}, {'value': '110', 'groupId': 'OG004'}, {'value': '110', 'groupId': 'OG005'}, {'value': '55', 'groupId': 'OG006'}, {'value': '55', 'groupId': 'OG007'}, {'value': '56', 'groupId': 'OG008'}, {'value': '54', 'groupId': 'OG009'}, {'value': '109', 'groupId': 'OG010'}, {'value': '110', 'groupId': 'OG011'}, {'value': '58', 'groupId': 'OG012'}, {'value': '57', 'groupId': 'OG013'}, {'value': '113', 'groupId': 'OG014'}, {'value': '115', 'groupId': 'OG015'}, {'value': '56', 'groupId': 'OG016'}, {'value': '55', 'groupId': 'OG017'}, {'value': '111', 'groupId': 'OG018'}, {'value': '112', 'groupId': 'OG019'}, {'value': '56', 'groupId': 'OG020'}, {'value': '55', 'groupId': 'OG021'}, {'value': '112', 'groupId': 'OG022'}, {'value': '115', 'groupId': 'OG023'}]}], 'groups': [{'id': 'OG000', 'title': 'A10 PBO Q2W', 'description': 'Participants received atorvastatin 10 mg once daily during the 4 week lipid stabilization period and then in combination with placebo (PBO) subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG001', 'title': 'A10 PBO QM', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month (QM) and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG002', 'title': 'A10 EZE (Q2W)', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe (EZE) orally once daily for up to 12 weeks.'}, {'id': 'OG003', 'title': 'A10 EZE (QM)', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.'}, {'id': 'OG004', 'title': 'A10 EvoMab Q2W', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab (EvoMab) by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG005', 'title': 'A10 EvoMab QM', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG006', 'title': 'A80 PBO Q2W', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG007', 'title': 'A80 PBO QM', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG008', 'title': 'A80 EZE (Q2W)', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once daily for up to 12 weeks.'}, {'id': 'OG009', 'title': 'A80 EZE (QM)', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.'}, {'id': 'OG010', 'title': 'A80 EvoMab Q2W', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG011', 'title': 'A80 EvoMab QM', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG012', 'title': 'R5 PBO Q2W', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG013', 'title': 'R5 PBO QM', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG014', 'title': 'R5 EvoMab Q2W', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG015', 'title': 'R5 EvoMab QM', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG016', 'title': 'R40 PBO Q2W', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG017', 'title': 'R40 PBO QM', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG018', 'title': 'R40 EvoMab Q2W', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG019', 'title': 'R40 EvoMab QM', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG020', 'title': 'S40 PBO Q2W', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG021', 'title': 'S40 PBO QM', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG022', 'title': 'S40 EvoMab Q2W', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG023', 'title': 'S40 EvoMab QM', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.'}], 'classes': [{'categories': [{'measurements': [{'value': '6.51', 'spread': '3.56', 'groupId': 'OG000'}, {'value': '9.53', 'spread': '4.45', 'groupId': 'OG001'}, {'value': '-5.35', 'spread': '3.74', 'groupId': 'OG002'}, {'value': '1.77', 'spread': '4.41', 'groupId': 'OG003'}, {'value': '-6.85', 'spread': '2.56', 'groupId': 'OG004'}, {'value': '-11.77', 'spread': '3.11', 'groupId': 'OG005'}, {'value': '6.24', 'spread': '4.03', 'groupId': 'OG006'}, {'value': '8.31', 'spread': '4.26', 'groupId': 'OG007'}, {'value': '-8.52', 'spread': '3.93', 'groupId': 'OG008'}, {'value': '-6.13', 'spread': '4.31', 'groupId': 'OG009'}, {'value': '-8.96', 'spread': '2.82', 'groupId': 'OG010'}, {'value': '-6.38', 'spread': '3.05', 'groupId': 'OG011'}, {'value': '12.86', 'spread': '3.95', 'groupId': 'OG012'}, {'value': '12.54', 'spread': '4.58', 'groupId': 'OG013'}, {'value': '-12.22', 'spread': '2.86', 'groupId': 'OG014'}, {'value': '-7.25', 'spread': '3.23', 'groupId': 'OG015'}, {'value': '7.06', 'spread': '3.76', 'groupId': 'OG016'}, {'value': '8.13', 'spread': '3.72', 'groupId': 'OG017'}, {'value': '-9.09', 'spread': '2.71', 'groupId': 'OG018'}, {'value': '-15.05', 'spread': '2.58', 'groupId': 'OG019'}, {'value': '8.64', 'spread': '6.01', 'groupId': 'OG020'}, {'value': '16.37', 'spread': '7.15', 'groupId': 'OG021'}, {'value': '-14.57', 'spread': '5.17', 'groupId': 'OG022'}, {'value': '-16.50', 'spread': '5.87', 'groupId': 'OG023'}]}]}], 'analyses': [{'pValue': '0.088', 'groupIds': ['OG000', 'OG004'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-13.36', 'ciLowerLimit': '-21.99', 'ciUpperLimit': '-4.74', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.38', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '0.005', 'groupIds': ['OG001', 'OG005'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-21.31', 'ciLowerLimit': '-31.98', 'ciUpperLimit': '-10.64', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.41', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '1.00', 'groupIds': ['OG002', 'OG004'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-1.50', 'ciLowerLimit': '-10.27', 'ciUpperLimit': '7.27', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.45', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '0.056', 'groupIds': ['OG003', 'OG005'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-13.54', 'ciLowerLimit': '-24.17', 'ciUpperLimit': '-2.91', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.39', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '0.073', 'groupIds': ['OG006', 'OG010'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-15.21', 'ciLowerLimit': '-24.88', 'ciUpperLimit': '-5.54', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.91', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '0.027', 'groupIds': ['OG007', 'OG011'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-14.69', 'ciLowerLimit': '-24.97', 'ciUpperLimit': '-4.42', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.21', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '1.00', 'groupIds': ['OG008', 'OG010'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.44', 'ciLowerLimit': '-9.94', 'ciUpperLimit': '9.05', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.82', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '0.62', 'groupIds': ['OG009', 'OG011'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.25', 'ciLowerLimit': '-10.66', 'ciUpperLimit': '10.16', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.28', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG012', 'OG014'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-25.07', 'ciLowerLimit': '-34.64', 'ciUpperLimit': '-15.50', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.85', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '0.007', 'groupIds': ['OG013', 'OG015'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-19.79', 'ciLowerLimit': '-30.81', 'ciUpperLimit': '-8.77', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.58', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '0.005', 'groupIds': ['OG016', 'OG018'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-16.15', 'ciLowerLimit': '-25.27', 'ciUpperLimit': '-7.03', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.61', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG017', 'OG019'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-23.18', 'ciLowerLimit': '-32.11', 'ciUpperLimit': '-14.25', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.52', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG020', 'OG022'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-23.21', 'ciLowerLimit': '-33.00', 'ciUpperLimit': '-13.43', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.95', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG021', 'OG023'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-32.87', 'ciLowerLimit': '-43.60', 'ciUpperLimit': '-22.14', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.43', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline and Weeks 10 and 12', 'unitOfMeasure': 'percent change', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set'}, {'type': 'SECONDARY', 'title': 'Percent Change From Baseline in Very Low-Density Cholesterol (VLDL-C) at Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '56', 'groupId': 'OG000'}, {'value': '55', 'groupId': 'OG001'}, {'value': '56', 'groupId': 'OG002'}, {'value': '55', 'groupId': 'OG003'}, {'value': '110', 'groupId': 'OG004'}, {'value': '110', 'groupId': 'OG005'}, {'value': '55', 'groupId': 'OG006'}, {'value': '55', 'groupId': 'OG007'}, {'value': '56', 'groupId': 'OG008'}, {'value': '54', 'groupId': 'OG009'}, {'value': '109', 'groupId': 'OG010'}, {'value': '110', 'groupId': 'OG011'}, {'value': '58', 'groupId': 'OG012'}, {'value': '57', 'groupId': 'OG013'}, {'value': '113', 'groupId': 'OG014'}, {'value': '115', 'groupId': 'OG015'}, {'value': '56', 'groupId': 'OG016'}, {'value': '55', 'groupId': 'OG017'}, {'value': '111', 'groupId': 'OG018'}, {'value': '112', 'groupId': 'OG019'}, {'value': '56', 'groupId': 'OG020'}, {'value': '55', 'groupId': 'OG021'}, {'value': '112', 'groupId': 'OG022'}, {'value': '115', 'groupId': 'OG023'}]}], 'groups': [{'id': 'OG000', 'title': 'A10 PBO Q2W', 'description': 'Participants received atorvastatin 10 mg once daily during the 4 week lipid stabilization period and then in combination with placebo (PBO) subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG001', 'title': 'A10 PBO QM', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month (QM) and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG002', 'title': 'A10 EZE (Q2W)', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe (EZE) orally once daily for up to 12 weeks.'}, {'id': 'OG003', 'title': 'A10 EZE (QM)', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.'}, {'id': 'OG004', 'title': 'A10 EvoMab Q2W', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab (EvoMab) by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG005', 'title': 'A10 EvoMab QM', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG006', 'title': 'A80 PBO Q2W', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG007', 'title': 'A80 PBO QM', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG008', 'title': 'A80 EZE (Q2W)', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once daily for up to 12 weeks.'}, {'id': 'OG009', 'title': 'A80 EZE (QM)', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.'}, {'id': 'OG010', 'title': 'A80 EvoMab Q2W', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG011', 'title': 'A80 EvoMab QM', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG012', 'title': 'R5 PBO Q2W', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG013', 'title': 'R5 PBO QM', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG014', 'title': 'R5 EvoMab Q2W', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG015', 'title': 'R5 EvoMab QM', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG016', 'title': 'R40 PBO Q2W', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG017', 'title': 'R40 PBO QM', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG018', 'title': 'R40 EvoMab Q2W', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG019', 'title': 'R40 EvoMab QM', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG020', 'title': 'S40 PBO Q2W', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG021', 'title': 'S40 PBO QM', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG022', 'title': 'S40 EvoMab Q2W', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG023', 'title': 'S40 EvoMab QM', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.'}], 'classes': [{'categories': [{'measurements': [{'value': '8.32', 'spread': '4.00', 'groupId': 'OG000'}, {'value': '14.74', 'spread': '5.91', 'groupId': 'OG001'}, {'value': '-4.61', 'spread': '4.19', 'groupId': 'OG002'}, {'value': '3.45', 'spread': '5.89', 'groupId': 'OG003'}, {'value': '-6.16', 'spread': '2.88', 'groupId': 'OG004'}, {'value': '-11.73', 'spread': '4.16', 'groupId': 'OG005'}, {'value': '6.73', 'spread': '4.45', 'groupId': 'OG006'}, {'value': '8.54', 'spread': '5.00', 'groupId': 'OG007'}, {'value': '-7.92', 'spread': '4.32', 'groupId': 'OG008'}, {'value': '-6.00', 'spread': '5.04', 'groupId': 'OG009'}, {'value': '-9.69', 'spread': '3.05', 'groupId': 'OG010'}, {'value': '-1.06', 'spread': '3.58', 'groupId': 'OG011'}, {'value': '13.79', 'spread': '5.05', 'groupId': 'OG012'}, {'value': '12.47', 'spread': '5.31', 'groupId': 'OG013'}, {'value': '-8.20', 'spread': '3.64', 'groupId': 'OG014'}, {'value': '-6.28', 'spread': '3.78', 'groupId': 'OG015'}, {'value': '10.09', 'spread': '4.65', 'groupId': 'OG016'}, {'value': '8.59', 'spread': '4.37', 'groupId': 'OG017'}, {'value': '-6.10', 'spread': '3.33', 'groupId': 'OG018'}, {'value': '-9.95', 'spread': '3.03', 'groupId': 'OG019'}, {'value': '7.63', 'spread': '6.26', 'groupId': 'OG020'}, {'value': '20.97', 'spread': '7.53', 'groupId': 'OG021'}, {'value': '-14.83', 'spread': '5.30', 'groupId': 'OG022'}, {'value': '-15.86', 'spread': '6.09', 'groupId': 'OG023'}]}]}], 'analyses': [{'pValue': '0.088', 'groupIds': ['OG000', 'OG004'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-14.47', 'ciLowerLimit': '-24.16', 'ciUpperLimit': '-4.78', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.92', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '0.005', 'groupIds': ['OG001', 'OG005'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-26.47', 'ciLowerLimit': '-40.71', 'ciUpperLimit': '-12.24', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '7.22', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '1.00', 'groupIds': ['OG002', 'OG004'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-1.54', 'ciLowerLimit': '-11.41', 'ciUpperLimit': '8.32', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.00', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '0.056', 'groupIds': ['OG003', 'OG005'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-15.19', 'ciLowerLimit': '-29.40', 'ciUpperLimit': '-0.97', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '7.21', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '0.073', 'groupIds': ['OG006', 'OG010'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-16.42', 'ciLowerLimit': '-27.05', 'ciUpperLimit': '-5.80', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.39', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '0.027', 'groupIds': ['OG007', 'OG011'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-9.60', 'ciLowerLimit': '-21.68', 'ciUpperLimit': '2.48', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '6.13', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '1.00', 'groupIds': ['OG008', 'OG010'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-1.78', 'ciLowerLimit': '-12.16', 'ciUpperLimit': '8.61', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.27', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '0.62', 'groupIds': ['OG009', 'OG011'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '4.94', 'ciLowerLimit': '-7.25', 'ciUpperLimit': '17.14', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '6.18', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG012', 'OG014'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-21.98', 'ciLowerLimit': '-34.24', 'ciUpperLimit': '-9.73', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '6.20', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '0.007', 'groupIds': ['OG013', 'OG015'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-18.75', 'ciLowerLimit': '-31.60', 'ciUpperLimit': '-5.90', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '6.50', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '0.005', 'groupIds': ['OG016', 'OG018'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-16.19', 'ciLowerLimit': '-27.46', 'ciUpperLimit': '-4.92', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.70', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG017', 'OG019'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-18.54', 'ciLowerLimit': '-29.04', 'ciUpperLimit': '-8.05', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.31', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG020', 'OG022'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-22.45', 'ciLowerLimit': '-33.09', 'ciUpperLimit': '-11.81', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.39', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG021', 'OG023'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-36.83', 'ciLowerLimit': '-48.96', 'ciUpperLimit': '-24.70', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '6.14', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline and Week 12', 'unitOfMeasure': 'percent change', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set'}, {'type': 'SECONDARY', 'title': 'Percent Change From Baseline in HDL-C at the Mean of Weeks 10 and 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '56', 'groupId': 'OG000'}, {'value': '55', 'groupId': 'OG001'}, {'value': '56', 'groupId': 'OG002'}, {'value': '55', 'groupId': 'OG003'}, {'value': '110', 'groupId': 'OG004'}, {'value': '110', 'groupId': 'OG005'}, {'value': '55', 'groupId': 'OG006'}, {'value': '55', 'groupId': 'OG007'}, {'value': '56', 'groupId': 'OG008'}, {'value': '54', 'groupId': 'OG009'}, {'value': '109', 'groupId': 'OG010'}, {'value': '110', 'groupId': 'OG011'}, {'value': '58', 'groupId': 'OG012'}, {'value': '57', 'groupId': 'OG013'}, {'value': '113', 'groupId': 'OG014'}, {'value': '115', 'groupId': 'OG015'}, {'value': '56', 'groupId': 'OG016'}, {'value': '55', 'groupId': 'OG017'}, {'value': '111', 'groupId': 'OG018'}, {'value': '112', 'groupId': 'OG019'}, {'value': '56', 'groupId': 'OG020'}, {'value': '55', 'groupId': 'OG021'}, {'value': '112', 'groupId': 'OG022'}, {'value': '115', 'groupId': 'OG023'}]}], 'groups': [{'id': 'OG000', 'title': 'A10 PBO Q2W', 'description': 'Participants received atorvastatin 10 mg once daily during the 4 week lipid stabilization period and then in combination with placebo (PBO) subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG001', 'title': 'A10 PBO QM', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month (QM) and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG002', 'title': 'A10 EZE (Q2W)', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe (EZE) orally once daily for up to 12 weeks.'}, {'id': 'OG003', 'title': 'A10 EZE (QM)', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.'}, {'id': 'OG004', 'title': 'A10 EvoMab Q2W', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab (EvoMab) by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG005', 'title': 'A10 EvoMab QM', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG006', 'title': 'A80 PBO Q2W', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG007', 'title': 'A80 PBO QM', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG008', 'title': 'A80 EZE (Q2W)', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once daily for up to 12 weeks.'}, {'id': 'OG009', 'title': 'A80 EZE (QM)', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.'}, {'id': 'OG010', 'title': 'A80 EvoMab Q2W', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG011', 'title': 'A80 EvoMab QM', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG012', 'title': 'R5 PBO Q2W', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG013', 'title': 'R5 PBO QM', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG014', 'title': 'R5 EvoMab Q2W', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG015', 'title': 'R5 EvoMab QM', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG016', 'title': 'R40 PBO Q2W', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG017', 'title': 'R40 PBO QM', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG018', 'title': 'R40 EvoMab Q2W', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG019', 'title': 'R40 EvoMab QM', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG020', 'title': 'S40 PBO Q2W', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG021', 'title': 'S40 PBO QM', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG022', 'title': 'S40 EvoMab Q2W', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG023', 'title': 'S40 EvoMab QM', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.'}], 'classes': [{'categories': [{'measurements': [{'value': '-0.99', 'spread': '1.50', 'groupId': 'OG000'}, {'value': '-0.45', 'spread': '1.94', 'groupId': 'OG001'}, {'value': '-1.13', 'spread': '1.56', 'groupId': 'OG002'}, {'value': '-0.92', 'spread': '1.92', 'groupId': 'OG003'}, {'value': '5.54', 'spread': '1.07', 'groupId': 'OG004'}, {'value': '7.66', 'spread': '1.37', 'groupId': 'OG005'}, {'value': '4.48', 'spread': '1.73', 'groupId': 'OG006'}, {'value': '-1.37', 'spread': '1.85', 'groupId': 'OG007'}, {'value': '0.86', 'spread': '1.68', 'groupId': 'OG008'}, {'value': '-0.59', 'spread': '1.86', 'groupId': 'OG009'}, {'value': '8.44', 'spread': '1.20', 'groupId': 'OG010'}, {'value': '7.76', 'spread': '1.31', 'groupId': 'OG011'}, {'value': '0.87', 'spread': '1.52', 'groupId': 'OG012'}, {'value': '-0.94', 'spread': '2.55', 'groupId': 'OG013'}, {'value': '6.23', 'spread': '1.10', 'groupId': 'OG014'}, {'value': '7.72', 'spread': '1.80', 'groupId': 'OG015'}, {'value': '-0.60', 'spread': '1.56', 'groupId': 'OG016'}, {'value': '-0.40', 'spread': '1.81', 'groupId': 'OG017'}, {'value': '4.86', 'spread': '1.12', 'groupId': 'OG018'}, {'value': '6.35', 'spread': '1.26', 'groupId': 'OG019'}, {'value': '0.13', 'spread': '2.75', 'groupId': 'OG020'}, {'value': '-2.14', 'spread': '2.72', 'groupId': 'OG021'}, {'value': '10.35', 'spread': '2.26', 'groupId': 'OG022'}, {'value': '6.71', 'spread': '2.25', 'groupId': 'OG023'}]}]}], 'analyses': [{'pValue': '0.034', 'groupIds': ['OG000', 'OG004'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '6.53', 'ciLowerLimit': '2.91', 'ciUpperLimit': '10.15', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '1.84', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '0.017', 'groupIds': ['OG001', 'OG005'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '8.11', 'ciLowerLimit': '3.43', 'ciUpperLimit': '12.79', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.37', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '0.001', 'groupIds': ['OG002', 'OG004'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '6.67', 'ciLowerLimit': '3.00', 'ciUpperLimit': '10.34', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '1.86', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '0.006', 'groupIds': ['OG003', 'OG005'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '8.57', 'ciLowerLimit': '3.93', 'ciUpperLimit': '13.22', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.36', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '0.85', 'groupIds': ['OG006', 'OG010'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '3.95', 'ciLowerLimit': '-0.19', 'ciUpperLimit': '8.09', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.10', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG007', 'OG011'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '9.13', 'ciLowerLimit': '4.68', 'ciUpperLimit': '13.58', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.26', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '0.003', 'groupIds': ['OG008', 'OG010'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '7.57', 'ciLowerLimit': '3.51', 'ciUpperLimit': '11.64', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.06', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '0.003', 'groupIds': ['OG009', 'OG011'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '8.35', 'ciLowerLimit': '3.86', 'ciUpperLimit': '12.84', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.28', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG012', 'OG014'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '5.36', 'ciLowerLimit': '1.68', 'ciUpperLimit': '9.04', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '1.87', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '0.010', 'groupIds': ['OG013', 'OG015'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '8.66', 'ciLowerLimit': '2.51', 'ciUpperLimit': '14.80', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.11', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '0.013', 'groupIds': ['OG016', 'OG018'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '5.46', 'ciLowerLimit': '1.69', 'ciUpperLimit': '9.23', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '1.91', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '0.002', 'groupIds': ['OG017', 'OG019'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '6.75', 'ciLowerLimit': '2.40', 'ciUpperLimit': '11.10', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.20', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG020', 'OG022'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '10.23', 'ciLowerLimit': '5.13', 'ciUpperLimit': '15.32', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.58', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG021', 'OG023'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '8.85', 'ciLowerLimit': '4.73', 'ciUpperLimit': '12.97', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.09', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline and Weeks 10 and 12', 'unitOfMeasure': 'percent change', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set'}, {'type': 'SECONDARY', 'title': 'Percent Change From Baseline in HDL-C at Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '56', 'groupId': 'OG000'}, {'value': '55', 'groupId': 'OG001'}, {'value': '56', 'groupId': 'OG002'}, {'value': '55', 'groupId': 'OG003'}, {'value': '110', 'groupId': 'OG004'}, {'value': '110', 'groupId': 'OG005'}, {'value': '55', 'groupId': 'OG006'}, {'value': '55', 'groupId': 'OG007'}, {'value': '56', 'groupId': 'OG008'}, {'value': '54', 'groupId': 'OG009'}, {'value': '109', 'groupId': 'OG010'}, {'value': '110', 'groupId': 'OG011'}, {'value': '58', 'groupId': 'OG012'}, {'value': '57', 'groupId': 'OG013'}, {'value': '113', 'groupId': 'OG014'}, {'value': '115', 'groupId': 'OG015'}, {'value': '56', 'groupId': 'OG016'}, {'value': '55', 'groupId': 'OG017'}, {'value': '111', 'groupId': 'OG018'}, {'value': '112', 'groupId': 'OG019'}, {'value': '56', 'groupId': 'OG020'}, {'value': '55', 'groupId': 'OG021'}, {'value': '112', 'groupId': 'OG022'}, {'value': '115', 'groupId': 'OG023'}]}], 'groups': [{'id': 'OG000', 'title': 'A10 PBO Q2W', 'description': 'Participants received atorvastatin 10 mg once daily during the 4 week lipid stabilization period and then in combination with placebo (PBO) subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG001', 'title': 'A10 PBO QM', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month (QM) and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG002', 'title': 'A10 EZE (Q2W)', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe (EZE) orally once daily for up to 12 weeks.'}, {'id': 'OG003', 'title': 'A10 EZE (QM)', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.'}, {'id': 'OG004', 'title': 'A10 EvoMab Q2W', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab (EvoMab) by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG005', 'title': 'A10 EvoMab QM', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG006', 'title': 'A80 PBO Q2W', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG007', 'title': 'A80 PBO QM', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG008', 'title': 'A80 EZE (Q2W)', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once daily for up to 12 weeks.'}, {'id': 'OG009', 'title': 'A80 EZE (QM)', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.'}, {'id': 'OG010', 'title': 'A80 EvoMab Q2W', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG011', 'title': 'A80 EvoMab QM', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.'}, {'id': 'OG012', 'title': 'R5 PBO Q2W', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG013', 'title': 'R5 PBO QM', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG014', 'title': 'R5 EvoMab Q2W', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG015', 'title': 'R5 EvoMab QM', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG016', 'title': 'R40 PBO Q2W', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG017', 'title': 'R40 PBO QM', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG018', 'title': 'R40 EvoMab Q2W', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG019', 'title': 'R40 EvoMab QM', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG020', 'title': 'S40 PBO Q2W', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG021', 'title': 'S40 PBO QM', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'OG022', 'title': 'S40 EvoMab Q2W', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'OG023', 'title': 'S40 EvoMab QM', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.'}], 'classes': [{'categories': [{'measurements': [{'value': '0.22', 'spread': '1.72', 'groupId': 'OG000'}, {'value': '0.01', 'spread': '2.02', 'groupId': 'OG001'}, {'value': '-1.76', 'spread': '1.78', 'groupId': 'OG002'}, {'value': '-0.40', 'spread': '1.99', 'groupId': 'OG003'}, {'value': '7.04', 'spread': '1.23', 'groupId': 'OG004'}, {'value': '7.88', 'spread': '1.42', 'groupId': 'OG005'}, {'value': '5.02', 'spread': '1.88', 'groupId': 'OG006'}, {'value': '0.30', 'spread': '2.01', 'groupId': 'OG007'}, {'value': '0.62', 'spread': '1.83', 'groupId': 'OG008'}, {'value': '0.21', 'spread': '2.01', 'groupId': 'OG009'}, {'value': '9.09', 'spread': '1.29', 'groupId': 'OG010'}, {'value': '7.36', 'spread': '1.43', 'groupId': 'OG011'}, {'value': '2.87', 'spread': '1.87', 'groupId': 'OG012'}, {'value': '-0.16', 'spread': '2.64', 'groupId': 'OG013'}, {'value': '6.07', 'spread': '1.35', 'groupId': 'OG014'}, {'value': '7.18', 'spread': '1.87', 'groupId': 'OG015'}, {'value': '-0.39', 'spread': '1.86', 'groupId': 'OG016'}, {'value': '0.73', 'spread': '1.98', 'groupId': 'OG017'}, {'value': '4.65', 'spread': '1.34', 'groupId': 'OG018'}, {'value': '5.57', 'spread': '1.37', 'groupId': 'OG019'}, {'value': '1.14', 'spread': '2.96', 'groupId': 'OG020'}, {'value': '-2.65', 'spread': '2.87', 'groupId': 'OG021'}, {'value': '10.92', 'spread': '2.38', 'groupId': 'OG022'}, {'value': '6.41', 'spread': '2.34', 'groupId': 'OG023'}]}]}], 'analyses': [{'pValue': '0.034', 'groupIds': ['OG000', 'OG004'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '6.83', 'ciLowerLimit': '2.66', 'ciUpperLimit': '10.99', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.11', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '0.017', 'groupIds': ['OG001', 'OG005'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '7.87', 'ciLowerLimit': '3.01', 'ciUpperLimit': '12.73', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.46', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '0.001', 'groupIds': ['OG002', 'OG004'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '8.81', 'ciLowerLimit': '4.58', 'ciUpperLimit': '13.03', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.14', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '0.006', 'groupIds': ['OG003', 'OG005'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '8.28', 'ciLowerLimit': '3.46', 'ciUpperLimit': '13.11', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.45', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '0.85', 'groupIds': ['OG006', 'OG010'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '4.07', 'ciLowerLimit': '-0.42', 'ciUpperLimit': '8.57', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.28', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG007', 'OG011'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '7.05', 'ciLowerLimit': '2.22', 'ciUpperLimit': '11.89', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.45', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '0.003', 'groupIds': ['OG008', 'OG010'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '8.47', 'ciLowerLimit': '4.07', 'ciUpperLimit': '12.87', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.23', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '0.003', 'groupIds': ['OG009', 'OG011'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '7.14', 'ciLowerLimit': '2.29', 'ciUpperLimit': '11.99', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.46', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG012', 'OG014'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '3.20', 'ciLowerLimit': '-1.33', 'ciUpperLimit': '7.73', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.30', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '0.010', 'groupIds': ['OG013', 'OG015'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '7.35', 'ciLowerLimit': '0.97', 'ciUpperLimit': '13.72', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.23', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '0.013', 'groupIds': ['OG016', 'OG018'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '5.04', 'ciLowerLimit': '0.52', 'ciUpperLimit': '9.56', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.29', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '0.002', 'groupIds': ['OG017', 'OG019'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '4.84', 'ciLowerLimit': '0.07', 'ciUpperLimit': '9.60', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.41', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG020', 'OG022'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '9.78', 'ciLowerLimit': '4.05', 'ciUpperLimit': '15.51', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.90', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit.'}, {'pValue': '<0.001', 'groupIds': ['OG021', 'OG023'], 'paramType': 'LS Mean Treatment Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '9.06', 'ciLowerLimit': '4.40', 'ciUpperLimit': '13.72', 'pValueComment': 'Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.36', 'statisticalMethod': 'Repeated measures linear effects model', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'statisticalComment': 'The model included treatment group, stratification factors, scheduled visit and the interaction of treatment with scheduled visit'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline and Week 12', 'unitOfMeasure': 'percent change', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'A10 PBO Q2W', 'description': 'Participants received atorvastatin 10 mg once daily during the 4 week lipid stabilization period and then in combination with placebo (PBO) subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once daily for up to 12 weeks.'}, {'id': 'FG001', 'title': 'A10 PBO QM', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month (QM) and placebo tablets once daily for up to 12 weeks.'}, {'id': 'FG002', 'title': 'A10 EZE (Q2W)', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe (EZE) orally once daily for up to 12 weeks.'}, {'id': 'FG003', 'title': 'A10 EZE (QM)', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.'}, {'id': 'FG004', 'title': 'A10 EvoMab Q2W', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab (EvoMab) by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.'}, {'id': 'FG005', 'title': 'A10 EvoMab QM', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.'}, {'id': 'FG006', 'title': 'A80 PBO Q2W', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.'}, {'id': 'FG007', 'title': 'A80 PBO QM', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.'}, {'id': 'FG008', 'title': 'A80 EZE (Q2W)', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once daily for up to 12 weeks.'}, {'id': 'FG009', 'title': 'A80 EZE (QM)', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.'}, {'id': 'FG010', 'title': 'A80 EvoMab Q2W', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.'}, {'id': 'FG011', 'title': 'A80 EvoMab QM', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.'}, {'id': 'FG012', 'title': 'R5 PBO Q2W', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'FG013', 'title': 'R5 PBO QM', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'FG014', 'title': 'R5 EvoMab Q2W', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'FG015', 'title': 'R5 EvoMab QM', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'FG016', 'title': 'R40 PBO Q2W', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'FG017', 'title': 'R40 PBO QM', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'FG018', 'title': 'R40 EvoMab Q2W', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'FG019', 'title': 'R40 EvoMab QM', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'FG020', 'title': 'S40 PBO Q2W', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'FG021', 'title': 'S40 PBO QM', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'FG022', 'title': 'S40 EvoMab Q2W', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'FG023', 'title': 'S40 EvoMab QM', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '56'}, {'groupId': 'FG001', 'numSubjects': '55'}, {'groupId': 'FG002', 'numSubjects': '56'}, {'groupId': 'FG003', 'numSubjects': '55'}, {'groupId': 'FG004', 'numSubjects': '110'}, {'groupId': 'FG005', 'numSubjects': '110'}, {'groupId': 'FG006', 'numSubjects': '55'}, {'groupId': 'FG007', 'numSubjects': '55'}, {'groupId': 'FG008', 'numSubjects': '56'}, {'groupId': 'FG009', 'numSubjects': '54'}, {'groupId': 'FG010', 'numSubjects': '110'}, {'groupId': 'FG011', 'numSubjects': '110'}, {'groupId': 'FG012', 'numSubjects': '58'}, {'groupId': 'FG013', 'numSubjects': '57'}, {'groupId': 'FG014', 'numSubjects': '114'}, {'groupId': 'FG015', 'numSubjects': '115'}, {'groupId': 'FG016', 'numSubjects': '56'}, {'groupId': 'FG017', 'numSubjects': '56'}, {'groupId': 'FG018', 'numSubjects': '111'}, {'groupId': 'FG019', 'numSubjects': '112'}, {'groupId': 'FG020', 'numSubjects': '56'}, {'groupId': 'FG021', 'numSubjects': '55'}, {'groupId': 'FG022', 'numSubjects': '112'}, {'groupId': 'FG023', 'numSubjects': '115'}]}, {'type': 'Received Treatment', 'achievements': [{'groupId': 'FG000', 'numSubjects': '56'}, {'groupId': 'FG001', 'numSubjects': '55'}, {'groupId': 'FG002', 'numSubjects': '56'}, {'groupId': 'FG003', 'numSubjects': '55'}, {'groupId': 'FG004', 'numSubjects': '110'}, {'groupId': 'FG005', 'numSubjects': '110'}, {'groupId': 'FG006', 'numSubjects': '55'}, {'groupId': 'FG007', 'numSubjects': '55'}, {'groupId': 'FG008', 'numSubjects': '56'}, {'groupId': 'FG009', 'numSubjects': '54'}, {'groupId': 'FG010', 'numSubjects': '109'}, {'groupId': 'FG011', 'numSubjects': '110'}, {'groupId': 'FG012', 'numSubjects': '58'}, {'groupId': 'FG013', 'numSubjects': '57'}, {'groupId': 'FG014', 'numSubjects': '113'}, {'groupId': 'FG015', 'numSubjects': '115'}, {'groupId': 'FG016', 'numSubjects': '56'}, {'groupId': 'FG017', 'numSubjects': '55'}, {'groupId': 'FG018', 'numSubjects': '111'}, {'groupId': 'FG019', 'numSubjects': '112'}, {'groupId': 'FG020', 'numSubjects': '56'}, {'groupId': 'FG021', 'numSubjects': '55'}, {'groupId': 'FG022', 'numSubjects': '112'}, {'groupId': 'FG023', 'numSubjects': '115'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '54'}, {'groupId': 'FG001', 'numSubjects': '54'}, {'groupId': 'FG002', 'numSubjects': '51'}, {'groupId': 'FG003', 'numSubjects': '55'}, {'groupId': 'FG004', 'numSubjects': '108'}, {'groupId': 'FG005', 'numSubjects': '107'}, {'groupId': 'FG006', 'numSubjects': '48'}, {'groupId': 'FG007', 'numSubjects': '55'}, {'groupId': 'FG008', 'numSubjects': '53'}, {'groupId': 'FG009', 'numSubjects': '53'}, {'groupId': 'FG010', 'numSubjects': '102'}, {'groupId': 'FG011', 'numSubjects': '108'}, {'groupId': 'FG012', 'numSubjects': '54'}, {'groupId': 'FG013', 'numSubjects': '57'}, {'groupId': 'FG014', 'numSubjects': '102'}, {'groupId': 'FG015', 'numSubjects': '112'}, {'groupId': 'FG016', 'numSubjects': '55'}, {'groupId': 'FG017', 'numSubjects': '55'}, {'groupId': 'FG018', 'numSubjects': '105'}, {'groupId': 'FG019', 'numSubjects': '110'}, {'groupId': 'FG020', 'numSubjects': '52'}, {'groupId': 'FG021', 'numSubjects': '54'}, {'groupId': 'FG022', 'numSubjects': '109'}, {'groupId': 'FG023', 'numSubjects': '113'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '2'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '5'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '2'}, {'groupId': 'FG005', 'numSubjects': '3'}, {'groupId': 'FG006', 'numSubjects': '7'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '3'}, {'groupId': 'FG009', 'numSubjects': '1'}, {'groupId': 'FG010', 'numSubjects': '8'}, {'groupId': 'FG011', 'numSubjects': '2'}, {'groupId': 'FG012', 'numSubjects': '4'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '12'}, {'groupId': 'FG015', 'numSubjects': '3'}, {'groupId': 'FG016', 'numSubjects': '1'}, {'groupId': 'FG017', 'numSubjects': '1'}, {'groupId': 'FG018', 'numSubjects': '6'}, {'groupId': 'FG019', 'numSubjects': '2'}, {'groupId': 'FG020', 'numSubjects': '4'}, {'groupId': 'FG021', 'numSubjects': '1'}, {'groupId': 'FG022', 'numSubjects': '3'}, {'groupId': 'FG023', 'numSubjects': '2'}]}], 'dropWithdraws': [{'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '2'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '4'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '3'}, {'groupId': 'FG006', 'numSubjects': '4'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '1'}, {'groupId': 'FG009', 'numSubjects': '1'}, {'groupId': 'FG010', 'numSubjects': '2'}, {'groupId': 'FG011', 'numSubjects': '2'}, {'groupId': 'FG012', 'numSubjects': '2'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '6'}, {'groupId': 'FG015', 'numSubjects': '3'}, {'groupId': 'FG016', 'numSubjects': '0'}, {'groupId': 'FG017', 'numSubjects': '1'}, {'groupId': 'FG018', 'numSubjects': '1'}, {'groupId': 'FG019', 'numSubjects': '1'}, {'groupId': 'FG020', 'numSubjects': '2'}, {'groupId': 'FG021', 'numSubjects': '1'}, {'groupId': 'FG022', 'numSubjects': '2'}, {'groupId': 'FG023', 'numSubjects': '1'}]}, {'type': 'Decision by sponsor', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '1'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '2'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '2'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '2'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '6'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '1'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '5'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}, {'groupId': 'FG017', 'numSubjects': '0'}, {'groupId': 'FG018', 'numSubjects': '4'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '2'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'groupId': 'FG022', 'numSubjects': '1'}, {'groupId': 'FG023', 'numSubjects': '0'}]}, {'type': 'Lost to Follow-up', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '1'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '1'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '1'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}, {'groupId': 'FG017', 'numSubjects': '0'}, {'groupId': 'FG018', 'numSubjects': '1'}, {'groupId': 'FG019', 'numSubjects': '1'}, {'groupId': 'FG020', 'numSubjects': '0'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'groupId': 'FG022', 'numSubjects': '0'}, {'groupId': 'FG023', 'numSubjects': '1'}]}, {'type': 'Death', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '1'}, {'groupId': 'FG017', 'numSubjects': '0'}, {'groupId': 'FG018', 'numSubjects': '0'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '0'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'groupId': 'FG022', 'numSubjects': '0'}, {'groupId': 'FG023', 'numSubjects': '0'}]}]}], 'recruitmentDetails': 'Adults aged 18 to 80 years with screening low-density lipoprotein cholesterol (LDL-C) ≥ 150 mg/dL (no statin at screening), ≥ 100 mg/dL (non-intensive statin at screening), or ≥ 80 mg/dL (intensive statin at screening) and fasting triglycerides ≤ 400 mg/dL.\n\nFirst patient enrolled on 15 January 2013; Last patient enrolled on 10 July 2013.', 'preAssignmentDetails': '2067 patients were first randomized to 1 of the 5 open-label statin cohorts (atorvastatin 10 mg or 80 mg, rosuvastatin 5 mg or 40 mg, or simvastatin 40 mg); 1899 were then randomized to blinded investigational product.\n\nRandomization into the statin dose cohorts was stratified by entry statin therapy and by use of certain concomitant medications.'}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '56', 'groupId': 'BG000'}, {'value': '55', 'groupId': 'BG001'}, {'value': '56', 'groupId': 'BG002'}, {'value': '55', 'groupId': 'BG003'}, {'value': '110', 'groupId': 'BG004'}, {'value': '110', 'groupId': 'BG005'}, {'value': '55', 'groupId': 'BG006'}, {'value': '55', 'groupId': 'BG007'}, {'value': '56', 'groupId': 'BG008'}, {'value': '54', 'groupId': 'BG009'}, {'value': '110', 'groupId': 'BG010'}, {'value': '110', 'groupId': 'BG011'}, {'value': '58', 'groupId': 'BG012'}, {'value': '57', 'groupId': 'BG013'}, {'value': '114', 'groupId': 'BG014'}, {'value': '115', 'groupId': 'BG015'}, {'value': '56', 'groupId': 'BG016'}, {'value': '56', 'groupId': 'BG017'}, {'value': '111', 'groupId': 'BG018'}, {'value': '112', 'groupId': 'BG019'}, {'value': '56', 'groupId': 'BG020'}, {'value': '55', 'groupId': 'BG021'}, {'value': '112', 'groupId': 'BG022'}, {'value': '115', 'groupId': 'BG023'}, {'value': '1899', 'groupId': 'BG024'}]}], 'groups': [{'id': 'BG000', 'title': 'A10 PBO Q2W', 'description': 'Participants received atorvastatin 10 mg once daily during the 4 week lipid stabilization period and then in combination with placebo (PBO) subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once daily for up to 12 weeks.'}, {'id': 'BG001', 'title': 'A10 PBO QM', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month (QM) and placebo tablets once daily for up to 12 weeks.'}, {'id': 'BG002', 'title': 'A10 EZE (Q2W)', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe (EZE) orally once daily for up to 12 weeks.'}, {'id': 'BG003', 'title': 'A10 EZE (QM)', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.'}, {'id': 'BG004', 'title': 'A10 EvoMab Q2W', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab (EvoMab) by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.'}, {'id': 'BG005', 'title': 'A10 EvoMab QM', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.'}, {'id': 'BG006', 'title': 'A80 PBO Q2W', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.'}, {'id': 'BG007', 'title': 'A80 PBO QM', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.'}, {'id': 'BG008', 'title': 'A80 EZE (Q2W)', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once daily for up to 12 weeks.'}, {'id': 'BG009', 'title': 'A80 EZE (QM)', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once daily for up to 12 weeks.'}, {'id': 'BG010', 'title': 'A80 EvoMab Q2W', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once daily for up to 12 weeks.'}, {'id': 'BG011', 'title': 'A80 EvoMab QM', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once daily for up to 12 weeks.'}, {'id': 'BG012', 'title': 'R5 PBO Q2W', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'BG013', 'title': 'R5 PBO QM', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'BG014', 'title': 'R5 EvoMab Q2W', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'BG015', 'title': 'R5 EvoMab QM', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'BG016', 'title': 'R40 PBO Q2W', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'BG017', 'title': 'R40 PBO QM', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'BG018', 'title': 'R40 EvoMab Q2W', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'BG019', 'title': 'R40 EvoMab QM', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'BG020', 'title': 'S40 PBO Q2W', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'BG021', 'title': 'S40 PBO QM', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'BG022', 'title': 'S40 EvoMab Q2W', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.'}, {'id': 'BG023', 'title': 'S40 EvoMab QM', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.'}, {'id': 'BG024', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '58.3', 'spread': '10.5', 'groupId': 'BG000'}, {'value': '62.2', 'spread': '10.4', 'groupId': 'BG001'}, {'value': '61.0', 'spread': '9.0', 'groupId': 'BG002'}, {'value': '60.6', 'spread': '9.2', 'groupId': 'BG003'}, {'value': '58.3', 'spread': '8.4', 'groupId': 'BG004'}, {'value': '59.6', 'spread': '11.1', 'groupId': 'BG005'}, {'value': '57.1', 'spread': '9.9', 'groupId': 'BG006'}, {'value': '58.8', 'spread': '11.5', 'groupId': 'BG007'}, {'value': '60.5', 'spread': '10.2', 'groupId': 'BG008'}, {'value': '61.1', 'spread': '8.9', 'groupId': 'BG009'}, {'value': '59.7', 'spread': '10.2', 'groupId': 'BG010'}, {'value': '60.1', 'spread': '10.2', 'groupId': 'BG011'}, {'value': '61.2', 'spread': '9.1', 'groupId': 'BG012'}, {'value': '59.6', 'spread': '9.2', 'groupId': 'BG013'}, {'value': '58.9', 'spread': '11.2', 'groupId': 'BG014'}, {'value': '59.3', 'spread': '10.5', 'groupId': 'BG015'}, {'value': '60.2', 'spread': '8.7', 'groupId': 'BG016'}, {'value': '58.3', 'spread': '11.3', 'groupId': 'BG017'}, {'value': '59.5', 'spread': '9.2', 'groupId': 'BG018'}, {'value': '59.6', 'spread': '9.0', 'groupId': 'BG019'}, {'value': '61.9', 'spread': '9.7', 'groupId': 'BG020'}, {'value': '61.5', 'spread': '10.3', 'groupId': 'BG021'}, {'value': '59.7', 'spread': '9.2', 'groupId': 'BG022'}, {'value': '61.5', 'spread': '9.6', 'groupId': 'BG023'}, {'value': '59.8', 'spread': '9.9', 'groupId': 'BG024'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '24', 'groupId': 'BG000'}, {'value': '28', 'groupId': 'BG001'}, {'value': '29', 'groupId': 'BG002'}, {'value': '28', 'groupId': 'BG003'}, {'value': '56', 'groupId': 'BG004'}, {'value': '44', 'groupId': 'BG005'}, {'value': '22', 'groupId': 'BG006'}, {'value': '24', 'groupId': 'BG007'}, {'value': '24', 'groupId': 'BG008'}, {'value': '28', 'groupId': 'BG009'}, {'value': '44', 'groupId': 'BG010'}, {'value': '48', 'groupId': 'BG011'}, {'value': '35', 'groupId': 'BG012'}, {'value': '27', 'groupId': 'BG013'}, {'value': '52', 'groupId': 'BG014'}, {'value': '51', 'groupId': 'BG015'}, {'value': '21', 'groupId': 'BG016'}, {'value': '27', 'groupId': 'BG017'}, {'value': '43', 'groupId': 'BG018'}, {'value': '52', 'groupId': 'BG019'}, {'value': '32', 'groupId': 'BG020'}, {'value': '28', 'groupId': 'BG021'}, {'value': '45', 'groupId': 'BG022'}, {'value': '59', 'groupId': 'BG023'}, {'value': '871', 'groupId': 'BG024'}]}, {'title': 'Male', 'measurements': [{'value': '32', 'groupId': 'BG000'}, {'value': '27', 'groupId': 'BG001'}, {'value': '27', 'groupId': 'BG002'}, {'value': '27', 'groupId': 'BG003'}, {'value': '54', 'groupId': 'BG004'}, {'value': '66', 'groupId': 'BG005'}, {'value': '33', 'groupId': 'BG006'}, {'value': '31', 'groupId': 'BG007'}, {'value': '32', 'groupId': 'BG008'}, {'value': '26', 'groupId': 'BG009'}, {'value': '66', 'groupId': 'BG010'}, {'value': '62', 'groupId': 'BG011'}, {'value': '23', 'groupId': 'BG012'}, {'value': '30', 'groupId': 'BG013'}, {'value': '62', 'groupId': 'BG014'}, {'value': '64', 'groupId': 'BG015'}, {'value': '35', 'groupId': 'BG016'}, {'value': '29', 'groupId': 'BG017'}, {'value': '68', 'groupId': 'BG018'}, {'value': '60', 'groupId': 'BG019'}, {'value': '24', 'groupId': 'BG020'}, {'value': '27', 'groupId': 'BG021'}, {'value': '67', 'groupId': 'BG022'}, {'value': '56', 'groupId': 'BG023'}, {'value': '1028', 'groupId': 'BG024'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race/Ethnicity, Customized', 'classes': [{'title': 'Hispanic or Latino', 'categories': [{'measurements': [{'value': '3', 'groupId': 'BG000'}, {'value': '2', 'groupId': 'BG001'}, {'value': '2', 'groupId': 'BG002'}, {'value': '1', 'groupId': 'BG003'}, {'value': '5', 'groupId': 'BG004'}, {'value': '2', 'groupId': 'BG005'}, {'value': '5', 'groupId': 'BG006'}, {'value': '5', 'groupId': 'BG007'}, {'value': '4', 'groupId': 'BG008'}, {'value': '4', 'groupId': 'BG009'}, {'value': '5', 'groupId': 'BG010'}, {'value': '7', 'groupId': 'BG011'}, {'value': '2', 'groupId': 'BG012'}, {'value': '4', 'groupId': 'BG013'}, {'value': '6', 'groupId': 'BG014'}, {'value': '3', 'groupId': 'BG015'}, {'value': '2', 'groupId': 'BG016'}, {'value': '3', 'groupId': 'BG017'}, {'value': '6', 'groupId': 'BG018'}, {'value': '5', 'groupId': 'BG019'}, {'value': '1', 'groupId': 'BG020'}, {'value': '2', 'groupId': 'BG021'}, {'value': '3', 'groupId': 'BG022'}, {'value': '5', 'groupId': 'BG023'}, {'value': '87', 'groupId': 'BG024'}]}]}, {'title': 'Not Hispanic or Latino', 'categories': [{'measurements': [{'value': '53', 'groupId': 'BG000'}, {'value': '53', 'groupId': 'BG001'}, {'value': '54', 'groupId': 'BG002'}, {'value': '54', 'groupId': 'BG003'}, {'value': '105', 'groupId': 'BG004'}, {'value': '108', 'groupId': 'BG005'}, {'value': '50', 'groupId': 'BG006'}, {'value': '50', 'groupId': 'BG007'}, {'value': '52', 'groupId': 'BG008'}, {'value': '50', 'groupId': 'BG009'}, {'value': '105', 'groupId': 'BG010'}, {'value': '103', 'groupId': 'BG011'}, {'value': '56', 'groupId': 'BG012'}, {'value': '53', 'groupId': 'BG013'}, {'value': '108', 'groupId': 'BG014'}, {'value': '112', 'groupId': 'BG015'}, {'value': '54', 'groupId': 'BG016'}, {'value': '53', 'groupId': 'BG017'}, {'value': '105', 'groupId': 'BG018'}, {'value': '107', 'groupId': 'BG019'}, {'value': '55', 'groupId': 'BG020'}, {'value': '53', 'groupId': 'BG021'}, {'value': '109', 'groupId': 'BG022'}, {'value': '110', 'groupId': 'BG023'}, {'value': '1812', 'groupId': 'BG024'}]}]}], 'paramType': 'NUMBER', 'unitOfMeasure': 'participants'}, {'title': 'Race/Ethnicity, Customized', 'classes': [{'title': 'American Indian or Alaska Native', 'categories': [{'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '0', 'groupId': 'BG006'}, {'value': '0', 'groupId': 'BG007'}, {'value': '0', 'groupId': 'BG008'}, {'value': '0', 'groupId': 'BG009'}, {'value': '0', 'groupId': 'BG010'}, {'value': '0', 'groupId': 'BG011'}, {'value': '0', 'groupId': 'BG012'}, {'value': '0', 'groupId': 'BG013'}, {'value': '0', 'groupId': 'BG014'}, {'value': '0', 'groupId': 'BG015'}, {'value': '0', 'groupId': 'BG016'}, {'value': '0', 'groupId': 'BG017'}, {'value': '0', 'groupId': 'BG018'}, {'value': '0', 'groupId': 'BG019'}, {'value': '0', 'groupId': 'BG020'}, {'value': '0', 'groupId': 'BG021'}, {'value': '1', 'groupId': 'BG022'}, {'value': '0', 'groupId': 'BG023'}, {'value': '1', 'groupId': 'BG024'}]}]}, {'title': 'Asian', 'categories': [{'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '2', 'groupId': 'BG002'}, {'value': '1', 'groupId': 'BG003'}, {'value': '3', 'groupId': 'BG004'}, {'value': '4', 'groupId': 'BG005'}, {'value': '1', 'groupId': 'BG006'}, {'value': '0', 'groupId': 'BG007'}, {'value': '0', 'groupId': 'BG008'}, {'value': '3', 'groupId': 'BG009'}, {'value': '1', 'groupId': 'BG010'}, {'value': '1', 'groupId': 'BG011'}, {'value': '0', 'groupId': 'BG012'}, {'value': '0', 'groupId': 'BG013'}, {'value': '2', 'groupId': 'BG014'}, {'value': '1', 'groupId': 'BG015'}, {'value': '1', 'groupId': 'BG016'}, {'value': '0', 'groupId': 'BG017'}, {'value': '0', 'groupId': 'BG018'}, {'value': '0', 'groupId': 'BG019'}, {'value': '3', 'groupId': 'BG020'}, {'value': '0', 'groupId': 'BG021'}, {'value': '1', 'groupId': 'BG022'}, {'value': '0', 'groupId': 'BG023'}, {'value': '25', 'groupId': 'BG024'}]}]}, {'title': 'Black or African American', 'categories': [{'measurements': [{'value': '3', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}, {'value': '2', 'groupId': 'BG003'}, {'value': '9', 'groupId': 'BG004'}, {'value': '4', 'groupId': 'BG005'}, {'value': '1', 'groupId': 'BG006'}, {'value': '2', 'groupId': 'BG007'}, {'value': '3', 'groupId': 'BG008'}, {'value': '4', 'groupId': 'BG009'}, {'value': '3', 'groupId': 'BG010'}, {'value': '4', 'groupId': 'BG011'}, {'value': '2', 'groupId': 'BG012'}, {'value': '1', 'groupId': 'BG013'}, {'value': '7', 'groupId': 'BG014'}, {'value': '5', 'groupId': 'BG015'}, {'value': '0', 'groupId': 'BG016'}, {'value': '3', 'groupId': 'BG017'}, {'value': '5', 'groupId': 'BG018'}, {'value': '3', 'groupId': 'BG019'}, {'value': '3', 'groupId': 'BG020'}, {'value': '1', 'groupId': 'BG021'}, {'value': '4', 'groupId': 'BG022'}, {'value': '5', 'groupId': 'BG023'}, {'value': '75', 'groupId': 'BG024'}]}]}, {'title': 'Native Hawaiian or Other Pacific Islander', 'categories': [{'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '0', 'groupId': 'BG006'}, {'value': '1', 'groupId': 'BG007'}, {'value': '0', 'groupId': 'BG008'}, {'value': '1', 'groupId': 'BG009'}, {'value': '0', 'groupId': 'BG010'}, {'value': '0', 'groupId': 'BG011'}, {'value': '0', 'groupId': 'BG012'}, {'value': '0', 'groupId': 'BG013'}, {'value': '0', 'groupId': 'BG014'}, {'value': '1', 'groupId': 'BG015'}, {'value': '0', 'groupId': 'BG016'}, {'value': '0', 'groupId': 'BG017'}, {'value': '0', 'groupId': 'BG018'}, {'value': '0', 'groupId': 'BG019'}, {'value': '1', 'groupId': 'BG020'}, {'value': '0', 'groupId': 'BG021'}, {'value': '0', 'groupId': 'BG022'}, {'value': '0', 'groupId': 'BG023'}, {'value': '4', 'groupId': 'BG024'}]}]}, {'title': 'White', 'categories': [{'measurements': [{'value': '52', 'groupId': 'BG000'}, {'value': '55', 'groupId': 'BG001'}, {'value': '53', 'groupId': 'BG002'}, {'value': '52', 'groupId': 'BG003'}, {'value': '97', 'groupId': 'BG004'}, {'value': '101', 'groupId': 'BG005'}, {'value': '51', 'groupId': 'BG006'}, {'value': '52', 'groupId': 'BG007'}, {'value': '53', 'groupId': 'BG008'}, {'value': '46', 'groupId': 'BG009'}, {'value': '105', 'groupId': 'BG010'}, {'value': '105', 'groupId': 'BG011'}, {'value': '56', 'groupId': 'BG012'}, {'value': '56', 'groupId': 'BG013'}, {'value': '104', 'groupId': 'BG014'}, {'value': '107', 'groupId': 'BG015'}, {'value': '55', 'groupId': 'BG016'}, {'value': '52', 'groupId': 'BG017'}, {'value': '105', 'groupId': 'BG018'}, {'value': '109', 'groupId': 'BG019'}, {'value': '49', 'groupId': 'BG020'}, {'value': '54', 'groupId': 'BG021'}, {'value': '106', 'groupId': 'BG022'}, {'value': '110', 'groupId': 'BG023'}, {'value': '1785', 'groupId': 'BG024'}]}]}, {'title': 'Other', 'categories': [{'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '1', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '2', 'groupId': 'BG006'}, {'value': '0', 'groupId': 'BG007'}, {'value': '0', 'groupId': 'BG008'}, {'value': '0', 'groupId': 'BG009'}, {'value': '1', 'groupId': 'BG010'}, {'value': '0', 'groupId': 'BG011'}, {'value': '0', 'groupId': 'BG012'}, {'value': '0', 'groupId': 'BG013'}, {'value': '1', 'groupId': 'BG014'}, {'value': '1', 'groupId': 'BG015'}, {'value': '0', 'groupId': 'BG016'}, {'value': '1', 'groupId': 'BG017'}, {'value': '0', 'groupId': 'BG018'}, {'value': '0', 'groupId': 'BG019'}, {'value': '0', 'groupId': 'BG020'}, {'value': '0', 'groupId': 'BG021'}, {'value': '0', 'groupId': 'BG022'}, {'value': '0', 'groupId': 'BG023'}, {'value': '7', 'groupId': 'BG024'}]}]}, {'title': 'Mixed Race', 'categories': [{'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '1', 'groupId': 'BG005'}, {'value': '0', 'groupId': 'BG006'}, {'value': '0', 'groupId': 'BG007'}, {'value': '0', 'groupId': 'BG008'}, {'value': '0', 'groupId': 'BG009'}, {'value': '0', 'groupId': 'BG010'}, {'value': '0', 'groupId': 'BG011'}, {'value': '0', 'groupId': 'BG012'}, {'value': '0', 'groupId': 'BG013'}, {'value': '0', 'groupId': 'BG014'}, {'value': '0', 'groupId': 'BG015'}, {'value': '0', 'groupId': 'BG016'}, {'value': '0', 'groupId': 'BG017'}, {'value': '1', 'groupId': 'BG018'}, {'value': '0', 'groupId': 'BG019'}, {'value': '0', 'groupId': 'BG020'}, {'value': '0', 'groupId': 'BG021'}, {'value': '0', 'groupId': 'BG022'}, {'value': '0', 'groupId': 'BG023'}, {'value': '2', 'groupId': 'BG024'}]}]}], 'paramType': 'NUMBER', 'unitOfMeasure': 'participants'}, {'title': 'Stratification Factor: Entry Statin Therapy', 'classes': [{'title': 'Intensive statin use', 'categories': [{'measurements': [{'value': '18', 'groupId': 'BG000'}, {'value': '19', 'groupId': 'BG001'}, {'value': '10', 'groupId': 'BG002'}, {'value': '14', 'groupId': 'BG003'}, {'value': '28', 'groupId': 'BG004'}, {'value': '35', 'groupId': 'BG005'}, {'value': '15', 'groupId': 'BG006'}, {'value': '12', 'groupId': 'BG007'}, {'value': '21', 'groupId': 'BG008'}, {'value': '11', 'groupId': 'BG009'}, {'value': '34', 'groupId': 'BG010'}, {'value': '35', 'groupId': 'BG011'}, {'value': '13', 'groupId': 'BG012'}, {'value': '13', 'groupId': 'BG013'}, {'value': '33', 'groupId': 'BG014'}, {'value': '38', 'groupId': 'BG015'}, {'value': '13', 'groupId': 'BG016'}, {'value': '13', 'groupId': 'BG017'}, {'value': '33', 'groupId': 'BG018'}, {'value': '37', 'groupId': 'BG019'}, {'value': '19', 'groupId': 'BG020'}, {'value': '13', 'groupId': 'BG021'}, {'value': '31', 'groupId': 'BG022'}, {'value': '34', 'groupId': 'BG023'}, {'value': '542', 'groupId': 'BG024'}]}]}, {'title': 'Non-intensive statin use', 'categories': [{'measurements': [{'value': '20', 'groupId': 'BG000'}, {'value': '25', 'groupId': 'BG001'}, {'value': '30', 'groupId': 'BG002'}, {'value': '21', 'groupId': 'BG003'}, {'value': '52', 'groupId': 'BG004'}, {'value': '40', 'groupId': 'BG005'}, {'value': '22', 'groupId': 'BG006'}, {'value': '27', 'groupId': 'BG007'}, {'value': '22', 'groupId': 'BG008'}, {'value': '21', 'groupId': 'BG009'}, {'value': '47', 'groupId': 'BG010'}, {'value': '46', 'groupId': 'BG011'}, {'value': '25', 'groupId': 'BG012'}, {'value': '28', 'groupId': 'BG013'}, {'value': '49', 'groupId': 'BG014'}, {'value': '42', 'groupId': 'BG015'}, {'value': '23', 'groupId': 'BG016'}, {'value': '22', 'groupId': 'BG017'}, {'value': '50', 'groupId': 'BG018'}, {'value': '44', 'groupId': 'BG019'}, {'value': '21', 'groupId': 'BG020'}, {'value': '26', 'groupId': 'BG021'}, {'value': '45', 'groupId': 'BG022'}, {'value': '48', 'groupId': 'BG023'}, {'value': '796', 'groupId': 'BG024'}]}]}, {'title': 'No statin use', 'categories': [{'measurements': [{'value': '18', 'groupId': 'BG000'}, {'value': '11', 'groupId': 'BG001'}, {'value': '16', 'groupId': 'BG002'}, {'value': '20', 'groupId': 'BG003'}, {'value': '30', 'groupId': 'BG004'}, {'value': '35', 'groupId': 'BG005'}, {'value': '18', 'groupId': 'BG006'}, {'value': '16', 'groupId': 'BG007'}, {'value': '13', 'groupId': 'BG008'}, {'value': '22', 'groupId': 'BG009'}, {'value': '29', 'groupId': 'BG010'}, {'value': '29', 'groupId': 'BG011'}, {'value': '20', 'groupId': 'BG012'}, {'value': '16', 'groupId': 'BG013'}, {'value': '32', 'groupId': 'BG014'}, {'value': '35', 'groupId': 'BG015'}, {'value': '20', 'groupId': 'BG016'}, {'value': '21', 'groupId': 'BG017'}, {'value': '28', 'groupId': 'BG018'}, {'value': '31', 'groupId': 'BG019'}, {'value': '16', 'groupId': 'BG020'}, {'value': '16', 'groupId': 'BG021'}, {'value': '36', 'groupId': 'BG022'}, {'value': '33', 'groupId': 'BG023'}, {'value': '561', 'groupId': 'BG024'}]}]}], 'paramType': 'NUMBER', 'description': 'Intensive statin use was defined as daily atorvastatin (40 mg or greater), rosuvastatin (20 mg or greater), simvastatin (80 mg), or any statin plus ezetimibe.', 'unitOfMeasure': 'participants'}, {'title': 'Low-Density Lipoprotein Cholesterol (LDL-C) Concentration', 'classes': [{'categories': [{'measurements': [{'value': '123.0', 'spread': '46.6', 'groupId': 'BG000'}, {'value': '123.7', 'spread': '47.9', 'groupId': 'BG001'}, {'value': '126.8', 'spread': '49.6', 'groupId': 'BG002'}, {'value': '119.3', 'spread': '28.1', 'groupId': 'BG003'}, {'value': '124.2', 'spread': '43.4', 'groupId': 'BG004'}, {'value': '126.1', 'spread': '50.4', 'groupId': 'BG005'}, {'value': '100.3', 'spread': '36.2', 'groupId': 'BG006'}, {'value': '94.7', 'spread': '31.9', 'groupId': 'BG007'}, {'value': '98.7', 'spread': '34.0', 'groupId': 'BG008'}, {'value': '92.3', 'spread': '19.3', 'groupId': 'BG009'}, {'value': '94.2', 'spread': '34.8', 'groupId': 'BG010'}, {'value': '93.8', 'spread': '32.3', 'groupId': 'BG011'}, {'value': '115.6', 'spread': '39.8', 'groupId': 'BG012'}, {'value': '119.9', 'spread': '39.1', 'groupId': 'BG013'}, {'value': '118.7', 'spread': '40.9', 'groupId': 'BG014'}, {'value': '122.9', 'spread': '42.0', 'groupId': 'BG015'}, {'value': '77.4', 'spread': '20.9', 'groupId': 'BG016'}, {'value': '102.9', 'spread': '49.3', 'groupId': 'BG017'}, {'value': '88.5', 'spread': '31.5', 'groupId': 'BG018'}, {'value': '88.5', 'spread': '31.3', 'groupId': 'BG019'}, {'value': '110.3', 'spread': '28.0', 'groupId': 'BG020'}, {'value': '108.6', 'spread': '30.9', 'groupId': 'BG021'}, {'value': '114.9', 'spread': '34.5', 'groupId': 'BG022'}, {'value': '123.7', 'spread': '48.5', 'groupId': 'BG023'}, {'value': '109.1', 'spread': '41.1', 'groupId': 'BG024'}]}]}], 'paramType': 'MEAN', 'description': 'Data are provided for the full analysis set (all participants randomized to investigational product (IP) who received at least 1 dose of IP (subcutaneously or orally). Baseline was measured after the lipid stabilization period and before administration of first dose of study drug.', 'unitOfMeasure': 'mg/dL', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Non-High-Density Lipoprotein Cholesterol (non-HDL-C) Concentration', 'classes': [{'categories': [{'measurements': [{'value': '149.1', 'spread': '46.9', 'groupId': 'BG000'}, {'value': '147.7', 'spread': '51.4', 'groupId': 'BG001'}, {'value': '153.8', 'spread': '53.2', 'groupId': 'BG002'}, {'value': '148.3', 'spread': '36.8', 'groupId': 'BG003'}, {'value': '152.3', 'spread': '45.6', 'groupId': 'BG004'}, {'value': '154.3', 'spread': '53.1', 'groupId': 'BG005'}, {'value': '124.2', 'spread': '39.3', 'groupId': 'BG006'}, {'value': '116.5', 'spread': '35.7', 'groupId': 'BG007'}, {'value': '124.8', 'spread': '35.4', 'groupId': 'BG008'}, {'value': '118.4', 'spread': '25.5', 'groupId': 'BG009'}, {'value': '120.2', 'spread': '42.3', 'groupId': 'BG010'}, {'value': '117.2', 'spread': '36.3', 'groupId': 'BG011'}, {'value': '141.1', 'spread': '41.6', 'groupId': 'BG012'}, {'value': '148.3', 'spread': '43.3', 'groupId': 'BG013'}, {'value': '146.6', 'spread': '43.2', 'groupId': 'BG014'}, {'value': '152.0', 'spread': '46.4', 'groupId': 'BG015'}, {'value': '103.9', 'spread': '25.7', 'groupId': 'BG016'}, {'value': '128.7', 'spread': '53.4', 'groupId': 'BG017'}, {'value': '113.5', 'spread': '36.0', 'groupId': 'BG018'}, {'value': '114.3', 'spread': '34.7', 'groupId': 'BG019'}, {'value': '138.4', 'spread': '29.3', 'groupId': 'BG020'}, {'value': '135.7', 'spread': '38.4', 'groupId': 'BG021'}, {'value': '146.8', 'spread': '41.8', 'groupId': 'BG022'}, {'value': '151.2', 'spread': '51.5', 'groupId': 'BG023'}, {'value': '150.3', 'spread': '27.6', 'groupId': 'BG024'}]}]}], 'paramType': 'MEAN', 'description': 'Data are provided for the full analysis set. Baseline was measured after the lipid stabilization period and before administration of first dose of study drug.', 'unitOfMeasure': 'mg/dL', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Apolipoprotein B Concentration', 'classes': [{'categories': [{'measurements': [{'value': '95.3', 'spread': '26.0', 'groupId': 'BG000'}, {'value': '95.3', 'spread': '29.6', 'groupId': 'BG001'}, {'value': '101.3', 'spread': '31.2', 'groupId': 'BG002'}, {'value': '94.6', 'spread': '20.4', 'groupId': 'BG003'}, {'value': '99.7', 'spread': '26.4', 'groupId': 'BG004'}, {'value': '97.3', 'spread': '28.9', 'groupId': 'BG005'}, {'value': '81.1', 'spread': '22.1', 'groupId': 'BG006'}, {'value': '80.1', 'spread': '21.4', 'groupId': 'BG007'}, {'value': '85.3', 'spread': '23.1', 'groupId': 'BG008'}, {'value': '78.7', 'spread': '16.9', 'groupId': 'BG009'}, {'value': '79.9', 'spread': '25.1', 'groupId': 'BG010'}, {'value': '77.9', 'spread': '21.5', 'groupId': 'BG011'}, {'value': '93.1', 'spread': '27.3', 'groupId': 'BG012'}, {'value': '95.9', 'spread': '25.2', 'groupId': 'BG013'}, {'value': '95.4', 'spread': '27.0', 'groupId': 'BG014'}, {'value': '97.2', 'spread': '26.9', 'groupId': 'BG015'}, {'value': '71.0', 'spread': '16.6', 'groupId': 'BG016'}, {'value': '84.8', 'spread': '29.7', 'groupId': 'BG017'}, {'value': '77.4', 'spread': '22.3', 'groupId': 'BG018'}, {'value': '78.7', 'spread': '23.1', 'groupId': 'BG019'}, {'value': '91.6', 'spread': '18.4', 'groupId': 'BG020'}, {'value': '89.8', 'spread': '20.7', 'groupId': 'BG021'}, {'value': '94.2', 'spread': '24.0', 'groupId': 'BG022'}, {'value': '96.5', 'spread': '27.5', 'groupId': 'BG023'}, {'value': '89.1', 'spread': '26.1', 'groupId': 'BG024'}]}]}], 'paramType': 'MEAN', 'description': 'Data are provided for the full analysis set. Baseline was measured after the lipid stabilization period and before administration of first dose of study drug.', 'unitOfMeasure': 'mg/dL', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Total Cholesterol/HDL-C Ratio', 'classes': [{'categories': [{'measurements': [{'value': '3.988', 'spread': '1.154', 'groupId': 'BG000'}, {'value': '3.859', 'spread': '1.396', 'groupId': 'BG001'}, {'value': '4.112', 'spread': '1.311', 'groupId': 'BG002'}, {'value': '4.002', 'spread': '1.100', 'groupId': 'BG003'}, {'value': '3.980', 'spread': '1.224', 'groupId': 'BG004'}, {'value': '4.100', 'spread': '1.636', 'groupId': 'BG005'}, {'value': '3.704', 'spread': '1.260', 'groupId': 'BG006'}, {'value': '3.461', 'spread': '1.093', 'groupId': 'BG007'}, {'value': '3.748', 'spread': '1.099', 'groupId': 'BG008'}, {'value': '3.540', 'spread': '1.100', 'groupId': 'BG009'}, {'value': '3.696', 'spread': '1.371', 'groupId': 'BG010'}, {'value': '3.462', 'spread': '1.000', 'groupId': 'BG011'}, {'value': '4.044', 'spread': '1.685', 'groupId': 'BG012'}, {'value': '3.891', 'spread': '1.234', 'groupId': 'BG013'}, {'value': '3.915', 'spread': '1.216', 'groupId': 'BG014'}, {'value': '4.178', 'spread': '1.932', 'groupId': 'BG015'}, {'value': '3.086', 'spread': '0.728', 'groupId': 'BG016'}, {'value': '3.547', 'spread': '1.355', 'groupId': 'BG017'}, {'value': '3.413', 'spread': '1.355', 'groupId': 'BG018'}, {'value': '3.307', 'spread': '1.061', 'groupId': 'BG019'}, {'value': '3.733', 'spread': '1.079', 'groupId': 'BG020'}, {'value': '3.595', 'spread': '1.345', 'groupId': 'BG021'}, {'value': '4.196', 'spread': '1.436', 'groupId': 'BG022'}, {'value': '3.924', 'spread': '1.420', 'groupId': 'BG023'}, {'value': '3.786', 'spread': '1.353', 'groupId': 'BG024'}]}]}], 'paramType': 'MEAN', 'description': 'Data are provided for the full analysis set. Baseline was measured after the lipid stabilization period and before administration of first dose of study drug.', 'unitOfMeasure': 'ratio', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Apolipoprotein B/Apolipoprotein A1 Ratio', 'classes': [{'categories': [{'measurements': [{'value': '0.666', 'spread': '0.216', 'groupId': 'BG000'}, {'value': '0.647', 'spread': '0.266', 'groupId': 'BG001'}, {'value': '0.692', 'spread': '0.243', 'groupId': 'BG002'}, {'value': '0.640', 'spread': '0.169', 'groupId': 'BG003'}, {'value': '0.663', 'spread': '0.217', 'groupId': 'BG004'}, {'value': '0.659', 'spread': '0.249', 'groupId': 'BG005'}, {'value': '0.603', 'spread': '0.221', 'groupId': 'BG006'}, {'value': '0.571', 'spread': '0.189', 'groupId': 'BG007'}, {'value': '0.640', 'spread': '0.234', 'groupId': 'BG008'}, {'value': '0.560', 'spread': '0.157', 'groupId': 'BG009'}, {'value': '0.593', 'spread': '0.227', 'groupId': 'BG010'}, {'value': '0.562', 'spread': '0.171', 'groupId': 'BG011'}, {'value': '0.661', 'spread': '0.273', 'groupId': 'BG012'}, {'value': '0.636', 'spread': '0.207', 'groupId': 'BG013'}, {'value': '0.640', 'spread': '0.249', 'groupId': 'BG014'}, {'value': '0.676', 'spread': '0.341', 'groupId': 'BG015'}, {'value': '0.479', 'spread': '0.129', 'groupId': 'BG016'}, {'value': '0.562', 'spread': '0.217', 'groupId': 'BG017'}, {'value': '0.538', 'spread': '0.227', 'groupId': 'BG018'}, {'value': '0.536', 'spread': '0.193', 'groupId': 'BG019'}, {'value': '0.611', 'spread': '0.179', 'groupId': 'BG020'}, {'value': '0.581', 'spread': '0.174', 'groupId': 'BG021'}, {'value': '0.657', 'spread': '0.193', 'groupId': 'BG022'}, {'value': '0.639', 'spread': '0.224', 'groupId': 'BG023'}, {'value': '0.614', 'spread': '0.229', 'groupId': 'BG024'}]}]}], 'paramType': 'MEAN', 'description': 'Data are provided for the full analysis set. Baseline was measured after the lipid stabilization period and before administration of first dose of study drug.', 'unitOfMeasure': 'ratio', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Lipoprotein(a) Concentration', 'classes': [{'categories': [{'measurements': [{'value': '31.5', 'groupId': 'BG000', 'lowerLimit': '13.0', 'upperLimit': '87.5'}, {'value': '41.0', 'groupId': 'BG001', 'lowerLimit': '15.0', 'upperLimit': '106.0'}, {'value': '37.0', 'groupId': 'BG002', 'lowerLimit': '9.5', 'upperLimit': '190.0'}, {'value': '33.0', 'groupId': 'BG003', 'lowerLimit': '8.0', 'upperLimit': '163.0'}, {'value': '27.0', 'groupId': 'BG004', 'lowerLimit': '8.0', 'upperLimit': '120.0'}, {'value': '49.0', 'groupId': 'BG005', 'lowerLimit': '11.0', 'upperLimit': '169.0'}, {'value': '53.0', 'groupId': 'BG006', 'lowerLimit': '15.0', 'upperLimit': '177.0'}, {'value': '50.0', 'groupId': 'BG007', 'lowerLimit': '13.0', 'upperLimit': '152.0'}, {'value': '25.0', 'groupId': 'BG008', 'lowerLimit': '12.0', 'upperLimit': '108.0'}, {'value': '61.5', 'groupId': 'BG009', 'lowerLimit': '12.0', 'upperLimit': '192.0'}, {'value': '32.0', 'groupId': 'BG010', 'lowerLimit': '11.5', 'upperLimit': '135.5'}, {'value': '24.5', 'groupId': 'BG011', 'lowerLimit': '8.0', 'upperLimit': '93.0'}, {'value': '34.0', 'groupId': 'BG012', 'lowerLimit': '8.0', 'upperLimit': '158.0'}, {'value': '35.0', 'groupId': 'BG013', 'lowerLimit': '14.0', 'upperLimit': '156.5'}, {'value': '38.0', 'groupId': 'BG014', 'lowerLimit': '11.0', 'upperLimit': '165.0'}, {'value': '32.0', 'groupId': 'BG015', 'lowerLimit': '9.0', 'upperLimit': '172.0'}, {'value': '28.5', 'groupId': 'BG016', 'lowerLimit': '7.0', 'upperLimit': '171.0'}, {'value': '33.0', 'groupId': 'BG017', 'lowerLimit': '11.0', 'upperLimit': '148.0'}, {'value': '41.0', 'groupId': 'BG018', 'lowerLimit': '10.0', 'upperLimit': '183.0'}, {'value': '49.5', 'groupId': 'BG019', 'lowerLimit': '11.0', 'upperLimit': '184.5'}, {'value': '36.5', 'groupId': 'BG020', 'lowerLimit': '17.5', 'upperLimit': '140.5'}, {'value': '28.0', 'groupId': 'BG021', 'lowerLimit': '13.0', 'upperLimit': '180.0'}, {'value': '32.5', 'groupId': 'BG022', 'lowerLimit': '13.0', 'upperLimit': '157.0'}, {'value': '37.0', 'groupId': 'BG023', 'lowerLimit': '11.0', 'upperLimit': '141.0'}, {'value': '34.0', 'groupId': 'BG024', 'lowerLimit': '11.0', 'upperLimit': '161.5'}]}]}], 'paramType': 'MEDIAN', 'description': 'Data are provided for the full analysis set. Baseline was measured after the lipid stabilization period and before administration of first dose of study drug.', 'unitOfMeasure': 'nmol/L', 'dispersionType': 'INTER_QUARTILE_RANGE'}, {'title': 'Triglyceride Concentration', 'classes': [{'categories': [{'measurements': [{'value': '112.0', 'groupId': 'BG000', 'lowerLimit': '83.0', 'upperLimit': '176.0'}, {'value': '108.0', 'groupId': 'BG001', 'lowerLimit': '83.0', 'upperLimit': '145.0'}, {'value': '129.5', 'groupId': 'BG002', 'lowerLimit': '94.0', 'upperLimit': '151.5'}, {'value': '119.0', 'groupId': 'BG003', 'lowerLimit': '87.0', 'upperLimit': '168.0'}, {'value': '135.0', 'groupId': 'BG004', 'lowerLimit': '99.0', 'upperLimit': '189.0'}, {'value': '119.0', 'groupId': 'BG005', 'lowerLimit': '84.0', 'upperLimit': '161.0'}, {'value': '104.0', 'groupId': 'BG006', 'lowerLimit': '82.0', 'upperLimit': '142.0'}, {'value': '104.0', 'groupId': 'BG007', 'lowerLimit': '76.0', 'upperLimit': '124.0'}, {'value': '133.0', 'groupId': 'BG008', 'lowerLimit': '89.0', 'upperLimit': '155.0'}, {'value': '109.0', 'groupId': 'BG009', 'lowerLimit': '80.0', 'upperLimit': '171.0'}, {'value': '104.0', 'groupId': 'BG010', 'lowerLimit': '81.0', 'upperLimit': '163.0'}, {'value': '106.5', 'groupId': 'BG011', 'lowerLimit': '79.0', 'upperLimit': '137.0'}, {'value': '112.5', 'groupId': 'BG012', 'lowerLimit': '89.0', 'upperLimit': '148.0'}, {'value': '134.0', 'groupId': 'BG013', 'lowerLimit': '86.0', 'upperLimit': '184.0'}, {'value': '116.0', 'groupId': 'BG014', 'lowerLimit': '90.0', 'upperLimit': '168.0'}, {'value': '121.0', 'groupId': 'BG015', 'lowerLimit': '93.0', 'upperLimit': '161.0'}, {'value': '128.0', 'groupId': 'BG016', 'lowerLimit': '91.5', 'upperLimit': '162.0'}, {'value': '116.0', 'groupId': 'BG017', 'lowerLimit': '78.0', 'upperLimit': '160.0'}, {'value': '102.0', 'groupId': 'BG018', 'lowerLimit': '79.0', 'upperLimit': '151.0'}, {'value': '119.5', 'groupId': 'BG019', 'lowerLimit': '87.0', 'upperLimit': '149.5'}, {'value': '124.0', 'groupId': 'BG020', 'lowerLimit': '90.0', 'upperLimit': '173.0'}, {'value': '106.0', 'groupId': 'BG021', 'lowerLimit': '87.0', 'upperLimit': '139.0'}, {'value': '129.0', 'groupId': 'BG022', 'lowerLimit': '91.5', 'upperLimit': '195.0'}, {'value': '110.0', 'groupId': 'BG023', 'lowerLimit': '84.0', 'upperLimit': '161.0'}, {'value': '116.0', 'groupId': 'BG024', 'lowerLimit': '86.0', 'upperLimit': '158.0'}]}]}], 'paramType': 'MEDIAN', 'description': 'Data are provided for the full analysis set. Baseline was measured after the lipid stabilization period and before administration of first dose of study drug.', 'unitOfMeasure': 'mg/dL', 'dispersionType': 'INTER_QUARTILE_RANGE'}, {'title': 'Very Low Density Lipoprotein Cholesterol (VLDL-C) Concentration', 'classes': [{'categories': [{'measurements': [{'value': '22.0', 'groupId': 'BG000', 'lowerLimit': '17.0', 'upperLimit': '35.0'}, {'value': '22.0', 'groupId': 'BG001', 'lowerLimit': '17.0', 'upperLimit': '29.0'}, {'value': '25.5', 'groupId': 'BG002', 'lowerLimit': '19.0', 'upperLimit': '30.0'}, {'value': '24.0', 'groupId': 'BG003', 'lowerLimit': '17.0', 'upperLimit': '33.0'}, {'value': '27.0', 'groupId': 'BG004', 'lowerLimit': '20.0', 'upperLimit': '38.0'}, {'value': '24.0', 'groupId': 'BG005', 'lowerLimit': '17.0', 'upperLimit': '32.0'}, {'value': '21.0', 'groupId': 'BG006', 'lowerLimit': '16.0', 'upperLimit': '28.0'}, {'value': '21.0', 'groupId': 'BG007', 'lowerLimit': '15.0', 'upperLimit': '25.0'}, {'value': '26.5', 'groupId': 'BG008', 'lowerLimit': '18.0', 'upperLimit': '31.0'}, {'value': '22.0', 'groupId': 'BG009', 'lowerLimit': '16.0', 'upperLimit': '34.0'}, {'value': '21.0', 'groupId': 'BG010', 'lowerLimit': '16.0', 'upperLimit': '33.0'}, {'value': '21.0', 'groupId': 'BG011', 'lowerLimit': '16.0', 'upperLimit': '27.0'}, {'value': '22.5', 'groupId': 'BG012', 'lowerLimit': '18.0', 'upperLimit': '30.0'}, {'value': '27.0', 'groupId': 'BG013', 'lowerLimit': '17.0', 'upperLimit': '37.0'}, {'value': '23.0', 'groupId': 'BG014', 'lowerLimit': '18.0', 'upperLimit': '34.0'}, {'value': '24.0', 'groupId': 'BG015', 'lowerLimit': '19.0', 'upperLimit': '32.0'}, {'value': '26.0', 'groupId': 'BG016', 'lowerLimit': '18.5', 'upperLimit': '32.5'}, {'value': '23.0', 'groupId': 'BG017', 'lowerLimit': '16.0', 'upperLimit': '32.0'}, {'value': '20.0', 'groupId': 'BG018', 'lowerLimit': '16.0', 'upperLimit': '30.0'}, {'value': '24.0', 'groupId': 'BG019', 'lowerLimit': '17.0', 'upperLimit': '30.0'}, {'value': '25.0', 'groupId': 'BG020', 'lowerLimit': '18.0', 'upperLimit': '34.5'}, {'value': '21.0', 'groupId': 'BG021', 'lowerLimit': '17.0', 'upperLimit': '26.0'}, {'value': '26.0', 'groupId': 'BG022', 'lowerLimit': '18.5', 'upperLimit': '39.0'}, {'value': '22.0', 'groupId': 'BG023', 'lowerLimit': '17.0', 'upperLimit': '32.0'}, {'value': '23.0', 'groupId': 'BG024', 'lowerLimit': '17.0', 'upperLimit': '32.0'}]}]}], 'paramType': 'MEDIAN', 'description': 'Data are provided for the full analysis set. Baseline was measured after the lipid stabilization period and before administration of first dose of study drug.', 'unitOfMeasure': 'mg/dL', 'dispersionType': 'INTER_QUARTILE_RANGE'}, {'title': 'HDL-C Concentration', 'classes': [{'categories': [{'measurements': [{'value': '54.1', 'spread': '16.6', 'groupId': 'BG000'}, {'value': '57.9', 'spread': '18.4', 'groupId': 'BG001'}, {'value': '54.1', 'spread': '17.2', 'groupId': 'BG002'}, {'value': '52.7', 'spread': '13.7', 'groupId': 'BG003'}, {'value': '56.0', 'spread': '17.9', 'groupId': 'BG004'}, {'value': '56.1', 'spread': '17.8', 'groupId': 'BG005'}, {'value': '50.6', 'spread': '15.6', 'groupId': 'BG006'}, {'value': '50.9', 'spread': '13.0', 'groupId': 'BG007'}, {'value': '48.7', 'spread': '12.6', 'groupId': 'BG008'}, {'value': '51.6', 'spread': '15.1', 'groupId': 'BG009'}, {'value': '48.5', 'spread': '12.9', 'groupId': 'BG010'}, {'value': '50.8', 'spread': '13.5', 'groupId': 'BG011'}, {'value': '52.1', 'spread': '14.9', 'groupId': 'BG012'}, {'value': '55.5', 'spread': '16.0', 'groupId': 'BG013'}, {'value': '54.5', 'spread': '15.0', 'groupId': 'BG014'}, {'value': '54.0', 'spread': '16.0', 'groupId': 'BG015'}, {'value': '52.8', 'spread': '12.9', 'groupId': 'BG016'}, {'value': '56.0', 'spread': '18.7', 'groupId': 'BG017'}, {'value': '53.2', 'spread': '16.4', 'groupId': 'BG018'}, {'value': '53.8', 'spread': '14.6', 'groupId': 'BG019'}, {'value': '55.0', 'spread': '14.2', 'groupId': 'BG020'}, {'value': '59.9', 'spread': '21.8', 'groupId': 'BG021'}, {'value': '49.7', 'spread': '12.6', 'groupId': 'BG022'}, {'value': '57.3', 'spread': '17.4', 'groupId': 'BG023'}, {'value': '53.5', 'spread': '15.9', 'groupId': 'BG024'}]}]}], 'paramType': 'MEAN', 'description': 'Data are provided for the full anlaysis set. Baseline was measured after the lipid stabilization period and before administration of first dose of study drug.', 'unitOfMeasure': 'mg/dL', 'dispersionType': 'STANDARD_DEVIATION'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 2067}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2013-01-15', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2022-11', 'dispFirstSubmitDate': '2014-05-02', 'completionDateStruct': {'date': '2013-12-04', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2022-11-04', 'studyFirstSubmitDate': '2013-01-07', 'dispFirstSubmitQcDate': '2014-05-02', 'resultsFirstSubmitDate': '2015-09-01', 'studyFirstSubmitQcDate': '2013-01-08', 'dispFirstPostDateStruct': {'date': '2014-05-20', 'type': 'ESTIMATED'}, 'lastUpdatePostDateStruct': {'date': '2022-11-08', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2015-11-18', 'studyFirstPostDateStruct': {'date': '2013-01-09', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2015-12-22', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2013-11-12', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12', 'timeFrame': 'Baseline and Week 12'}, {'measure': 'Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12', 'timeFrame': 'Baseline and Weeks 10 and 12'}], 'secondaryOutcomes': [{'measure': 'Change From Baseline in LDL-C at at the Mean of Weeks 10 and 12', 'timeFrame': 'Baseline and Weeks 10 and 12'}, {'measure': 'Change From Baseline in LDL-C at Week 12', 'timeFrame': 'Baseline and Week 12'}, {'measure': 'Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) at the Mean of Weeks 10 and 12', 'timeFrame': 'Baseline and Weeks 10 and 12'}, {'measure': 'Percent Change From Baseline in Non-HDL-C at Week 12', 'timeFrame': 'Baseline and Week 12'}, {'measure': 'Percent Change From Baseline in Apolipoprotein B at the Mean of Weeks 10 and 12', 'timeFrame': 'Baseline and Weeks 10 and 12'}, {'measure': 'Percent Change From Baseline in Apolipoprotein B at Week 12', 'timeFrame': 'Baseline and Week 12'}, {'measure': 'Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at the Mean of Weeks 10 and 12', 'timeFrame': 'Baseline and Weeks 10 and 12'}, {'measure': 'Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at Week 12', 'timeFrame': 'Baseline and Week 12'}, {'measure': 'Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at the Mean of Weeks 10 and 12', 'timeFrame': 'Baseline and Weeks 10 and 12'}, {'measure': 'Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 12', 'timeFrame': 'Baseline and Week 12'}, {'measure': 'Percentage of Participants Who Achieved a Mean LDL-C at Weeks 10 and 12 of Less Than 70 mg/dL', 'timeFrame': 'Weeks 10 and 12'}, {'measure': 'Percentage of Participants Who Achieved LDL-C < 70 mg/dL at Week 12', 'timeFrame': 'Week 12'}, {'measure': 'Percent Change From Baseline in Lipoprotein(a) at the Mean of Weeks 10 and 12', 'timeFrame': 'Baseline and Weeks 10 and 12'}, {'measure': 'Percent Change From Baseline in Lipoprotein(a) at Week 12', 'timeFrame': 'Baseline and Week 12'}, {'measure': 'Percent Change From Baseline in Triglycerides at the Mean of Weeks 10 and 12', 'timeFrame': 'Baseline and Weeks 10 and 12'}, {'measure': 'Percent Change From Baseline in Triglycerides at Week 12', 'timeFrame': 'Baseline and Week 12'}, {'measure': 'Percent Change From Baseline in Very Low-Density Cholesterol (VLDL-C) at the Mean of Weeks 10 and 12', 'timeFrame': 'Baseline and Weeks 10 and 12'}, {'measure': 'Percent Change From Baseline in Very Low-Density Cholesterol (VLDL-C) at Week 12', 'timeFrame': 'Baseline and Week 12'}, {'measure': 'Percent Change From Baseline in HDL-C at the Mean of Weeks 10 and 12', 'timeFrame': 'Baseline and Weeks 10 and 12'}, {'measure': 'Percent Change From Baseline in HDL-C at Week 12', 'timeFrame': 'Baseline and Week 12'}]}, 'oversightModule': {'oversightHasDmc': True}, 'conditionsModule': {'keywords': ['High cholesterol, Treatment for high cholesterol, Lowering cholesterol, Lowering high cholesterol, Hypercholesterolemia'], 'conditions': ['Hyperlipidemia']}, 'referencesModule': {'references': [{'pmid': '24825642', 'type': 'BACKGROUND', 'citation': 'Robinson JG, Nedergaard BS, Rogers WJ, Fialkow J, Neutel JM, Ramstad D, Somaratne R, Legg JC, Nelson P, Scott R, Wasserman SM, Weiss R; LAPLACE-2 Investigators. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA. 2014 May 14;311(18):1870-82. doi: 10.1001/jama.2014.4030.'}, {'pmid': '24481874', 'type': 'BACKGROUND', 'citation': 'Robinson JG, Rogers WJ, Nedergaard BS, Fialkow J, Neutel JM, Ramstad D, Somaratne R, Legg JC, Nelson P, Scott R, Wasserman SM, Weiss R. Rationale and design of LAPLACE-2: a phase 3, randomized, double-blind, placebo- and ezetimibe-controlled trial evaluating the efficacy and safety of evolocumab in subjects with hypercholesterolemia on background statin therapy. Clin Cardiol. 2014 Apr;37(4):195-203. doi: 10.1002/clc.22252. Epub 2014 Jan 30.'}, {'pmid': '33325247', 'type': 'BACKGROUND', 'citation': 'Daviglus ML, Ferdinand KC, Lopez JAG, Wu Y, Monsalvo ML, Rodriguez CJ. Effects of Evolocumab on Low-Density Lipoprotein Cholesterol, Non-High Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a) by Race and Ethnicity: A Meta-Analysis of Individual Participant Data From Double-Blind and Open-Label Extension Studies. J Am Heart Assoc. 2021 Jan 5;10(1):e016839. doi: 10.1161/JAHA.120.016839. Epub 2020 Dec 16.'}, {'pmid': '32564340', 'type': 'BACKGROUND', 'citation': 'Koren MJ, Jones PH, Robinson JG, Sullivan D, Cho L, Hucko T, Lopez JAG, Fleishman AN, Somaratne R, Stroes E. A Comparison of Ezetimibe and Evolocumab for Atherogenic Lipid Reduction in Four Patient Populations: A Pooled Efficacy and Safety Analysis of Three Phase 3 Studies. Cardiol Ther. 2020 Dec;9(2):447-465. doi: 10.1007/s40119-020-00181-8. Epub 2020 Jun 20.'}, {'pmid': '29736889', 'type': 'BACKGROUND', 'citation': 'Kuchimanchi M, Grover A, Emery MG, Somaratne R, Wasserman SM, Gibbs JP, Doshi S. Population pharmacokinetics and exposure-response modeling and simulation for evolocumab in healthy volunteers and patients with hypercholesterolemia. J Pharmacokinet Pharmacodyn. 2018 Jun;45(3):505-522. doi: 10.1007/s10928-018-9592-y. Epub 2018 May 7.'}, {'pmid': '29353350', 'type': 'BACKGROUND', 'citation': 'Kasichayanula S, Grover A, Emery MG, Gibbs MA, Somaratne R, Wasserman SM, Gibbs JP. Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor. Clin Pharmacokinet. 2018 Jul;57(7):769-779. doi: 10.1007/s40262-017-0620-7.'}, {'pmid': '30755061', 'type': 'BACKGROUND', 'citation': 'Shapiro MD, Minnier J, Tavori H, Kassahun H, Flower A, Somaratne R, Fazio S. Relationship Between Low-Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab. J Am Heart Assoc. 2019 Feb 19;8(4):e010932. doi: 10.1161/JAHA.118.010932.'}, {'pmid': '30120772', 'type': 'BACKGROUND', 'citation': 'Stroes E, Robinson JG, Raal FJ, Dufour R, Sullivan D, Kassahun H, Ma Y, Wasserman SM, Koren MJ. Consistent LDL-C response with evolocumab among patient subgroups in PROFICIO: A pooled analysis of 3146 patients from phase 3 studies. Clin Cardiol. 2018 Oct;41(10):1328-1335. doi: 10.1002/clc.23049. Epub 2018 Oct 21.'}, {'pmid': '28249876', 'type': 'BACKGROUND', 'citation': 'Toth PP, Descamps O, Genest J, Sattar N, Preiss D, Dent R, Djedjos C, Wu Y, Geller M, Uhart M, Somaratne R, Wasserman SM; PROFICIO Investigators. Pooled Safety Analysis of Evolocumab in Over 6000 Patients From Double-Blind and Open-Label Extension Studies. Circulation. 2017 May 9;135(19):1819-1831. doi: 10.1161/CIRCULATIONAHA.116.025233. Epub 2017 Mar 1.'}, {'pmid': '32114889', 'type': 'BACKGROUND', 'citation': 'Toth PP, Jones SR, Monsalvo ML, Elliott-Davey M, Lopez JAG, Banach M. Effect of Evolocumab on Non-High-Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a): A Pooled Analysis of Phase 2 and Phase 3 Studies. J Am Heart Assoc. 2020 Mar 3;9(5):e014129. doi: 10.1161/JAHA.119.014129. Epub 2020 Mar 2.'}, {'pmid': '29768954', 'type': 'BACKGROUND', 'citation': 'Wasserman SM, Sabatine MS, Koren MJ, Giugliano RP, Legg JC, Emery MG, Doshi S, Liu T, Somaratne R, Gibbs JP. Comparison of LDL-C Reduction Using Different Evolocumab Doses and Intervals: Biological Insights and Treatment Implications. J Cardiovasc Pharmacol Ther. 2018 Sep;23(5):423-432. doi: 10.1177/1074248418774043. Epub 2018 May 16.'}, {'pmid': '30852766', 'type': 'BACKGROUND', 'citation': 'May HT, Muhlestein JB, Ma Y, Lopez JAG, Coll B, Nelson J. Effects of Evolocumab on the ApoA1 Remnant Ratio: A Pooled Analysis of Phase 3 Studies. Cardiol Ther. 2019 Jun;8(1):91-102. doi: 10.1007/s40119-019-0133-6. Epub 2019 Mar 9.'}], 'seeAlsoLinks': [{'url': 'http://www.amgentrials.com', 'label': 'AmgenTrials clinical trials website'}]}, 'descriptionModule': {'briefSummary': 'The primary objective was to evaluate the effect of 12 weeks of evolocumab administered subcutaneously every 2 weeks (Q2W) and monthly (QM) when used in combination with a statin, compared with placebo, on percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in patients with primary hypercholesterolemia and mixed dyslipidemia.', 'detailedDescription': 'Prior to the first randomization, participants entered a screening period to determine eligibility. During screening, all participants received subcutaneous placebo corresponding to the once monthly dose volume. Participants who completed the screening period and met eligibility criteria were randomized to 1 of 5 open-label statin cohorts (atorvastatin 10 mg or 80 mg, rosuvastatin 5 mg or 40 mg, or simvastatin 40 mg) for a 4 week lipid stabilization period based on statin therapy at the time of study entry (no statin use vs non-intensive statin use vs intensive statin use).\n\nAfter the 4-week lipid-stabilization period, eligible patients taking rosuvastatin or simvastatin during the lipid-stabilization phase were then randomized to 1 of 4 treatment groups: evolocumab (140 mg, subcutaneous, every 2 weeks) or matching placebo (subcutaneous, every 2 weeks), or evolocumab (420 mg, subcutaneous, monthly) or matching placebo (subcutaneous, monthly). Patients taking atorvastatin during the lipid-stabilization phase were then randomized to 1 of 6 treatment groups: evolocumab (140 mg, subcutaneous, every 2 weeks) and placebo (oral, daily), evolocumab (420 mg, subcutaneous, monthly) and placebo (oral, daily), placebo (subcutaneous, every 2 weeks) and placebo (oral, daily) or ezetimibe (10 mg, oral, daily), or placebo (subcutaneous, monthly) and placebo (oral, daily) or ezetimibe (10 mg, oral, daily).\n\nA participant was considered randomized into the study after successfully completing the screening period, meeting all inclusion/exclusion criteria, and undergoing both randomization procedures.\n\nParticipants randomized to simvastatin who were taking verapamil or diltiazem prior to randomization received simvastatin 10 mg once daily (QD) while participants who were taking amlodipine, amiodarone or ranolazine prior to randomization received simvastatin 20 mg QD. All other participants randomized to simvastatin received simvastatin 40 mg QD.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '80 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Male or female ≥ 18 to ≤ 80 years of age\n* Subjects not taking a statin must have fasting LDL-C of at least 150 mg/dL (4.0 mmol/L)\n* Subjects already on a non-intensive statin must have fasting LDL-C at screening ≥ 100 mg/dL (2.6 mmol/L)\n* Subjects already on a intensive statin must have fasting LDL-C at screening ≥ 80 mg/dL (2.1 mmol/L)\n* Fasting triglycerides ≤ 400 mg/dL (4.5 mmol/L)\n\nExclusion Criteria:\n\n* Statin intolerance\n* New York Heart association (NYHA) III or IV heart failure\n* Uncontrolled hypertension\n* Uncontrolled cardiac arrhythmia\n* Type 1 diabetes, poorly controlled type 2 diabetes\n* Uncontrolled hypothyroidism or hyperthyroidism'}, 'identificationModule': {'nctId': 'NCT01763866', 'acronym': 'LAPLACE-2', 'briefTitle': 'LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2', 'organization': {'class': 'INDUSTRY', 'fullName': 'Amgen'}, 'officialTitle': 'A Double-blind, Randomized, Placebo and Ezetimibe Controlled, Multicenter Study to Evaluate Safety, Tolerability and Efficacy of AMG 145 on LDL-C in Combination With Statin Therapy in Subjects With Primary Hypercholesterolemia and Mixed Dyslipidemia', 'orgStudyIdInfo': {'id': '20110115'}, 'secondaryIdInfos': [{'id': '2012-001363-70', 'type': 'EUDRACT_NUMBER'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'PLACEBO_COMPARATOR', 'label': 'A10 PBO Q2W', 'description': 'Participants received atorvastatin 10 mg once daily during the 4 week lipid stabilization period and then in combination with placebo (PBO) subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once daily for up to 12 weeks.', 'interventionNames': ['Drug: Placebo to Evolocumab', 'Drug: Placebo to Ezetimibe', 'Drug: Atorvastatin']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'A10 PBO QM', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every month (QM) and placebo tablets once a day for up to 12 weeks.', 'interventionNames': ['Drug: Placebo to Evolocumab', 'Drug: Placebo to Ezetimibe', 'Drug: Atorvastatin']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'A10 EZE (Q2W)', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe (EZE) orally once a day for up to 12 weeks.', 'interventionNames': ['Drug: Ezetimibe', 'Drug: Placebo to Evolocumab', 'Drug: Atorvastatin']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'A10 EZE (QM)', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.', 'interventionNames': ['Drug: Ezetimibe', 'Drug: Placebo to Evolocumab', 'Drug: Atorvastatin']}, {'type': 'EXPERIMENTAL', 'label': 'A10 EvoMab Q2W', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then with 140 mg evolocumab (EvoMab) by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.', 'interventionNames': ['Biological: Evolocumab', 'Drug: Placebo to Ezetimibe', 'Drug: Atorvastatin']}, {'type': 'EXPERIMENTAL', 'label': 'A10 EvoMab QM', 'description': 'Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks', 'interventionNames': ['Biological: Evolocumab', 'Drug: Placebo to Ezetimibe', 'Drug: Atorvastatin']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'A80 PBO Q2W', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.', 'interventionNames': ['Drug: Placebo to Evolocumab', 'Drug: Placebo to Ezetimibe', 'Drug: Atorvastatin']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'A80 PBO QM', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every month and placebo tablets once a day for up to 12 weeks.', 'interventionNames': ['Drug: Placebo to Evolocumab', 'Drug: Placebo to Ezetimibe', 'Drug: Atorvastatin']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'A80 EZE (Q2W)', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for up to 12 weeks.', 'interventionNames': ['Drug: Ezetimibe', 'Drug: Placebo to Evolocumab', 'Drug: Atorvastatin']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'A80 EZE (QM)', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.', 'interventionNames': ['Drug: Ezetimibe', 'Drug: Placebo to Evolocumab', 'Drug: Atorvastatin']}, {'type': 'EXPERIMENTAL', 'label': 'A80 EvoMab Q2W', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then with 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.', 'interventionNames': ['Biological: Evolocumab', 'Drug: Placebo to Ezetimibe', 'Drug: Atorvastatin']}, {'type': 'EXPERIMENTAL', 'label': 'A80 EvoMab QM', 'description': 'Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.', 'interventionNames': ['Biological: Evolocumab', 'Drug: Placebo to Ezetimibe', 'Drug: Atorvastatin']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'R5 PBO Q2W', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.', 'interventionNames': ['Drug: Placebo to Evolocumab', 'Drug: Rosuvastatin']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'R5 PBO QM', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every month for up to 12 weeks.', 'interventionNames': ['Drug: Placebo to Evolocumab', 'Drug: Rosuvastatin']}, {'type': 'EXPERIMENTAL', 'label': 'R5 EvoMab Q2W', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.', 'interventionNames': ['Biological: Evolocumab', 'Drug: Rosuvastatin']}, {'type': 'EXPERIMENTAL', 'label': 'R5 EvoMab QM', 'description': 'Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.', 'interventionNames': ['Biological: Evolocumab', 'Drug: Rosuvastatin']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'R40 PBO Q2W', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.', 'interventionNames': ['Drug: Placebo to Evolocumab', 'Drug: Rosuvastatin']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'R40 PBO QM', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every month for up to 12 weeks.', 'interventionNames': ['Drug: Placebo to Evolocumab', 'Drug: Rosuvastatin']}, {'type': 'EXPERIMENTAL', 'label': 'R40 EvoMab Q2W', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.', 'interventionNames': ['Biological: Evolocumab', 'Drug: Rosuvastatin']}, {'type': 'EXPERIMENTAL', 'label': 'R40 EvoMab QM', 'description': 'Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.', 'interventionNames': ['Biological: Evolocumab', 'Drug: Rosuvastatin']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'S40 PBO Q2W', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.', 'interventionNames': ['Drug: Placebo to Evolocumab', 'Drug: Simvastatin']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'S40 PBO QM', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every month for up to 12 weeks.', 'interventionNames': ['Drug: Placebo to Evolocumab', 'Drug: Simvastatin']}, {'type': 'EXPERIMENTAL', 'label': 'S40 EvoMab Q2W', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.', 'interventionNames': ['Biological: Evolocumab', 'Drug: Simvastatin']}, {'type': 'EXPERIMENTAL', 'label': 'S40 EvoMab QM', 'description': 'Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.', 'interventionNames': ['Biological: Evolocumab', 'Drug: Simvastatin']}], 'interventions': [{'name': 'Evolocumab', 'type': 'BIOLOGICAL', 'otherNames': ['AMG 145', 'Repatha'], 'description': 'Administered by subcutaneous injection', 'armGroupLabels': ['A10 EvoMab Q2W', 'A10 EvoMab QM', 'A80 EvoMab Q2W', 'A80 EvoMab QM', 'R40 EvoMab Q2W', 'R40 EvoMab QM', 'R5 EvoMab Q2W', 'R5 EvoMab QM', 'S40 EvoMab Q2W', 'S40 EvoMab QM']}, {'name': 'Ezetimibe', 'type': 'DRUG', 'otherNames': ['Zetia'], 'description': 'Administered orally once a day', 'armGroupLabels': ['A10 EZE (Q2W)', 'A10 EZE (QM)', 'A80 EZE (Q2W)', 'A80 EZE (QM)']}, {'name': 'Placebo to Evolocumab', 'type': 'DRUG', 'description': 'Administered by subcutaneous injection', 'armGroupLabels': ['A10 EZE (Q2W)', 'A10 EZE (QM)', 'A10 PBO Q2W', 'A10 PBO QM', 'A80 EZE (Q2W)', 'A80 EZE (QM)', 'A80 PBO Q2W', 'A80 PBO QM', 'R40 PBO Q2W', 'R40 PBO QM', 'R5 PBO Q2W', 'R5 PBO QM', 'S40 PBO Q2W', 'S40 PBO QM']}, {'name': 'Placebo to Ezetimibe', 'type': 'DRUG', 'description': 'Administered orally once a day', 'armGroupLabels': ['A10 EvoMab Q2W', 'A10 EvoMab QM', 'A10 PBO Q2W', 'A10 PBO QM', 'A80 EvoMab Q2W', 'A80 EvoMab QM', 'A80 PBO Q2W', 'A80 PBO QM']}, {'name': 'Atorvastatin', 'type': 'DRUG', 'otherNames': ['Lipitor'], 'description': 'Administered orally once a day', 'armGroupLabels': ['A10 EZE (Q2W)', 'A10 EZE (QM)', 'A10 EvoMab Q2W', 'A10 EvoMab QM', 'A10 PBO Q2W', 'A10 PBO QM', 'A80 EZE (Q2W)', 'A80 EZE (QM)', 'A80 EvoMab Q2W', 'A80 EvoMab QM', 'A80 PBO Q2W', 'A80 PBO QM']}, {'name': 'Rosuvastatin', 'type': 'DRUG', 'otherNames': ['Crestor'], 'description': 'Administered orally once a day', 'armGroupLabels': ['R40 EvoMab Q2W', 'R40 EvoMab QM', 'R40 PBO Q2W', 'R40 PBO QM', 'R5 EvoMab Q2W', 'R5 EvoMab QM', 'R5 PBO Q2W', 'R5 PBO QM']}, {'name': 'Simvastatin', 'type': 'DRUG', 'otherNames': ['Zocor'], 'description': 'Administered orally once a day', 'armGroupLabels': ['S40 EvoMab Q2W', 'S40 EvoMab QM', 'S40 PBO Q2W', 'S40 PBO QM']}]}, 'contactsLocationsModule': {'locations': [{'zip': '35294', 'city': 'Birmingham', 'state': 'Alabama', 'country': 'United States', 'facility': 'Research Site', 'geoPoint': {'lat': 33.52066, 'lon': -86.80249}}, {'zip': '85306', 'city': 'Glendale', 'state': 'Arizona', 'country': 'United States', 'facility': 'Research Site', 'geoPoint': {'lat': 33.53865, 'lon': -112.18599}}, {'zip': '85710', 'city': 'Tucson', 'state': 'Arizona', 'country': 'United States', 'facility': 'Research Site', 'geoPoint': {'lat': 32.22174, 'lon': -110.92648}}, {'zip': '85712', 'city': 'Tucson', 'state': 'Arizona', 'country': 'United States', 'facility': 'Research Site', 'geoPoint': {'lat': 32.22174, 'lon': -110.92648}}, {'zip': '95608', 'city': 'Carmichael', 'state': 'California', 'country': 'United States', 'facility': 'Research Site', 'geoPoint': {'lat': 38.61713, 'lon': -121.32828}}, {'zip': '91436', 'city': 'Encino', 'state': 'California', 'country': 'United States', 'facility': 'Research Site', 'geoPoint': {'lat': 34.15917, 'lon': -118.50119}}, {'zip': '90822', 'city': 'Long Beach', 'state': 'California', 'country': 'United States', 'facility': 'Research Site', 'geoPoint': {'lat': 33.76696, 'lon': -118.18923}}, {'zip': '92663', 'city': 'Newport Beach', 'state': 'California', 'country': 'United States', 'facility': 'Research Site', 'geoPoint': {'lat': 33.61891, 'lon': -117.92895}}, {'zip': '92123', 'city': 'San Diego', 'state': 'California', 'country': 'United States', 'facility': 'Research Site', 'geoPoint': {'lat': 32.71571, 'lon': -117.16472}}, {'zip': '92705', 'city': 'Santa Ana', 'state': 'California', 'country': 'United States', 'facility': 'Research Site', 'geoPoint': {'lat': 33.74557, 'lon': -117.86783}}, {'zip': '95405', 'city': 'Santa Rosa', 'state': 'California', 'country': 'United States', 'facility': 'Research Site', 'geoPoint': {'lat': 38.44047, 'lon': -122.71443}}, {'zip': '91360', 'city': 'Thousand Oaks', 'state': 'California', 'country': 'United States', 'facility': 'Research Site', 'geoPoint': {'lat': 34.17056, 'lon': -118.83759}}, {'zip': '90509', 'city': 'Torrance', 'state': 'California', 'country': 'United States', 'facility': 'Research Site', 'geoPoint': {'lat': 33.83585, 'lon': -118.34063}}, {'zip': '92780', 'city': 'Tustin', 'state': 'California', 'country': 'United States', 'facility': 'Research Site', 'geoPoint': {'lat': 33.74585, 'lon': -117.82617}}, {'zip': '91361', 'city': 'Westlake Village', 'state': 'California', 'country': 'United States', 'facility': 'Research Site', 'geoPoint': {'lat': 34.14584, 'lon': -118.80565}}, {'zip': '80120', 'city': 'Littleton', 'state': 'Colorado', 'country': 'United States', 'facility': 'Research Site', 'geoPoint': {'lat': 39.61332, 'lon': -105.01665}}, {'zip': '32117', 'city': 'Daytona Beach', 'state': 'Florida', 'country': 'United States', 'facility': 'Research Site', 'geoPoint': {'lat': 29.21081, 'lon': -81.02283}}, {'zip': '32223', 'city': 'Jacksonville', 'state': 'Florida', 'country': 'United States', 'facility': 'Research Site', 'geoPoint': {'lat': 30.33218, 'lon': -81.65565}}, {'zip': '32901', 'city': 'Melbourne', 'state': 'Florida', 'country': 'United States', 'facility': 'Research Site', 'geoPoint': {'lat': 28.08363, 'lon': -80.60811}}, {'zip': '33173', 'city': 'Miami', 'state': 'Florida', 'country': 'United States', 'facility': 'Research Site', 'geoPoint': {'lat': 25.77427, 'lon': -80.19366}}, {'zip': '33952', 'city': 'Port Charlotte', 'state': 'Florida', 'country': 'United States', 'facility': 'Research Site', 'geoPoint': {'lat': 26.97617, 'lon': -82.09064}}, {'zip': '30328', 'city': 'Atlanta', 'state': 'Georgia', 'country': 'United States', 'facility': 'Research Site', 'geoPoint': {'lat': 33.749, 'lon': -84.38798}}, {'zip': '30342', 'city': 'Atlanta', 'state': 'Georgia', 'country': 'United States', 'facility': 'Research Site', 'geoPoint': {'lat': 33.749, 'lon': -84.38798}}, {'zip': '83704', 'city': 'Boise', 'state': 'Idaho', 'country': 'United States', 'facility': 'Research Site', 'geoPoint': {'lat': 43.6135, 'lon': -116.20345}}, {'zip': '46320', 'city': 'Hammond', 'state': 'Indiana', 'country': 'United States', 'facility': 'Research Site', 'geoPoint': {'lat': 41.58337, 'lon': -87.50004}}, {'zip': '46237', 'city': 'Indianapolis', 'state': 'Indiana', 'country': 'United States', 'facility': 'Research Site', 'geoPoint': {'lat': 39.76838, 'lon': -86.15804}}, {'zip': '46383', 'city': 'Valparaiso', 'state': 'Indiana', 'country': 'United States', 'facility': 'Research Site', 'geoPoint': {'lat': 41.47309, 'lon': -87.06114}}, {'zip': '52242', 'city': 'Iowa City', 'state': 'Iowa', 'country': 'United States', 'facility': 'Research Site', 'geoPoint': {'lat': 41.66113, 'lon': -91.53017}}, {'zip': '41017', 'city': 'Crestview Hills', 'state': 'Kentucky', 'country': 'United States', 'facility': 'Research Site', 'geoPoint': {'lat': 39.02728, 'lon': -84.58494}}, {'zip': '71203', 'city': 'Monroe', 'state': 'Louisiana', 'country': 'United States', 'facility': 'Research Site', 'geoPoint': {'lat': 32.50931, 'lon': -92.1193}}, {'zip': '04210', 'city': 'Auburn', 'state': 'Maine', 'country': 'United States', 'facility': 'Research Site', 'geoPoint': {'lat': 44.09785, 'lon': -70.23117}}, {'zip': '04401', 'city': 'Bangor', 'state': 'Maine', 'country': 'United States', 'facility': 'Research Site', 'geoPoint': {'lat': 44.79884, 'lon': -68.77265}}, {'zip': '04101', 'city': 'Portland', 'state': 'Maine', 'country': 'United States', 'facility': 'Research Site', 'geoPoint': {'lat': 43.65737, 'lon': -70.2589}}, {'zip': '21201', 'city': 'Baltimore', 'state': 'Maryland', 'country': 'United States', 'facility': 'Research Site', 'geoPoint': {'lat': 39.29038, 'lon': -76.61219}}, {'zip': '48197', 'city': 'Ypsilanti', 'state': 'Michigan', 'country': 'United States', 'facility': 'Research Site', 'geoPoint': {'lat': 42.24115, 'lon': -83.61299}}, {'zip': '38801', 'city': 'Tupelo', 'state': 'Mississippi', 'country': 'United States', 'facility': 'Research Site', 'geoPoint': {'lat': 34.25807, 'lon': -88.70464}}, {'zip': '59102', 'city': 'Billings', 'state': 'Montana', 'country': 'United States', 'facility': 'Research Site', 'geoPoint': {'lat': 45.78329, 'lon': -108.50069}}, {'zip': '08043', 'city': 'Voorhees Township', 'state': 'New Jersey', 'country': 'United States', 'facility': 'Research Site', 'geoPoint': {'lat': 40.4795, 'lon': -74.49062}}, {'zip': '13104', 'city': 'Manlius', 'state': 'New York', 'country': 'United States', 'facility': 'Research Site', 'geoPoint': {'lat': 43.00201, 'lon': -75.97686}}, {'zip': '14609', 'city': 'Rochester', 'state': 'New York', 'country': 'United States', 'facility': 'Research Site', 'geoPoint': {'lat': 43.15478, 'lon': -77.61556}}, {'zip': '13210', 'city': 'Syracuse', 'state': 'New York', 'country': 'United States', 'facility': 'Research Site', 'geoPoint': {'lat': 43.04812, 'lon': -76.14742}}, {'zip': '14221', 'city': 'Williamsville', 'state': 'New York', 'country': 'United States', 'facility': 'Research Site', 'geoPoint': {'lat': 42.96395, 'lon': -78.73781}}, {'zip': '27103', 'city': 'Winston-Salem', 'state': 'North Carolina', 'country': 'United States', 'facility': 'Research Site', 'geoPoint': {'lat': 36.09986, 'lon': -80.24422}}, {'zip': '43907', 'city': 'Cadiz', 'state': 'Ohio', 'country': 'United States', 'facility': 'Research Site', 'geoPoint': {'lat': 40.27285, 'lon': -80.99676}}, {'zip': '44708', 'city': 'Canton', 'state': 'Ohio', 'country': 'United States', 'facility': 'Research Site', 'geoPoint': {'lat': 40.79895, 'lon': -81.37845}}, {'zip': '45219', 'city': 'Cincinnati', 'state': 'Ohio', 'country': 'United States', 'facility': 'Research Site', 'geoPoint': {'lat': 39.12711, 'lon': -84.51439}}, {'zip': '45227', 'city': 'Cincinnati', 'state': 'Ohio', 'country': 'United States', 'facility': 'Research Site', 'geoPoint': {'lat': 39.12711, 'lon': -84.51439}}, {'zip': '45414', 'city': 'Dayton', 'state': 'Ohio', 'country': 'United States', 'facility': 'Research Site', 'geoPoint': {'lat': 39.75895, 'lon': -84.19161}}, {'zip': '44906', 'city': 'Mansfield', 'state': 'Ohio', 'country': 'United States', 'facility': 'Research Site', 'geoPoint': {'lat': 40.75839, 'lon': -82.51545}}, {'zip': '43302', 'city': 'Marion', 'state': 'Ohio', 'country': 'United States', 'facility': 'Research Site', 'geoPoint': {'lat': 40.58867, 'lon': -83.12852}}, {'zip': '44870', 'city': 'Sandusky', 'state': 'Ohio', 'country': 'United States', 'facility': 'Research Site', 'geoPoint': {'lat': 41.44894, 'lon': -82.70796}}, {'zip': '73069', 'city': 'Norman', 'state': 'Oklahoma', 'country': 'United States', 'facility': 'Research Site', 'geoPoint': {'lat': 35.22257, 'lon': -97.43948}}, {'zip': '16635', 'city': 'Duncansville', 'state': 'Pennsylvania', 'country': 'United States', 'facility': 'Research Site', 'geoPoint': {'lat': 40.42341, 'lon': -78.4339}}, {'zip': '15216', 'city': 'Pittsburgh', 'state': 'Pennsylvania', 'country': 'United States', 'facility': 'Research Site', 'geoPoint': {'lat': 40.44062, 'lon': -79.99589}}, {'zip': '17405', 'city': 'York', 'state': 'Pennsylvania', 'country': 'United States', 'facility': 'Research Site', 'geoPoint': {'lat': 39.9626, 'lon': -76.72774}}, {'zip': '29501', 'city': 'Florence', 'state': 'South Carolina', 'country': 'United States', 'facility': 'Research Site', 'geoPoint': {'lat': 34.19543, 'lon': -79.76256}}, {'zip': '57701', 'city': 'Rapid City', 'state': 'South Dakota', 'country': 'United States', 'facility': 'Research Site', 'geoPoint': {'lat': 44.08054, 'lon': -103.23101}}, {'zip': '38301', 'city': 'Jackson', 'state': 'Tennessee', 'country': 'United States', 'facility': 'Research Site', 'geoPoint': {'lat': 35.61452, 'lon': -88.81395}}, {'zip': '38305', 'city': 'Jackson', 'state': 'Tennessee', 'country': 'United States', 'facility': 'Research Site', 'geoPoint': {'lat': 35.61452, 'lon': -88.81395}}, {'zip': '75231', 'city': 'Dallas', 'state': 'Texas', 'country': 'United States', 'facility': 'Research Site', 'geoPoint': {'lat': 32.78306, 'lon': -96.80667}}, {'zip': '77074', 'city': 'Houston', 'state': 'Texas', 'country': 'United States', 'facility': 'Research Site', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'zip': '78229', 'city': 'San Antonio', 'state': 'Texas', 'country': 'United States', 'facility': 'Research Site', 'geoPoint': {'lat': 29.42412, 'lon': -98.49363}}, {'zip': '23435', 'city': 'Suffolk', 'state': 'Virginia', 'country': 'United States', 'facility': 'Research Site', 'geoPoint': {'lat': 36.72836, 'lon': -76.58496}}, {'zip': '22601', 'city': 'Winchester', 'state': 'Virginia', 'country': 'United States', 'facility': 'Research Site', 'geoPoint': {'lat': 39.18566, 'lon': -78.16333}}, {'zip': '98405', 'city': 'Tacoma', 'state': 'Washington', 'country': 'United States', 'facility': 'Research Site', 'geoPoint': {'lat': 47.25288, 'lon': -122.44429}}, {'zip': '2022', 'city': 'Sydney', 'state': 'New South Wales', 'country': 'Australia', 'facility': 'Research Site', 'geoPoint': {'lat': -33.86785, 'lon': 151.20732}}, {'zip': '5035', 'city': 'Ashford', 'state': 'South Australia', 'country': 'Australia', 'facility': 'Research Site', 'geoPoint': {'lat': -34.94859, 'lon': 138.57457}}, {'zip': '5063', 'city': 'Fullarton', 'state': 'South Australia', 'country': 'Australia', 'facility': 'Research Site', 'geoPoint': {'lat': -34.951, 'lon': 138.629}}, {'zip': '3065', 'city': 'Fitzroy', 'state': 'Victoria', 'country': 'Australia', 'facility': 'Research Site', 'geoPoint': {'lat': -37.79839, 'lon': 144.97833}}, {'zip': '3081', 'city': 'Heidelberg Heights', 'state': 'Victoria', 'country': 'Australia', 'facility': 'Research Site', 'geoPoint': {'lat': -37.74313, 'lon': 145.05695}}, {'zip': '3121', 'city': 'Richmond', 'state': 'Victoria', 'country': 'Australia', 'facility': 'Research Site', 'geoPoint': {'lat': -37.81819, 'lon': 145.00176}}, {'zip': '8370', 'city': 'Blankenberge', 'country': 'Belgium', 'facility': 'Research Site', 'geoPoint': {'lat': 51.31306, 'lon': 3.13227}}, {'zip': '4032', 'city': 'ChÃªnÃ©e', 'country': 'Belgium', 'facility': 'Research Site'}, {'zip': '3500', 'city': 'Hasselt', 'country': 'Belgium', 'facility': 'Research Site', 'geoPoint': {'lat': 50.93106, 'lon': 5.33781}}, {'zip': '8400', 'city': 'Ostend', 'country': 'Belgium', 'facility': 'Research Site', 'geoPoint': {'lat': 51.21551, 'lon': 2.927}}, {'zip': '3120', 'city': 'Tremelo', 'country': 'Belgium', 'facility': 'Research Site', 'geoPoint': {'lat': 50.99231, 'lon': 4.70807}}, {'zip': '1800', 'city': 'Vilvoorde', 'country': 'Belgium', 'facility': 'Research Site', 'geoPoint': {'lat': 50.92814, 'lon': 4.42938}}, {'zip': 'V5G 1T4', 'city': 'Burnaby', 'state': 'British Columbia', 'country': 'Canada', 'facility': 'Research Site', 'geoPoint': {'lat': 49.26636, 'lon': -122.95263}}, {'zip': 'V1Y 1E4', 'city': 'Kelowna', 'state': 'British Columbia', 'country': 'Canada', 'facility': 'Research Site', 'geoPoint': {'lat': 49.88307, 'lon': -119.48568}}, {'zip': 'V1Y 1V6', 'city': 'Kelowna', 'state': 'British Columbia', 'country': 'Canada', 'facility': 'Research Site', 'geoPoint': {'lat': 49.88307, 'lon': -119.48568}}, {'zip': 'V3V 1N1', 'city': 'Surrey', 'state': 'British Columbia', 'country': 'Canada', 'facility': 'Research Site', 'geoPoint': {'lat': 49.10635, 'lon': -122.82509}}, {'zip': 'A1A 3R5', 'city': 'Saint Johnâ€™s', 'state': 'Newfoundland and Labrador', 'country': 'Canada', 'facility': 'Research Site'}, {'zip': 'N1R 6V6', 'city': 'Cambridge', 'state': 'Ontario', 'country': 'Canada', 'facility': 'Research Site', 'geoPoint': {'lat': 43.3601, 'lon': -80.31269}}, {'zip': 'L8L 2X2', 'city': 'Hamilton', 'state': 'Ontario', 'country': 'Canada', 'facility': 'Research Site', 'geoPoint': {'lat': 43.25011, 'lon': -79.84963}}, {'zip': 'N5W 6A2', 'city': 'London', 'state': 'Ontario', 'country': 'Canada', 'facility': 'Research Site', 'geoPoint': {'lat': 42.98339, 'lon': -81.23304}}, {'zip': 'L3Y 5G8', 'city': 'Newmarket', 'state': 'Ontario', 'country': 'Canada', 'facility': 'Research Site', 'geoPoint': {'lat': 44.05011, 'lon': -79.46631}}, {'zip': 'L1J 2K1', 'city': 'Oshawa', 'state': 'Ontario', 'country': 'Canada', 'facility': 'Research Site', 'geoPoint': {'lat': 43.90012, 'lon': -78.84957}}, {'zip': 'N7T 4X3', 'city': 'Sarnia', 'state': 'Ontario', 'country': 'Canada', 'facility': 'Research Site', 'geoPoint': {'lat': 42.97866, 'lon': -82.40407}}, {'zip': 'M1P 2T7', 'city': 'Scarborough Village', 'state': 'Ontario', 'country': 'Canada', 'facility': 'Research Site', 'geoPoint': {'lat': 43.73899, 'lon': -79.22124}}, {'zip': 'M8V 3X8', 'city': 'Toronto', 'state': 'Ontario', 'country': 'Canada', 'facility': 'Research Site', 'geoPoint': {'lat': 43.70643, 'lon': -79.39864}}, {'zip': 'M9V 4B4', 'city': 'Toronto', 'state': 'Ontario', 'country': 'Canada', 'facility': 'Research Site', 'geoPoint': {'lat': 43.70643, 'lon': -79.39864}}, {'zip': 'N4S 5P5', 'city': 'Woodstock', 'state': 'Ontario', 'country': 'Canada', 'facility': 'Research Site', 'geoPoint': {'lat': 43.13339, 'lon': -80.7497}}, {'zip': 'J4X 1S4', 'city': 'Brossard', 'state': 'Quebec', 'country': 'Canada', 'facility': 'Research Site', 'geoPoint': {'lat': 45.45008, 'lon': -73.46583}}, {'zip': 'J4V 2G8', 'city': 'Greenfield Park', 'state': 'Quebec', 'country': 'Canada', 'facility': 'Research Site', 'geoPoint': {'lat': 45.48649, 'lon': -73.46223}}, {'zip': 'H8S 2E4', 'city': 'Lachine', 'state': 'Quebec', 'country': 'Canada', 'facility': 'Research Site', 'geoPoint': {'lat': 45.43177, 'lon': -73.66899}}, {'zip': 'J4N 0C9', 'city': 'Longueuil', 'state': 'Quebec', 'country': 'Canada', 'facility': 'Research Site', 'geoPoint': {'lat': 45.5152, 'lon': -73.46818}}, {'zip': 'H4N 2W2', 'city': 'Montreal', 'state': 'Quebec', 'country': 'Canada', 'facility': 'Research Site', 'geoPoint': {'lat': 45.50884, 'lon': -73.58781}}, {'zip': 'H9R 3J1', 'city': 'Pointe-Claire', 'state': 'Quebec', 'country': 'Canada', 'facility': 'Research Site', 'geoPoint': {'lat': 45.44868, 'lon': -73.81669}}, {'zip': '602 00', 'city': 'Brno', 'country': 'Czechia', 'facility': 'Research Site', 'geoPoint': {'lat': 49.19522, 'lon': 16.60796}}, {'zip': '603 00', 'city': 'Brno', 'country': 'Czechia', 'facility': 'Research Site', 'geoPoint': {'lat': 49.19522, 'lon': 16.60796}}, {'zip': '272 01', 'city': 'Kladno', 'country': 'Czechia', 'facility': 'Research Site', 'geoPoint': {'lat': 50.14734, 'lon': 14.10285}}, {'zip': '412 01', 'city': 'Litoměřice', 'country': 'Czechia', 'facility': 'Research Site', 'geoPoint': {'lat': 50.53348, 'lon': 14.1318}}, {'zip': '676 02', 'city': 'Moravské Budějovice', 'country': 'Czechia', 'facility': 'Research Site', 'geoPoint': {'lat': 49.05209, 'lon': 15.80864}}, {'zip': '775 20', 'city': 'Olomouc', 'country': 'Czechia', 'facility': 'Research Site', 'geoPoint': {'lat': 49.59552, 'lon': 17.25175}}, {'zip': '530 02', 'city': 'Pardubice', 'country': 'Czechia', 'facility': 'Research Site', 'geoPoint': {'lat': 50.04075, 'lon': 15.77659}}, {'zip': '120 00', 'city': 'Prague', 'country': 'Czechia', 'facility': 'Research Site', 'geoPoint': {'lat': 50.08804, 'lon': 14.42076}}, {'zip': '130 00', 'city': 'Prague', 'country': 'Czechia', 'facility': 'Research Site', 'geoPoint': {'lat': 50.08804, 'lon': 14.42076}}, {'zip': '140 21', 'city': 'Prague', 'country': 'Czechia', 'facility': 'Research Site', 'geoPoint': {'lat': 50.08804, 'lon': 14.42076}}, {'zip': '274 01', 'city': 'Slaný', 'country': 'Czechia', 'facility': 'Research Site', 'geoPoint': {'lat': 50.23046, 'lon': 14.08693}}, {'zip': '568 25', 'city': 'Svitavy', 'country': 'Czechia', 'facility': 'Research Site', 'geoPoint': {'lat': 49.75594, 'lon': 16.46829}}, {'zip': '562 18', 'city': 'Ústí nad Orlicí', 'country': 'Czechia', 'facility': 'Research Site', 'geoPoint': {'lat': 49.97387, 'lon': 16.39361}}, {'zip': '9000', 'city': 'Aalborg', 'country': 'Denmark', 'facility': 'Research Site', 'geoPoint': {'lat': 57.048, 'lon': 9.9187}}, {'zip': '2750', 'city': 'Ballerup Municipality', 'country': 'Denmark', 'facility': 'Research Site', 'geoPoint': {'lat': 55.73165, 'lon': 12.36328}}, {'zip': '7100', 'city': 'Vejle', 'country': 'Denmark', 'facility': 'Research Site', 'geoPoint': {'lat': 55.70927, 'lon': 9.5357}}, {'zip': '29200', 'city': 'Brest', 'country': 'France', 'facility': 'Research Site', 'geoPoint': {'lat': 48.39029, 'lon': -4.48628}}, {'zip': '14033', 'city': 'Caen', 'country': 'France', 'facility': 'Research Site', 'geoPoint': {'lat': 49.18585, 'lon': -0.35912}}, {'zip': '21034', 'city': 'Dijon', 'country': 'France', 'facility': 'Research Site', 'geoPoint': {'lat': 47.31344, 'lon': 5.01391}}, {'zip': '71200', 'city': 'Le Creusot', 'country': 'France', 'facility': 'Research Site', 'geoPoint': {'lat': 46.80714, 'lon': 4.41632}}, {'zip': '34295', 'city': 'Montpellier', 'country': 'France', 'facility': 'Research Site', 'geoPoint': {'lat': 43.61093, 'lon': 3.87635}}, {'zip': '44093', 'city': 'Nantes', 'country': 'France', 'facility': 'Research Site', 'geoPoint': {'lat': 47.21725, 'lon': -1.55336}}, {'zip': '75013', 'city': 'Paris', 'country': 'France', 'facility': 'Research Site', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'zip': '75571', 'city': 'Paris', 'country': 'France', 'facility': 'Research Site', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'zip': '86000', 'city': 'Poitiers', 'country': 'France', 'facility': 'Research Site', 'geoPoint': {'lat': 46.58261, 'lon': 0.34348}}, {'zip': '67091', 'city': 'Strasbourg', 'country': 'France', 'facility': 'Research Site', 'geoPoint': {'lat': 48.58392, 'lon': 7.74553}}, {'zip': '79189', 'city': 'Bad Krozingen', 'country': 'Germany', 'facility': 'Research Site', 'geoPoint': {'lat': 47.91667, 'lon': 7.7}}, {'zip': '10367', 'city': 'Berlin', 'country': 'Germany', 'facility': 'Research Site', 'geoPoint': {'lat': 52.52437, 'lon': 13.41053}}, {'zip': '10787', 'city': 'Berlin', 'country': 'Germany', 'facility': 'Research Site', 'geoPoint': {'lat': 52.52437, 'lon': 13.41053}}, {'zip': '79106', 'city': 'Freiburg im Breisgau', 'country': 'Germany', 'facility': 'Research Site', 'geoPoint': {'lat': 47.9959, 'lon': 7.85222}}, {'zip': '69120', 'city': 'Heidelberg', 'country': 'Germany', 'facility': 'Research Site', 'geoPoint': {'lat': 49.40768, 'lon': 8.69079}}, {'zip': '12627', 'city': 'Hellersdorf', 'country': 'Germany', 'facility': 'Research Site', 'geoPoint': {'lat': 52.53319, 'lon': 13.6088}}, {'zip': '66421', 'city': 'Homburg', 'country': 'Germany', 'facility': 'Research Site', 'geoPoint': {'lat': 49.32637, 'lon': 7.33867}}, {'zip': '04103', 'city': 'Leipzig', 'country': 'Germany', 'facility': 'Research Site', 'geoPoint': {'lat': 51.33962, 'lon': 12.37129}}, {'zip': '39104', 'city': 'Magdeburg', 'country': 'Germany', 'facility': 'Research Site', 'geoPoint': {'lat': 52.13129, 'lon': 11.63189}}, {'zip': '88605', 'city': 'Messkirch', 'country': 'Germany', 'facility': 'Research Site', 'geoPoint': {'lat': 47.99457, 'lon': 9.11479}}, {'zip': '58455', 'city': 'Witten', 'country': 'Germany', 'facility': 'Research Site', 'geoPoint': {'lat': 51.44362, 'lon': 7.35258}}, {'city': 'Hong Kong', 'country': 'Hong Kong', 'facility': 'Research Site', 'geoPoint': {'lat': 22.27832, 'lon': 114.17469}}, {'city': 'New Territories', 'country': 'Hong Kong', 'facility': 'Research Site', 'geoPoint': {'lat': 22.42441, 'lon': 114.11095}}, {'zip': '6500', 'city': 'Baja', 'country': 'Hungary', 'facility': 'Research Site', 'geoPoint': {'lat': 46.18299, 'lon': 18.95307}}, {'zip': '4100', 'city': 'Berettyóújfalu', 'country': 'Hungary', 'facility': 'Research Site', 'geoPoint': {'lat': 47.22362, 'lon': 21.53656}}, {'zip': '2400', 'city': 'Dunaújváros', 'country': 'Hungary', 'facility': 'Research Site', 'geoPoint': {'lat': 46.96479, 'lon': 18.93974}}, {'zip': '3300', 'city': 'Eger', 'country': 'Hungary', 'facility': 'Research Site', 'geoPoint': {'lat': 47.90265, 'lon': 20.37329}}, {'zip': '3200', 'city': 'Gyöngyös', 'country': 'Hungary', 'facility': 'Research Site', 'geoPoint': {'lat': 47.78257, 'lon': 19.928}}, {'zip': '6800', 'city': 'Hódmezővásárhely', 'country': 'Hungary', 'facility': 'Research Site', 'geoPoint': {'lat': 46.41667, 'lon': 20.33333}}, {'zip': '5100', 'city': 'Jászberény', 'country': 'Hungary', 'facility': 'Research Site', 'geoPoint': {'lat': 47.5, 'lon': 19.91667}}, {'zip': '2921', 'city': 'Komárom', 'country': 'Hungary', 'facility': 'Research Site', 'geoPoint': {'lat': 47.74318, 'lon': 18.11913}}, {'zip': '8700', 'city': 'Marcali', 'country': 'Hungary', 'facility': 'Research Site', 'geoPoint': {'lat': 46.58498, 'lon': 17.41196}}, {'zip': '9200', 'city': 'Mosonmagyaróvár', 'country': 'Hungary', 'facility': 'Research Site', 'geoPoint': {'lat': 47.86789, 'lon': 17.26994}}, {'zip': '7624', 'city': 'Pécs', 'country': 'Hungary', 'facility': 'Research Site', 'geoPoint': {'lat': 46.07617, 'lon': 18.22814}}, {'zip': '40138', 'city': 'Bologna', 'country': 'Italy', 'facility': 'Research Site', 'geoPoint': {'lat': 44.49381, 'lon': 11.33875}}, {'zip': '09134', 'city': 'Cagliari', 'country': 'Italy', 'facility': 'Research Site', 'geoPoint': {'lat': 39.23054, 'lon': 9.11917}}, {'zip': '66100', 'city': 'Chieti', 'country': 'Italy', 'facility': 'Research Site', 'geoPoint': {'lat': 42.34827, 'lon': 14.16494}}, {'zip': '44124', 'city': 'Ferrara', 'country': 'Italy', 'facility': 'Research Site', 'geoPoint': {'lat': 44.83804, 'lon': 11.62057}}, {'zip': '20162', 'city': 'Milan', 'country': 'Italy', 'facility': 'Research Site', 'geoPoint': {'lat': 42.78235, 'lon': 12.59836}}, {'zip': '80131', 'city': 'Napoli', 'country': 'Italy', 'facility': 'Research Site', 'geoPoint': {'lat': 40.87618, 'lon': 14.5195}}, {'zip': '35128', 'city': 'Padua', 'country': 'Italy', 'facility': 'Research Site', 'geoPoint': {'lat': 45.40797, 'lon': 11.88586}}, {'zip': '06129', 'city': 'Perugia', 'country': 'Italy', 'facility': 'Research Site', 'geoPoint': {'lat': 43.1122, 'lon': 12.38878}}, {'zip': '56124', 'city': 'Pisa', 'country': 'Italy', 'facility': 'Research Site', 'geoPoint': {'lat': 43.70853, 'lon': 10.4036}}, {'zip': '34149', 'city': 'Trieste', 'country': 'Italy', 'facility': 'Research Site', 'geoPoint': {'lat': 45.64953, 'lon': 13.77678}}, {'zip': '37520', 'city': 'León', 'state': 'Guanajuato', 'country': 'Mexico', 'facility': 'Research Site', 'geoPoint': {'lat': 21.12908, 'lon': -101.67374}}, {'zip': '44100', 'city': 'Guadalajara', 'state': 'Jalisco', 'country': 'Mexico', 'facility': 'Research Site', 'geoPoint': {'lat': 20.67738, 'lon': -103.34749}}, {'zip': '44130', 'city': 'Guadalajara', 'state': 'Jalisco', 'country': 'Mexico', 'facility': 'Research Site', 'geoPoint': {'lat': 20.67738, 'lon': -103.34749}}, {'zip': '03800', 'city': 'Mexico City', 'state': 'Mexico City', 'country': 'Mexico', 'facility': 'Research Site', 'geoPoint': {'lat': 19.42847, 'lon': -99.12766}}, {'zip': '14000', 'city': 'Mexico City', 'state': 'Mexico City', 'country': 'Mexico', 'facility': 'Research Site', 'geoPoint': {'lat': 19.42847, 'lon': -99.12766}}, {'zip': '64460', 'city': 'Monterrey', 'state': 'Nuevo LeÃ³n', 'country': 'Mexico', 'facility': 'Research Site', 'geoPoint': {'lat': 25.68435, 'lon': -100.31721}}, {'zip': '78240', 'city': 'San Luis Potosí City', 'state': 'San Luis PotosÃ-', 'country': 'Mexico', 'facility': 'Research Site', 'geoPoint': {'lat': 22.15234, 'lon': -100.97135}}, {'zip': '89000', 'city': 'Tampico', 'state': 'Tamaulipas', 'country': 'Mexico', 'facility': 'Research Site', 'geoPoint': {'lat': 22.28519, 'lon': -97.87777}}, {'zip': '34270', 'city': 'Durango', 'country': 'Mexico', 'facility': 'Research Site', 'geoPoint': {'lat': 24.02032, 'lon': -104.65756}}, {'zip': '1066 EC', 'city': 'Amsterdam', 'country': 'Netherlands', 'facility': 'Research Site', 'geoPoint': {'lat': 52.37403, 'lon': 4.88969}}, {'zip': '1105 AZ', 'city': 'Amsterdam', 'country': 'Netherlands', 'facility': 'Research Site', 'geoPoint': {'lat': 52.37403, 'lon': 4.88969}}, {'zip': '1782 GZ', 'city': 'Den Helder', 'country': 'Netherlands', 'facility': 'Research Site', 'geoPoint': {'lat': 52.95988, 'lon': 4.75933}}, {'zip': '9728 NT', 'city': 'Groningen', 'country': 'Netherlands', 'facility': 'Research Site', 'geoPoint': {'lat': 53.21917, 'lon': 6.56667}}, {'zip': '7909 AA', 'city': 'Hoogeveen', 'country': 'Netherlands', 'facility': 'Research Site', 'geoPoint': {'lat': 52.7225, 'lon': 6.47639}}, {'zip': '3435 CM', 'city': 'Nieuwegein', 'country': 'Netherlands', 'facility': 'Research Site', 'geoPoint': {'lat': 52.02917, 'lon': 5.08056}}, {'zip': '6525 GA', 'city': 'Nijmegen', 'country': 'Netherlands', 'facility': 'Research Site', 'geoPoint': {'lat': 51.8425, 'lon': 5.85278}}, {'zip': '3045 PM', 'city': 'Rotterdam', 'country': 'Netherlands', 'facility': 'Research Site', 'geoPoint': {'lat': 51.9225, 'lon': 4.47917}}, {'zip': '5141 BM', 'city': 'Waalwijk', 'country': 'Netherlands', 'facility': 'Research Site', 'geoPoint': {'lat': 51.6825, 'lon': 5.07083}}, {'zip': '3331 LZ', 'city': 'Zwijndrecht', 'country': 'Netherlands', 'facility': 'Research Site', 'geoPoint': {'lat': 51.8175, 'lon': 4.63333}}, {'zip': '656055', 'city': 'Barnaul', 'country': 'Russia', 'facility': 'Research Site', 'geoPoint': {'lat': 53.36199, 'lon': 83.72786}}, {'zip': '650002', 'city': 'Kemerovo', 'country': 'Russia', 'facility': 'Research Site', 'geoPoint': {'lat': 55.35417, 'lon': 86.10435}}, {'zip': '121002', 'city': 'Moscow', 'country': 'Russia', 'facility': 'Research Site', 'geoPoint': {'lat': 55.75204, 'lon': 37.61781}}, {'zip': '121552', 'city': 'Moscow', 'country': 'Russia', 'facility': 'Research Site', 'geoPoint': {'lat': 55.75204, 'lon': 37.61781}}, {'zip': '127299', 'city': 'Moscow', 'country': 'Russia', 'facility': 'Research Site', 'geoPoint': {'lat': 55.75204, 'lon': 37.61781}}, {'zip': '630047', 'city': 'Novosibirsk', 'country': 'Russia', 'facility': 'Research Site', 'geoPoint': {'lat': 55.02259, 'lon': 82.93175}}, {'zip': '192242', 'city': 'Saint Petersburg', 'country': 'Russia', 'facility': 'Research Site', 'geoPoint': {'lat': 59.93863, 'lon': 30.31413}}, {'zip': '194156', 'city': 'Saint Petersburg', 'country': 'Russia', 'facility': 'Research Site', 'geoPoint': {'lat': 59.93863, 'lon': 30.31413}}, {'zip': '197022', 'city': 'Saint Petersburg', 'country': 'Russia', 'facility': 'Research Site', 'geoPoint': {'lat': 59.93863, 'lon': 30.31413}}, {'zip': '197341', 'city': 'Saint Petersburg', 'country': 'Russia', 'facility': 'Research Site', 'geoPoint': {'lat': 59.93863, 'lon': 30.31413}}, {'zip': '410054', 'city': 'Saratov', 'country': 'Russia', 'facility': 'Research Site', 'geoPoint': {'lat': 51.54048, 'lon': 45.9901}}, {'zip': '1449', 'city': 'Alberton', 'state': 'Gauteng', 'country': 'South Africa', 'facility': 'Research Site', 'geoPoint': {'lat': -26.26786, 'lon': 28.12225}}, {'zip': '2196', 'city': 'Johannesburg', 'state': 'Gauteng', 'country': 'South Africa', 'facility': 'Research Site', 'geoPoint': {'lat': -26.20227, 'lon': 28.04363}}, {'zip': '0140', 'city': 'Lyttelton', 'state': 'Gauteng', 'country': 'South Africa', 'facility': 'Research Site', 'geoPoint': {'lat': -25.82988, 'lon': 28.2012}}, {'zip': '0184', 'city': 'Pretoria', 'state': 'Gauteng', 'country': 'South Africa', 'facility': 'Research Site', 'geoPoint': {'lat': -25.74486, 'lon': 28.18783}}, {'zip': '7580', 'city': 'Kuils River', 'state': 'Western Cape', 'country': 'South Africa', 'facility': 'Research Site', 'geoPoint': {'lat': -33.94208, 'lon': 18.70663}}, {'zip': '7130', 'city': 'Somerset West', 'state': 'Western Cape', 'country': 'South Africa', 'facility': 'Research Site', 'geoPoint': {'lat': -34.08401, 'lon': 18.82113}}, {'zip': '9301', 'city': 'Bloemfontein', 'country': 'South Africa', 'facility': 'Research Site', 'geoPoint': {'lat': -29.12107, 'lon': 26.214}}, {'zip': '7405', 'city': 'Cape Town', 'country': 'South Africa', 'facility': 'Research Site', 'geoPoint': {'lat': -33.92584, 'lon': 18.42322}}, {'zip': '120-752', 'city': 'Seoul', 'country': 'South Korea', 'facility': 'Research Site', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '135-710', 'city': 'Seoul', 'country': 'South Korea', 'facility': 'Research Site', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '138-736', 'city': 'Seoul', 'country': 'South Korea', 'facility': 'Research Site', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '443-380', 'city': 'Suwon', 'country': 'South Korea', 'facility': 'Research Site', 'geoPoint': {'lat': 37.29111, 'lon': 127.00889}}, {'zip': '443-721', 'city': 'Suwon', 'country': 'South Korea', 'facility': 'Research Site', 'geoPoint': {'lat': 37.29111, 'lon': 127.00889}}, {'zip': '04001', 'city': 'AlmerÃ-a', 'state': 'AndalucÃ-a', 'country': 'Spain', 'facility': 'Research Site'}, {'zip': '04001', 'city': 'Almería', 'state': 'AndalucÃ-a', 'country': 'Spain', 'facility': 'Research Site', 'geoPoint': {'lat': 36.83814, 'lon': -2.45974}}, {'zip': '08003', 'city': 'Barcelona', 'state': 'CataluÃ±a', 'country': 'Spain', 'facility': 'Research Site', 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'zip': '08036', 'city': 'Barcelona', 'state': 'CataluÃ±a', 'country': 'Spain', 'facility': 'Research Site', 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'zip': '08907', 'city': "L'Hospitalet de Llobregat", 'state': 'CataluÃ±a', 'country': 'Spain', 'facility': 'Research Site', 'geoPoint': {'lat': 41.35967, 'lon': 2.10028}}, {'zip': '28223', 'city': 'Pozuelo de AlarcÃ³n', 'state': 'Madrid', 'country': 'Spain', 'facility': 'Research Site'}, {'zip': '28223', 'city': 'Pozuelo de Alarcón', 'state': 'Madrid', 'country': 'Spain', 'facility': 'Research Site', 'geoPoint': {'lat': 40.43293, 'lon': -3.81338}}, {'zip': '46010', 'city': 'Valencia', 'state': 'Valencia', 'country': 'Spain', 'facility': 'Research Site', 'geoPoint': {'lat': 39.47391, 'lon': -0.37966}}, {'zip': '28007', 'city': 'Madrid', 'country': 'Spain', 'facility': 'Research Site', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'zip': '28029', 'city': 'Madrid', 'country': 'Spain', 'facility': 'Research Site', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'zip': '701 46', 'city': 'Ã-rebro', 'country': 'Sweden', 'facility': 'Research Site'}, {'zip': '413 45', 'city': 'GÃ¶teborg', 'country': 'Sweden', 'facility': 'Research Site'}, {'zip': '222 21', 'city': 'Lund', 'country': 'Sweden', 'facility': 'Research Site', 'geoPoint': {'lat': 55.70584, 'lon': 13.19321}}, {'zip': '222 22', 'city': 'Lund', 'country': 'Sweden', 'facility': 'Research Site', 'geoPoint': {'lat': 55.70584, 'lon': 13.19321}}, {'zip': '171 45', 'city': 'Stockholm', 'country': 'Sweden', 'facility': 'Research Site', 'geoPoint': {'lat': 59.32938, 'lon': 18.06871}}, {'zip': '451 50', 'city': 'Uddevalla', 'country': 'Sweden', 'facility': 'Research Site', 'geoPoint': {'lat': 58.34784, 'lon': 11.9424}}, {'zip': '6500', 'city': 'Bellinzona', 'country': 'Switzerland', 'facility': 'Research Site', 'geoPoint': {'lat': 46.19278, 'lon': 9.01703}}, {'zip': '1211', 'city': 'Geneva', 'country': 'Switzerland', 'facility': 'Research Site', 'geoPoint': {'lat': 46.20222, 'lon': 6.14569}}, {'zip': '1011', 'city': 'Lausanne', 'country': 'Switzerland', 'facility': 'Research Site', 'geoPoint': {'lat': 46.516, 'lon': 6.63282}}, {'zip': '8596', 'city': 'Muensterlingen', 'country': 'Switzerland', 'facility': 'Research Site'}, {'zip': '9007', 'city': 'Sankt Gallen', 'country': 'Switzerland', 'facility': 'Research Site', 'geoPoint': {'lat': 47.42391, 'lon': 9.37477}}, {'zip': '8063', 'city': 'Zurich', 'country': 'Switzerland', 'facility': 'Research Site', 'geoPoint': {'lat': 47.36667, 'lon': 8.55}}, {'zip': '807', 'city': 'Kaohsiung City', 'country': 'Taiwan', 'facility': 'Research Site', 'geoPoint': {'lat': 22.61626, 'lon': 120.31333}}, {'zip': '83301', 'city': 'Kaohsiung City', 'country': 'Taiwan', 'facility': 'Research Site', 'geoPoint': {'lat': 22.61626, 'lon': 120.31333}}, {'zip': '100', 'city': 'Taipei', 'country': 'Taiwan', 'facility': 'Research Site', 'geoPoint': {'lat': 25.05306, 'lon': 121.52639}}, {'zip': 'B15 2SQ', 'city': 'Birmingham', 'country': 'United Kingdom', 'facility': 'Research Site', 'geoPoint': {'lat': 52.48142, 'lon': -1.89983}}, {'zip': 'FY3 7EN', 'city': 'Blackpool', 'country': 'United Kingdom', 'facility': 'Research Site', 'geoPoint': {'lat': 53.81667, 'lon': -3.05}}, {'zip': 'CF14 5GJ', 'city': 'Cardiff', 'country': 'United Kingdom', 'facility': 'Research Site', 'geoPoint': {'lat': 51.48, 'lon': -3.18}}, {'zip': 'S40 4TF', 'city': 'Chesterfield', 'country': 'United Kingdom', 'facility': 'Research Site', 'geoPoint': {'lat': 53.25, 'lon': -1.41667}}, {'zip': 'PR7 7NA', 'city': 'Chorley', 'country': 'United Kingdom', 'facility': 'Research Site', 'geoPoint': {'lat': 53.65, 'lon': -2.61667}}, {'zip': 'DN9 1EP', 'city': 'Doncaster', 'country': 'United Kingdom', 'facility': 'Research Site', 'geoPoint': {'lat': 53.52285, 'lon': -1.13116}}, {'zip': 'G20 0SP', 'city': 'Glasgow', 'country': 'United Kingdom', 'facility': 'Research Site', 'geoPoint': {'lat': 55.86515, 'lon': -4.25763}}, {'zip': 'G45 9AW', 'city': 'Glasgow', 'country': 'United Kingdom', 'facility': 'Research Site', 'geoPoint': {'lat': 55.86515, 'lon': -4.25763}}, {'zip': 'HA3 7LT', 'city': 'Harrow', 'country': 'United Kingdom', 'facility': 'Research Site', 'geoPoint': {'lat': 51.57835, 'lon': -0.33208}}, {'zip': 'L22 0LG', 'city': 'Liverpool', 'country': 'United Kingdom', 'facility': 'Research Site', 'geoPoint': {'lat': 53.41058, 'lon': -2.97794}}, {'zip': 'L7 8XP', 'city': 'Liverpool', 'country': 'United Kingdom', 'facility': 'Research Site', 'geoPoint': {'lat': 53.41058, 'lon': -2.97794}}, {'zip': 'M13 9WL', 'city': 'Manchester', 'country': 'United Kingdom', 'facility': 'Research Site', 'geoPoint': {'lat': 53.48095, 'lon': -2.23743}}, {'zip': 'M15 6SX', 'city': 'Manchester', 'country': 'United Kingdom', 'facility': 'Research Site', 'geoPoint': {'lat': 53.48095, 'lon': -2.23743}}, {'zip': 'RG2 0FT', 'city': 'Reading', 'country': 'United Kingdom', 'facility': 'Research Site', 'geoPoint': {'lat': 51.45625, 'lon': -0.97113}}, {'zip': 'RG2 0TG', 'city': 'Reading', 'country': 'United Kingdom', 'facility': 'Research Site', 'geoPoint': {'lat': 51.45625, 'lon': -0.97113}}, {'zip': 'DN15 7BH', 'city': 'Scunthorpe', 'country': 'United Kingdom', 'facility': 'Research Site', 'geoPoint': {'lat': 53.57905, 'lon': -0.65437}}, {'zip': 'WF1 4DG', 'city': 'Wakefield', 'country': 'United Kingdom', 'facility': 'Research Site', 'geoPoint': {'lat': 53.68331, 'lon': -1.49768}}, {'zip': 'YO21 1SD', 'city': 'Whitby', 'country': 'United Kingdom', 'facility': 'Research Site', 'geoPoint': {'lat': 54.48774, 'lon': -0.61498}}], 'overallOfficials': [{'name': 'MD', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Amgen'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Amgen', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}